 
Official Title:  A Phase I I, Randomized, Double -Blind Placebo -Controlled Study of 
Atezolizumab With or Without Bevacizumab in Combination With 
Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced 
Biliary Tract Cancer  
Study ID: [REMOVED]  
Document  Date : Protocol  Amendment  Version 6: 03-February -2023  
 
 
 
CONFIDENTIAL  
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland.   However, it may be implemented in individual countries by [CONTACT_26702]'s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contained in this document, especially 
any unpublished data, is the property of F.  Hoffmann -La [COMPANY_002] Ltd (or under its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review  by 
[CONTACT_10825], your staff, and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consen t from persons to whom the drug may be administered.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
Protocol GO42661, Version 6 PROTOCOL  
TITLE:  A PHASE II, RANDOMIZED, DOUBLE -BLIND 
PLACEBO -CONTROLLED STUDY OF 
ATEZOLIZUMAB WITH OR WITHOUT 
BEVACIZUMAB IN COMBINATION WITH 
CISPLATIN  PLUS GEMCITABINE IN PATIENTS 
WITH UNTREATED, ADVANCED BILIARY 
TRACT CANCER  
PROTOCOL NUMBER:  GO42661  
STUDY NAME  [CONTACT_169907]151  
VERSION NUMBER:  [ADDRESS_198184] NUMBER:  2020 -003759 -14 
IND NUMBER:  152,[ADDRESS_198185] NUMBER:  [STUDY_ID_REMOVED]  
TEST PRODUCTS:  Atezolizumab (RO5541267)  
Bevacizumab (RO4876646)  
MEDICAL MONITOR:   M.D., Ph.D.  
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd  
APPROVAL:  See electronic signature [CONTACT_169908].  

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
2/Protocol GO42661 , Version [ADDRESS_198186] 2020  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
3/Protocol GO42661 , Version 6 PROTOCOL AMENDMENT, VERSION 6:  
RATIONALE  
Protocol GO42661 has primarily been amended to  update risks and adverse event 
management guidelines for atezolizumab to align with the Atezolizumab Investigator's 
Brochure, Version 19 and Addenda 1 and 2 .  Substantive c hanges to the protocol, along 
with a rationale for each change, are summarized below:  
 The medical term  "Wegener granulomatosis" has been replaced by [CONTACT_169824]  "granulomatosis with polyangiitis" to align with the updated preferred term 
in MedDRA (Section  4.1.2 and Appendix 12).  
 The list of identified risks for atezolizumab has been revised to include pericardial 
disorders, myelitis, and facial paresis (Section  5.1.1). 
 Hemophagocytic lymphohistiocytos is has been updated from a potential risk to an 
identified risk associated with atezolizumab , and language has been revised 
accordingly (Section 5.1. 1). 
 The list of adverse events of special interest has been revised to include myelitis 
and facial paresis (Section 5.2.3 ). 
 A description of the technical and organizational security measures taken to 
protect personal data has been added to align with Clinical Trials Regulation 
requirements (Section  8.4). 
 Appendix  [ADDRESS_198187] previously experienced a 
pericardial disorder while receiving another immunostimulatory anti -cancer agent.  
 Appendix  12 has been revised to include autoimmune myelitis.  
 The adverse event man agement guidelines have been updated to align with the 
Atezolizumab Investigator's Brochure, Version 19 and Addenda 1 and 2  
(Appendix  15). 
 
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
4/Protocol GO42661 , Version [ADDRESS_198188] Cancer  .......................  29 
1.3 Background on Atezolizumab  ................................ ..................  30 
1.4 Background on Bevacizumab  ................................ ..................  31 
1.5 Study Rationale and Benefit Risk Assessment  .......................  31 
1.5.1  Rationale for Combining Chemotherapy with Anti PD-
1/PD -L1 Antibodies  ................................ ................................ .. 31 
1.5.2  Rationale for Combined Inhibition of PD -L1 and VEGF  ...........  32 
1.5.3  Rationale for Co mbining Anti PD-L1, Anti -VEGF, and 
Chemotherapy  ................................ ................................ .........  33 
1.5.4  Benefit -Risk Assessment during the COVID -19 Pandemic  ...... 33 
2. OBJECTIVES AND ENDPO INTS  ................................ .................  35 
3. STUDY DESIGN  ................................ ................................ ...........  38 
3.1 Description of the Study  ................................ ...........................  38 
3.2 End of Study and Length of Study  ................................ ...........  42 
3.3 Rationale for Study Design  ................................ ......................  42 
3.3.1  Rationale for Atezolizumab Dose and Schedule  ......................  42 
3.3.2  Rationale for Bevacizumab Dose and Schedule  ......................  42 
3.3.3  Rationale for Patient Population  ................................ ..............  42 
3.3.4  Rationale for Treatment Arms  ................................ ..................  43 
3.3.5  Rationale for Continued Treatment of 
Atezolizumab/Bevacizumab and Atezolizum ab/Placebo 
after Chemotherapy  ................................ ................................ . 43 
3.3.6  Rationale for Progression -Free Survival as the Primary 
Endpoint  ................................ ................................ ..................  44 
3.3.7  Rationale for Stratification Factors  ................................ ...........  44 

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
5/Protocol GO42661 , Version [ADDRESS_198189] Clinical Outcome 
Assessments  ................................ ................................ ...........  46 
4. MATERIALS AND METHOD S ................................ ......................  47 
4.1 Patients  ................................ ................................ ....................  47 
4.1.1  Inclusion Criteria  ................................ ................................ ...... 47 
4.1.2  Exclusion Criteria  ................................ ................................ ..... 51 
4.2 Method of Treatment Assignment and Blinding  .......................  55 
4.2.1  Blinding  ................................ ................................ ....................  55 
4.3 Study Treatment and Other Treatments Relevant to the 
Study Design  ................................ ................................ ...........  56 
4.3.1  Study Treatment Formulations and Packaging  ........................  57 
[IP_ADDRESS]  Atezolizumab  ................................ ................................ ...........  57 
[IP_ADDRESS]  Bevacizumab and Placebo  ................................ ......................  57 
[IP_ADDRESS]  Cisplatin and Gemcitabine  ................................ .......................  57 
4.3.2  Study Treatment Dosage, Administration, and Compliance  .... 57 
[IP_ADDRESS]  Atezolizumab  ................................ ................................ ...........  58 
[IP_ADDRESS]  Bevacizumab and Placebo  ................................ ......................  58 
4.3.3  Chemotherapy (Cisplatin and Gemcitabine)  ............................  [ADDRESS_198190] Handling and 
Accountability  ................................ ................................ ...........  60 
4.3.5  Continued Access to Atezolizumab and Bevacizumab  ............  61 
4.4 Concomitant Therapy  ................................ ..............................  61 
4.4.1  Permitted Therapy  ................................ ................................ ... 62 
4.4.2  Cautionary Therapy  ................................ ................................ . 64 
[IP_ADDRESS] Corticosteroids, Immunosuppressive Medications, and 
TNF- Inhibitors  ................................ ................................ ....... 64 
[IP_ADDRESS]  Herbal Therapi[INVESTIGATOR_014]  ................................ ................................ ..... 65 
4.4.3  Prohibited Therapy  ................................ ................................ .. 65 
[IP_ADDRESS]  Prohibited and Cautionary Therapy for Gemcitabine -
Treated Patients  ................................ ................................ ...... 66 
[IP_ADDRESS]  Prohibited and Cautionary Therapy for Cisplati n-Treated 
Patients  ................................ ................................ ....................  66 

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
6/Protocol GO42661 , Version 6 4.5 Study Assessments  ................................ ................................ . 66 
4.5.1  Informed Consent Forms and Screening Log  ..........................  67 
4.5.2  Medical History, Baseline Conditions, Concomitant 
Medication, and Demographic Da ta ................................ .........  67 
4.5.3  Physical Examinations  ................................ .............................  67 
4.5.4  Vital Signs  ................................ ................................ ................  67 
4.5.5  Tumor and Response Evaluations  ................................ ...........  68 
4.5.6  Laboratory, Biomarker, and Other Biological Samples  ............  69 
4.5.7  Electrocardiograms  ................................ ................................ .. 72 
4.5.8  Clinical Outcome Assessments  ................................ ...............  72 
[IP_ADDRESS]  Data Collection Methods for Clinical Outcome 
Assessments  ................................ ................................ ...........  73 
[IP_ADDRESS]  Description of Clinical Outcome Assessment Instruments  ....... 74 
4.5.9  Blood Samples for Whol e Exome Sequencing (Patients at 
Participating Sites)  ................................ ................................ ... 75 
4.5.10  Optional Tumor Biopsies  ................................ .........................  76 
4.5.11  Optional Stool Samples  ................................ ...........................  76 
4.5.12  Study Treatment Discontinuation  ................................ .............  77 
4.5.13  Patient Discontinuation from the Study  ................................ .... 78 
4.5.14  Study Discontinuation  ................................ ..............................  79 
4.5.15  Site Discontinuation  ................................ ................................ . 79 
5. ASSESSMENT OF SAFETY  ................................ .........................  79 
5.1 Safety Plan  ................................ ................................ ..............  79 
5.1.1  Risks Associated with Atezolizumab  ................................ ........  80 
5.1.2  Risks Associated with Bevacizumab  ................................ ........  80 
5.1.3  Risks Associated with Combination Use of Atezolizumab 
and Bevacizuma b ................................ ................................ .... 80 
5.1.4  Risks Associated with Cisplatin or Gemcitabine  ......................  80 
5.1.5  Cisplatin and Gemcitabine Dose Modifications  ........................  81 
5.2 Safety Parameters and Definitions  ................................ ..........  81 
5.2.1  Adverse Events  ................................ ................................ ........  81 
5.2.2  Serious Adverse Events (Immediately Reportable to the 
Sponsor)  ................................ ................................ ..................  82 

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
7/Protocol GO42661 , Version [ADDRESS_198191] (Immediately 
Reportable to the Sponsor)  ................................ ......................  82 
5.3 Methods and Timing for Capturing and Assessing 
Safety  Parameters  ................................ ................................ ... 84 
5.3.1  Adverse Event Reporting Period  ................................ ..............  84 
5.3.2  Eliciting Adverse Event Information  ................................ .........  84 
5.3.3  Assessment of Severity of Adverse Events  .............................  84 
5.3.4  Assessment of Causality of Adverse Events ............................  85 
5.3.5  Procedures for Recording Adverse  Events  ..............................  86 
[IP_ADDRESS]  Infusion -Related Reactions and Cytokine Release 
Syndrome  ................................ ................................ ................  86 
[IP_ADDRESS]  Diagnosis versus Signs and Symptoms  ................................ ... 87 
[IP_ADDRESS]  Adverse Events That Are Secondary to Other Events  .............  87 
[IP_ADDRESS]  Persistent or Recurrent Adverse Events  ................................ .. 87 
[IP_ADDRESS]  Abnormal Laboratory Values  ................................ ...................  88 
[IP_ADDRESS]  Abnormal Vital Sign Values  ................................ .....................  89 
[IP_ADDRESS]  Abnormal Liver Function Tests  ................................ ................  89 
[IP_ADDRESS]  Deaths  ................................ ................................ .....................  89 
[IP_ADDRESS]  Preexisting Medical Conditions  ................................ ................  90 
[IP_ADDRESS]  Lack of Efficacy or Worsening of Biliary Tract Cancer  .............  90 
[IP_ADDRESS]  Hospi[INVESTIGATOR_26589]  ............................  90 
[IP_ADDRESS]  Cases of Accidental Overdose or Medication Error  .................  91 
[IP_ADDRESS]  Patient -Reported Outcome Data  ................................ ..............  92 
[IP_ADDRESS]  Safety Biomarker Data  ................................ .............................  [ADDRESS_198192]  ................................ ..........  93 
[IP_ADDRESS]  Events That Occur prior to Study Treatment Initiation  .............  93 
[IP_ADDRESS]  Events That Occur after Study Treatment Initiation  .................  94 
5.4.3  Reporting Requirements for P regnancies  ................................  94 
[IP_ADDRESS]  Pregnancies in Female Patients  ................................ ..............  94 
[IP_ADDRESS]  Pregnancies in Female Partners of Male Patients  ...................  95 

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
8/Protocol GO42661 , Version 6 [IP_ADDRESS]  Abortions ................................ ................................ ..................  95 
[IP_ADDRESS]  Congenital Anomalies/Birth Defects  ................................ ........  [ADDRESS_198193] of Study  ................................ ..............  99 
6.3 Summaries of Demographic and Baseline Characteristics  ...... 99 
6.4 Efficacy Analyses  ................................ ................................ ..... 99 
6.4.1  Primary Efficacy Endpoint  ................................ ........................  99 
6.4.2  Secondary Efficacy Endpoints  ................................ ...............  100  
[IP_ADDRESS]  Overall Survival  ................................ ................................ ...... 100  
[IP_ADDRESS]  Confirmed Objective Response Rate  ................................ ..... 100  
[IP_ADDRESS]  Duration of Response  ................................ ............................  101  
[IP_ADDRESS]  Disease Control Rate  ................................ .............................  101  
[IP_ADDRESS]  Time to Confirmed Deterioration  ................................ ............  101  
6.4.3  Exploratory Efficacy Endpoints  ................................ ..............  101  
[IP_ADDRESS]  Exploratory Progression -Free Survival  ................................ .. 101  
[IP_ADDRESS]  Exploratory Overall Survival  ................................ ...................  101  
[IP_ADDRESS]  Exploratory Patient -Reported Outcome Endpoints  ................  102  
6.5 Safety Analyses  ................................ ................................ ..... 102  
6.5.1  Analyses of Exposure, Adverse Event, Laboratory, Vital 
Sign, and ECG Dat a ................................ ..............................  102  
6.5.2  Exploratory Analyses of PRO -CTCAE Data  ..........................  103  
6.6 Pharmacokinetic Analyses  ................................ .....................  103  
6.7 Immunogenicity Analyses  ................................ ......................  103  
6.8 Biomarker Analyses  ................................ ...............................  104  
6.9 Interim Analyses  ................................ ................................ .... 104  
6.9.1  Planned Interim Analysis  ................................ .......................  104  

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
9/Protocol GO42661 , Version [ADDRESS_198194] and Subsequent 
Bevacizumab/Placebo Infusions  ................................ .................  59 

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
10/Protocol GO42661 , Version [ADDRESS_198195] OF APPENDICES  
Appendix  1 Schedule of Activities  ................................ ................................  120  
Appendix  2 Schedule of Patient -Reported Outcome Assessments  .............  127  
Appendix  3 Schedule of Pharmacokinetic, Immunogenicity, and 
Biomarker  Samples  ................................ ................................ ... 129  
Appendix  4 Staging Criteria for Advanced Biliary Cancers  ..........................  130  
Appendix  5 Response Evaluation Criteria in Solid Tumors, 
Version  1.1 (RECIST v1.1) ................................ ........................  131  
Appendix  6 European Organisation for the Research and Treatment of 
Cancer Quality -of-Life Questionnaire (EORTC QLQ -C30)  ........  140  
Appendix  7 European Organisation for Research and Treatment of 
Cancer Quality -of-Life Questionnaire for 
Cholangiocarcinoma and Cancer of the Gallbladder (EORTC 
QLQ -BIL21)  ................................ ................................ ...............  142  
Appendix  8 European Organisation for Research and Treatment of 
Cancer Item Library 77 (EORTC IL77)  ................................ ...... 143  
Appendix  9 Patient Global Impression of Change and Its Importance 
(PGI-CI)................................ ................................ .....................  144  
Appendix  10 Patient Global Impression of Severity (PGI -S) ..........................  145  
Appendix  11 Patient -Reported Outcome Common Terminology Criteria for  
Adverse Events  (PRO -CTCAE)  ................................ ................  146  
Appendix  12 Preexisting Autoimmune Diseases and Immune Deficiencies  .. 147  
Appendix  13 Anaphylaxis Precautions  ................................ ...........................  148  
Appendix  14 Overall Guidelines for Management of Patients Who 
Experience Adverse  Events  ................................ ......................  149  
Appendix  15 Risks Associated  with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with 
Atezolizumab  ................................ ................................ ............  164  

Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
11/Protocol GO42661 , Version 6 PROTOCOL AMENDMENT ACCEPTANCE FORM  
TITLE:  A PHASE II, RANDOMIZED, DOUBLE -BLIND 
PLACEBO -CONTROLLED STUDY OF 
ATEZOLIZUMAB WITH OR WITHOUT 
BEVACIZUMAB IN COMBINATION WITH 
CISPLATIN PLUS GEMCITABINE IN PATIENTS 
WITH UNTREATED, ADVANCED BILIARY TRACT 
CANCER  
PROTOCOL NUMBER:  GO42661  
STUDY NAME  [CONTACT_169907]151  
VERSION NUMBER:  [ADDRESS_198196] NUMBER:  2020 -003759 -14 
IND NUMBER:  152,[ADDRESS_198197] NUMBER:  [STUDY_ID_REMOVED]  
TEST PRODUCT S: Atezolizumab  (RO5541267)  
Bevacizumab (RO4876646)  
MEDICAL MONITOR:   M.D., Ph.D. 
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd  
 
I agree to conduct the study in accordance with the current protocol.  
   
Principal Investigator's Name  (print)    
   
Principal Investigator's Signature   [CONTACT_77065].  Please return a copy of 
the signed form as instructed by [CONTACT_27860].  
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
12/Protocol GO42661 , Version 6 PROTOCOL SYNOPSIS  
TITLE:  A PHASE II, RANDOMIZED, DOUBLE -BLIND 
PLACEBO -CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR 
WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN 
PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, 
ADVANCED BILIARY TRACT CANCER  
PROTOCOL NUMBER:  GO42661  
STUDY NAME  [CONTACT_169907]151  
VERSION NUMBER:  [ADDRESS_198198] NUMBER:  2020 -003759 -14 
IND NUMBER:  152,[ADDRESS_198199] NUMBER:  [STUDY_ID_REMOVED]  
TEST PRODUCT S: Atezolizumab (RO5541267)  
Bevacizumab (RO4876646)  
PHASE:  II 
INDICATION:  Biliary tract cancer  
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd  
 
OBJECTIVES AND ENDPO INTS  
This study will evaluate the efficacy and safety of atezolizumab with bevacizumab in 
combination with cisplatin and gemcitabine (CisGem), compared with atezolizumab in 
combination with CisGem, in patients with advanced biliary tract cancer (BTC) (i.e., intrahepatic 
cholangiocarcinoma [iCCA] , extrahepatic CCA  [eCCA], or gallbladder cancer [ GBC]) who have 
not received prior systemic therapy.  Specific objectives and corresponding endpoints for the 
study are outlined in Table 1.  
In this protocol, study treatment  refers to the combination of treatments assigned to  patients 
as part of this study.  Patients will receive one of the following combinations of treatments:  
 Atezolizumab   Bevacizumab chemotherapy (CisGem), followed by 
[CONTACT_120422]   Bevacizumab  
 Atezolizum ab   Placebochemotherapy (CisGem), followed by [CONTACT_120422]   Placebo  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
13/Protocol GO42661 , Version 6 TABLE 1  OBJECTIVES A ND CORRESPONDING END POINTS  
Primary Efficacy Objective  Corresponding Endpoint  
 To evaluate the efficacy of 
Atezo   Bev   CisGem compared 
with Atezo   PBO   CisGem   PFS, defined as the time from randomization to the first 
occurrence of disease progression as determined by 
[CONTACT_3143] v1.1 or death 
from any cause (whichever occurs first)  
Secondary Efficacy Objective  Corresponding Endpoints  
 To evaluate the efficacy of 
Atezo   Bev   CisGem compared 
with Atezo   PBO   CisGem   OS, defined as the time from randomization to death 
from any cause  
 Confirmed ORR, defined as the proportion of patients 
with a CR or PR on two consecutive occasions 
 [ADDRESS_198200] v1.1  
 DOR, defined as the time from the first occurrence of 
a confirmed objective respon se to disease progression 
as determined by [CONTACT_3142]  v1.1 or death from any cause 
(whichever  occurs first)  
 DCR, defined as the proportion of patients with a CR or 
a PR on two consecutive occasions [ADDRESS_198201]  v1.1 
 TTCD in patient -reported physical functioning, role 
functioning, and quality of life, as measured by [CONTACT_169825] -C30 and/or 
EORTC IL77, and defin ed as the time from 
randomization to the first clinically meaningful 
deterioration that is either maintained for 
two consecutive assessments or followed by [CONTACT_120418] 3 weeks  
Exploratory Efficacy Objective  Corresponding Endpoints  
 To evaluate the efficacy of 
Atezo   Bev   CisGem compared 
with Atezo   PBO   CisGem   PFS rates at specified timepoints (e.g., 6 months and 
12 months), defined as the probability that a patient will 
be alive without experiencing disease progression, as 
determined by [CONTACT_3142]  v1.1, at specified timepoints  
 OS rates at specific timepoints (e.g., 6 months and 
12 months), defined as the probability that a patient will 
be alive at specified timepoints  
 Mean scores and changes in mean  scores from 
baseline in all scales of the EORTC QLQ -C30, EORTC 
IL77, and EORTC QLQ -BIL21  
 Proportion of responses on the PGI -CI and PGI -S 
Safety Objective  Corresponding Endpoints  
 To evaluate the safety of 
Atezo   Bev   CisGem compared 
with Atezo   PBO   CisGem   Incidence and severity of adverse events, with severity 
determined according to NCI CTCAE v5.0  
 Change from baseline in targeted vital signs  
 Change from baseline in targeted clinical laboratory 
test results  
  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
14/Protocol GO42661 , Version 6 TABLE 1  OBJECTIVES A ND CORRESPONDING END POINTS (CONT.)  
Exploratory Safety Objective  Corresponding Endpoints  
 To evaluate the treatment -related 
tolerability of Atezo   Bev   CisGem 
compared with Atezo   PBO   CisGem 
from the patient perspective   Frequency, severity, interference, and/or presence 
of select symptomatic treatment toxicities, as 
determined through use of the PRO -CTCAE  
 Change from baseline in select symptomatic 
treatment toxic ities, as determined by [CONTACT_169826] -CTCAE  
 Overall troublesomeness with treatment, as 
determined by [CONTACT_169827] -BIL21  
Pharmacokinetic Objective  Corresponding Endpoint  
 To characterize the pharmacokinetics 
of atezolizumab when given in 
combination with bevacizumab and/or 
gemcitabine/cisplatin   Serum concentration of atezolizumab at specified 
timepoints  
Immunogenicity Objective  Corresponding Endpoint  
 To evaluate the immune response to 
atezolizumab   Prevalence of ADAs to atezolizumab at baseline 
and incidence of ADAs to atezolizumab during the 
study  
Exploratory Immunogenicity 
Objective  Corresponding Endpoint  
 To evaluate potential effects of ADAs   Relationship between ADA status and efficacy, 
safety, or PK endpoints  
Exploratory Biomarker Objective  Corresponding Endpoint  
 To identify and/or evaluate 
biomarkers that are predictive of 
response to study treatment 
(i.e., predictive biomarkers), are early 
surrogates of efficacy, are associated 
with progression to a more severe 
disease state (i.e.,  prognostic 
biomarkers), are assoc iated with 
acquired resistance to study 
treatment, are associated with 
susceptibility to developi[INVESTIGATOR_169779] (i.e.,  safety biomarkers), 
can provide evidence of study 
treatment activity  
(i.e., pharmacodynamic biomarkers), 
or can increase the knowledge and 
understanding of disease biology and 
drug safety   Relationship between biomarkers in blood, serum, 
plasma, and tumor tissue  and efficacy, safety, PK, 
immunogenicity, or other biomarker e ndpoints  
  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
15/Protocol GO42661 , Version 6 TABLE 1  OBJECTIVES A ND CORRESPONDING END POINTS (CONT.)  
ADA   anti-drug antibody; Atezo   atezolizumab; Bev   bevacizumab; CisGem   cisplatin and 
gemcitabine;  CR   complete response; DCR   disease control rate; DOR   duration of response; 
EORTC   European Organisation for Research and Treatment of Cancer;  IL  Item Library; 
NCI CTCAE   National Cancer Institute Common Terminol ogy Criteria for Adverse Events ; 
ORR   objective response rate; OS   overall survival; PBO   placebo; PFS   progression -free 
survival; PGI-CI  Patient Global Impression of Change, Importance; PGI -S  Patient Global 
Impression of Severity; PK   pharmacokinetic;  PR   partial response; 
PRO -CTCAE   Patient -Reported Outcome Common Terminology Criteria for Adverse Events; 
QLQ -BIL21   Quality -of-Life Questionnaire for Cholangiocarcinoma and Cancer of the 
Gallbladder; QLQ -C30   Quality -of-Life Questionnaire for Cancer;  RECIST   Response 
Evaluation Criteria in Solid Tumors; SD   stable disease; TTCD   time to confirmed 
deterioration . 
 
STUDY DESIGN  
DESCRIPTION OF STUDY  
This is a Phase II, randomized, double -blind, placebo -controlled, multicenter study designed to 
evaluate the efficacy and safety of atezolizumab with bevacizumab in combination with CisGem, 
compared with atezolizumab i n combination with CisGem,  in patients with advanced BTC 
(i.e., iCCA, eCCA, or GBC) who have not received prior systemic therapy.  
The study will enroll globally approximately 150 patients, who will be randomized in a 1:1 ratio 
to one of two treatment arms.   The number of patients with either eCCA or GBC will be capped 
at a maximum of 50% of the total number of patients enrolled.  
Treatment will consist of a chemotherapy combination phase followed by a cancer 
immunotherapy (CIT)/placebo phase as outlined in T able 2.  
TABLE  2 STUDY TREATMENT  
Treatment 
Arm Dose, Route, and Regimen  
(Drugs Listed in Order of Administration)  
Chemotherapy Combination Phase a 
Cycles 18 
(21-Day Cycles)  CIT/Placebo Phase  
Cycles 9 and Beyond  
(21-Day Cycles)  
Arm A  AtezoBevCisGem  
 Atezolizumab 1200 mg IV on Day 1  
 Bevacizumab 15 mg/kg IV on Day 1  
 Cisplatin 25 mg/m2 IV on Days  1 and  8 
 Gemcitabine 1000 mg/m2 IV on Days  1 
and 8  AtezoBev 
 Atezolizumab 1200 mg IV on Day  1 
 Bevacizumab 15 mg/kg IV on Day  1 
Arm B  AtezoPBOCisGem  
 Atezolizumab 1200 mg IV on Day 1  
 Placebo IV on Day 1  
 Cisplatin 25 mg/m2 IV on Days  1 and  8 
 Gemcitabine 1000 mg/m2 IV on Days  1 
and 8 AtezoPBO  
 Atezolizumab 1200 mg IV on Day  1 
 Placebo IV on Day 1  
Atezo   atezolizumab; Bev   bevacizumab; CisGem   cisplatin  and gemcitabine; CIT   cancer 
immunotherapy; PBO   placebo.  
a Treatment during the chemotherapy combination phase will be administered on a [ADDRESS_198202]. 
 
Randomization will be stratified according to the following stratification factors:  
 Location of primary tumor (iCCA vs. eCCA vs. GBC)  
 Metastatic disease (yes vs. no)  
 Geographic region (Asia vs. rest of the world)  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
16/Protocol GO42661 , Version 6 Patients who do not meet the criteria for participation in this study (screen failure) may qualify 
for one re-screening  opportunity (for a total of two  screenings per participant) at the 
investigator's discretion.  Patients are not required to re -sign the Informed  Consent  Form if they 
are re -screened within [ADDRESS_198203] reasons for screen failure in the screening log.  
Patients will continue treatment as indicated in Table 2 until u nacceptable toxicity or loss of 
clinical benefit, as determined by [CONTACT_169828] (e.g., symptomatic deterioration such as pain 
secondary to disease).  In the absence  of unacceptable toxicity, patients who meet criteria for 
disease progression (as assessed by [CONTACT_169829], Version  1.1 [RECIST  v1.1])  while receiving atezolizumab will be permitted to 
continue the study treatment if they meet all of the following criteria:  
 Evidence of clinical benefit, as determined by [CONTACT_169830] a review of all 
available data  
 Absence of symptoms and signs (including laboratory values, such as new or worsening 
hypercalcemia) indicating unequivocal progression of disease  
 Absence of decline in Eastern Cooperative Oncology Group (ECOG) Performance Status 
that can be attributed to disease progression  
 Absence of tumor progression at critical anatomical sites (e.g., lep tomeningeal disease) that 
cannot be managed by [CONTACT_990] -allowed medical interventions  
 
Patients who transiently withhold or permanently discontinue one component of their treatment 
(i.e., either atezolizumab, bevacizumab/placebo, or chemotherapy) because o f toxicity may 
continue with the other components of study treatment, as long as the patients are experiencing 
clinical benefit in the opi[INVESTIGATOR_871].  However, bevacizumab/placebo should not be 
continued as a single agent.  
Patients will under go tumor assessments every 9 ( 1) weeks following treatment initiation .  
Sites will collect and send imaging used for tumor assessments to an independent review 
facility to enable potential centralized, independent review of response and progression 
endpoi nts. 
Following disease progression or loss of clinical benefit, patients will be followed for survival and 
subsequent anti -cancer therapi[INVESTIGATOR_169780], loss to follow -up, withdrawal of consent, or study 
termination by [CONTACT_1034], whichever occurs first.  
Patient -reported outcome (PRO) assessments will be completed before starting treatment, at 
specified timepoints during treatment, and at treatment discontinuation.  
Safety assessments will include the incidence, nature, and severity of adverse events and 
laboratory abnormalities graded per the National Cancer Institute Common Terminology Criteria 
for Adverse Events  (NCI CTCAE) , Version 5.0.  Laboratory safety assessments will include the 
regular monitoring of hematology and blood chemistry.  Serum samples wi ll be collected to 
monitor the pharmacokinetics of atezolizumab when administered in combination with 
bevacizumab and/or CisGem.  Patient samples, including archival tumor tissues, as well as 
serum and plasma, will be collected for future exploratory bioma rker assessments.  
NUMBER OF PATIENTS  
Approximately [ADDRESS_198204] meet the following criteria for study entry:  
 Signed Informed Consent Form  
 Age  18 years at the time of signing the Informed Consent Form  
 Ability to comply with the study protocol  
 Considered to be eligible to receive platinum -based chemotherapy, in the investigator’s 
judgment  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
17/Protocol GO42661 , Version 6  Documentation of recurrent/metastatic or  locally advanced unresectable disease based on 
computed tomography (CT) or magnetic resonance imaging (MRI) scans  
 Histologically or cytologically confirmed diagnosis of iCCA, eCCA, or GBC  
For patients with recurrent BTC, histologic confirmation of BTC at the time of resection is 
acceptable  
 No prior systemic therapy (including systemic investigational agents) for advanced BTC  
Prior chemotherapy or radiotherapy (with or without radio -sensitizing  chemotherapy) 
in the neoadjuvant or adjuvant setting is permitt ed provided this is completed at least 
[ADDRESS_198205] returned to baseline, or Grade  1 
or better.  
Previous use of herbal therapi[INVESTIGATOR_169781] -cancer 
activity included in the label is allowed, provided that these medications are discon tinued 
prior to Day 1 of Cycle 1.  
The following prior interventions are permitted, provided the patient has fully recovered:  
– Surgery:  Non -curative resection with macroscopic residual disease or palliative 
by[CONTACT_4897].  Patients who have previously unde rgone curative surgery must 
have evidence of non -resectable disease requiring systemic chemotherapy.  
– Photodynamic therapy:  Prior photodynamic therapy for localized disease with no 
evidence of metastatic disease or for localized disease to relieve biliary obstruction 
in the presence of metastatic disease, provided patient has clear evidence of 
disease progression requiring systemic chemotherapy.  
– Palliative radiotherapy:  Palliative radiotherapy, provided that all adverse events 
have resolved and the patient  has measurable disease outside the field of 
radiation.  
 At least one measurable untreated lesion (per RECIST v1.1)  
 Adequate biliary drainage with no evidence of ongoing infection  
If applicable, treatable and clinically relevant biliary duct obstruction mus t be relieved by 
[CONTACT_169831]/stenting at least [ADDRESS_198206] total bilirubin  2 upper limit of normal (ULN) and AST/ALT  5ULN for 
 2 weeks prior to Day  1 of Cycle  1.  Patients with improving biliary function who m eet all 
other inclusion criteria may be re -tested during the screening window.  
 Availability of a representative tumor specimen that is suitable for determination of PD-L1 
status via central testing  
A formalin -fixed, paraffin -embedded (FFPE) tumor specimen in a paraffin block 
(preferred) or at least 16  slides containing unstained, freshly cut, serial sections should 
be submitted along with an associated  pathology report  within 4  weeks  of randomization.  
If FFPE specimens described above are not available, any  type of specimen (including 
fine-needle aspi[INVESTIGATOR_1516], cell pellet specimens [e.g., from pleural effusion], and lavage 
samples) are also acceptable.  This specimen should be accompanied by [CONTACT_169832].  
If archival tissue is either insufficient or unavailable, a core -needle biopsy specimen 
should be collected during the screening period, if clinically feasible.  Trans -jugular 
biopsy tissue sample collections for patients who are at high risk of bleeding may be 
allowed.  
If archival ti ssue is either insufficient or unavailable and a fresh biopsy is not 
clinically feasible, the patient may still be eligible.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
18/Protocol GO42661 , Version 6  Negative HIV test at screening with the following exception:  Patients with a positive HIV 
test at screening are eligible provided they are stable on anti -retroviral therapy, have a CD4 
count  200/L, and have an undetectable viral load  
 Documented virology status of hepatitis, as confirmed by [CONTACT_169833]  B virus (HBV) 
or hepatitis C virus (HCV) tests  
– For patients with active HBV:  HBV DNA  500 IU/mL during screening, initiation of 
anti-HBV treatment at least 14 days prior to Day 1 of Cycle 1 and willingness to 
continue anti -HBV treatment during the study (per local standard of care [e.g., 
entecavir])  
– Patients with HCV, either with resolved infection (as evidenced by [CONTACT_169834]) or chronic infection (as evidenced by [CONTACT_83921]), are eligible  
 Eastern Cooperative Oncology Group Performance Status of 0 or 1  
 Life expectancy of  3 months  
 Adequate hematologic and end -organ function, defined by [CONTACT_169835], obtained within 7 days prior to Day 1 of Cycle 1 unless otherwise specified:  
– AST and ALT  2.5   ULN with the following exceptions:  
Patients with documented liver metastases:  AST and ALT  5ULN.  
– Serum bilirubin  2  ULN 
– Albumin  28 g/L ( 2.8 g/dL)  
– Creatinine clearance  60 mL/min (calculated using the Cockcroft -Gault formula)  
– Hemoglobin  90 g/L ( 9 g/dL)  
Patients may be transfused to meet this criterion.  
– Platelet count  100109/L ( 100,000/L) without transfusion  
– Lymphocyte count 0.5109/L ( 500/L) 
– ANC  1.5109/L (1500/L) without granulocyte colony -stimulating factor support  
– For patients not receiving therapeutic anticoagulation:  INR or aPTT  2 ULN 
– Proteinuria  2 on dipstick analysis (within 7 days prior to Day 1 of Cycle  1) 
Patients discovered to have   2 proteinuria on dipstick urinalysis at baseline should 
undergo a 24 -hour urine collection (or an alternative method such as protein: 
creatinine ratio, per local guidance) and must demonstrate  1 g of protein in 
24 hours.  
 For women of childbearing potential:  Agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive methods, and agreement to refrain from 
donating eggs as defined below:  
Women must remain abstinent or use contraceptive methods with a failure rate of 
1% per year while they are receiving atezolizumab and bevacizumab and for 
[ADDRESS_198207] refrain from donating eggs 
during this same period.  
A woman is considered to be of childbearing potential if she is postmenarchal,  has not 
reached a postmenopausal state ( 12 continuous months of amenorrhea with no 
identified cause other than menopause), and is not permanently infertile due to surgery 
(i.e., removal of ovaries, fallopi[INVESTIGATOR_2134], and/or uterus) or another cause as 
determined by [CONTACT_093] (e.g.,  Müllerian agenesis).  The definition of 
childbearing potential may be adapted for alignment with local guidelines or 
regulations.  
Examples of contraceptive methods with a failure rate of 1% per year include bilateral 
tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, 
hormone -releasing intrauterine devices, and copper intrauterine devices.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
19/Protocol GO42661 , Version 6 The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical tr ial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal 
are not adequate methods of contraception.  If  required per local guidelines or 
regulations, locally recognized adequate methods of contraception and information 
about the reliability of abstinence will be described in the local Informed Consent Form.  
 For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or use 
a condom, and agreement to refrain from donating sperm, as defined below:  
With a female partner of childbearing potential or pregnant female partner, men must 
remain abstinent or use a condom during the treatment period and for [ADDRESS_198208] refrain from donating sperm during this same period.  
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal 
are not adequate methods of preventing drug exposure.  If  required per local 
guidelines or regulations, locally rec ognized adequate methods of contraception and 
information about the reliability of abstinence will be described in the local 
Informed  Consent Form.  
 
Exclusion Criteria  
Patients who meet any of the following criteria will be excluded from study entry:  
 Recur rent disease  6 months after curative surgery or 6 months after the completion of 
adjuvant therapy (chemotherapy and/or radiation)  
 Prior local regional therapy such as radioembolization  
 Combined or mixed hepatocellular/CCA  
 Clinically significant hepatic encephalopathy within the 12  months prior to Day  1 of Cycle  12 
 National Cancer Institute Common Terminology Criteria for Adverse Events Grade  2 
peripheral neuropathy  
 Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric 
varices within 6 months prior to Day 1 of Cycle 1  
Patients at high risk of esophageal varices are required to undergo an 
esophagogastroduodenoscopy (EGD) during screening or must have undergone an 
EGD within 6 months of Day  1 of Cycle  1.  All size of varic es (small to large) must be 
assessed and treated per local standard of care prior to Day  [ADDRESS_198209] one of the following:  
– Presence or history of cirrhosis  
– Presence or history of portal hypertension  
– Presence or history of primary biliary cirrhosis, or primary sclerosing cholangitis  
– HBV or HCV infection  
– Evidence of gross vascular invasion (portal vein, hepatic vein or collateral 
vessels)  
– Evidence of splenomegaly  
– Platelet count  120   109/L (120,000/ L) and albumin   36 g/L (3.6 g/dL)  
– Evidence of portal vein occlusion due to malignant invasion or constriction  
– Evidence of varices by [CONTACT_169836] —F. Hoffmann -La [COMPANY_002] Ltd  
20/Protocol GO42661 , Version 6  Active or history of autoimmune disease or immune deficiency, including, but not limited to, 
myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, 
rheumatoid arthritis, inflammatory bowel disease, a ntiphospholipid antibody syndrome, 
granulomatosis with polyangiitis , Sjögren syndrome, Guillain -Barré syndrome, or multiple 
sclerosis, with the following exceptions:  
Patients with a history of autoimmune -related hypothyroidism who are on 
thyroid -replacemen t hormone are eligible for the study.  
Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are 
eligible for the study.  
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only ( e.g., patients with psoriatic arthritis are excluded) are eligible for 
the study provided all of following conditions are met:  
– Rash must cover  10% of body surface area.  
– Disease is well -controlled at baseline and requires only low -potency topi[INVESTIGATOR_169782].  
– There is no occurrence of acute exacerbations of the underlying condition 
requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic 
agents, oral calcineurin inhibitors, or high -potency or oral corticosteroids within 
the 12  months prior to Day 1 of Cycle 1.  
 History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis 
obliterans), drug -induced pneumonitis, or idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest CT scan  
 Significan t cardiovascular disease (such as [LOCATION_001] Heart Association Class  II or greater 
cardiac disease, myocardial infarction, or cerebrovascular accident) within 3  months prior to 
Day 1 of Cycle  1, unstable arrhythmia, or unstable angina  
 History of malignancy o ther than BTC within 5 years prior to screening, with the exception 
of malignancies with a negligible risk of metastasis or death (e.g., 5 -year ove rall survival 
[OS] rate  90%), such as adequately treated carcinoma in situ of the cervix, non -melanoma 
skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine 
cancer  
 Symptomatic, untreated, or actively progressing CNS metastases  
Asymptomatic patients with treated CNS lesions are eligible, provided that all of the 
following criter ia are met:  
– Measurable disease, per RECIST v1.1, must be present outside the CNS.  
– The patient has no history of intracranial hemorrhage or spi[INVESTIGATOR_76918].  
– Metastases are limited to the cerebellum or the supratentorial region (i.e. , no 
metastases to  the midbrain, pons, medulla, or spi[INVESTIGATOR_1831]).  
– There is no evidence of interim progression between completion of CNS -directed 
therapy and initiation of study treatment.  
– The patient has not undergone stereotactic radiotherapy within 7  days prior to 
initiation of study treatment, whole -brain radiotherapy within 14  days prior to 
initiation of study treatment, and neurosurgical resection within 28  days prior to 
initiation of study treatment.  
– The patient has no ongoing requirement for corticosteroids as therapy for CNS 
disease.  Anticonvulsant therapy at a stable dose is permitted.  
– Asymptomatic patients with CNS metastases newly detected at screening are 
eligible for the study after receiving radiotherapy or surgery, with no need to 
repeat the screening b rain scan.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
21/Protocol GO42661 , Version 6  For patients with lung metastases, if one of the following criteria applies:  
– Large, centrally located pulmonary metastases  
– Clear tumor infiltration into the thoracic great vessels seen on imaging  
– Clear cavitation of pulmonary lesions seen on ima ging 
 Active tuberculosis  
 Severe infection within [ADDRESS_198210] patient safety  
 Treatment with therapeutic oral or IV antibiotics within 2  weeks prior to Day  1 of Cycle  1 
Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or 
chronic obstructive pulmonary disease [C OPD] exacerbation) are eligible for the study, 
provided the signs of active infection have resolved.  
 Prior allogeneic stem cell or solid organ transplantation  
 On the waiting list for liver transplantation  
 Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that contraindicates the use of an investigational drug, may affect the 
interpretation of the results, or may render the patient at high risk from treatment 
complications  
 Pregnant or breastfeeding, or intending to become pregnant during the study or within 
[ADDRESS_198211] result 
within 1 4 days prior to Day 1 of Cycle 1.  
 Co-infection with HBV and HCV  
Patients with a history of HCV infection but who are negative for HCV RNA by 
[CONTACT_169837].  
 Uncontrolled or symptomatic hypercal cemia (ionized calcium  1.5 mmol/L, 
calcium   12 mg/dL, or corrected serum calcium   ULN)  
 History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or 
fusion proteins  
 History of allergic reactions to cisplatin or other platinum -containing compounds  
 Known hypersensitivity to gemcitabine  
 Known hypersensitivity to Chinese hamster ovary cell products or to any component of the 
atezolizumab or bevacizumab formulations  
 Treatment with a live, attenuated vaccine within 4 weeks p rior to Day  1 of Cycle  1 or 
anticipation of need for such a vaccine during atezolizumab treatment or within 5  months 
after the final dose of atezolizumab  
 Treatment with investigational therapy within 4 weeks prior to Day  1 of Cycle  1 
 Prior treatment with C D137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], including 
antiCTLA -4, antiPD-1, and anti PD-L1 therapeutic antibodies  
 Treatment with systemic immunostimulatory agents (including, but not limited to, interferon 
and interleukin -2) within 4 weeks or 5 drug -elimination half -lives (whichever is longer) prior 
to Day 1 of Cycle 1  
 Treatment with systemic immunosuppressive medication (including, but not limited to, 
corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antiTNF- agents) within 2  weeks prior to Day  1 of Cycle  1 or anticipation of need for 
systemic immunosuppressive medication during study treatment, with the following 
exceptions:  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
22/Protocol GO42661 , Version 6 Patients who received acute, low -dose systemic immunosuppressant medication or 
a one-time pulse dose of systemic immunosuppressant medication (e.g., [ADDRESS_198212] allergy) are eligible for the  study . 
Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for 
COPD or asthma, or low -dose c orticosteroids for orthostatic hypotension or adrenal 
insufficiency are eligible for the study.  
 Inadequately controlled arterial hypertension (defined as systolic blood pressure 
[BP]  150 mmHg and/or diastolic BP 100 mmHg), based on an average of at leas t 3 BP 
readings at 2  or more sessions  
Anti-hypertensive therapy to achieve these parameters is allowed.  
 History of hypertensive crisis or hypertensive encephalopathy  
 Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent 
peripheral arterial thrombosis) within 6  months prior to Day  1 of Cycle  1 
 History of hemoptysis ( 2.5 mL of bright red blood per epi[INVESTIGATOR_1865]) within 1  month prior to 
Day 1 of Cycle  1 
 Evidence of bleeding diathesis or significant coagulopathy (in the absence of t herapeutic 
anticoagulation)  
 Current or recent (within 10  days of Day 1 of Cycle 1) use of aspi[INVESTIGATOR_248] ( 325 mg/day) or 
current or recent treatment with dipyridamole, ticlopi[INVESTIGATOR_5325], clopi[INVESTIGATOR_7745], and cilostazol  
 Current or recent (within 10  days prior to Day 1 of C ycle 1) use of full -dose oral or 
parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to 
prophylactic) purpose  
Prophylactic anticoagulation for the patency of venous access devices is allowed 
provided the activity of the agent resul ts in an INR 1.5 ULN and aPTT is within 
normal limits (according to institutional standards) within 14 days prior to Day  1 of 
Cycle  1. 
Prophylactic use of low -molecular -weight heparin (i.e., 40  mg/day enoxaparin) is 
allowed.  However, the use of direct oral anticoagulant therapi[INVESTIGATOR_169783] 
(Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk.  
 Core biopsy or other minor surgical procedure, excluding placement of a vascular access 
device, within 3  days prior to Day  1 of C ycle 1 
 History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or 
intra-abdominal abscess within 6 months prior to Day  1 of Cycle  1 
 Evidence of abdominal free air that is not explained by [CONTACT_169838] 
 Serious, non -healing or dehiscing wound, active ulcer, or untreated bone fracture  
 Major surgical procedure within 4 weeks prior to Day 1 of Cycle 1 or anticipation of need for 
a major surgical procedure during the study  
 History of clinically significan t and uncontrolled intra -abdominal inflammatory disease within 
6 months prior to Day 1 of Cycle 1, including, but not limited to, peptic ulcer disease, 
diverticulitis, or colitis  
 Chronic daily treatment with a non -steroidal anti -inflammatory drug (NSAID)  
Occasional use of NSAIDs for the symptomatic relief of medical conditions such as 
headache or fever is allowed.  
 Preexisting renal impairment, myelosuppression, or hearing impairment  
 
END OF STUDY  
The end of this study is defined as the date at which the la st data required for study analysis are 
collected.   The end of study will occur once the last patient, last visit occurs following  the final 
OS analysis.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
23/Protocol GO42661 , Version [ADDRESS_198213] patient to the end of the study, is 
expected to be approximately 3 5 years.  
In addition, the Sponsor may decide to terminate the study at any time.  
If the Sponsor decides to terminate the study, patients who are still receiving study treatment or 
undergoing survival follow -up may b e enrolled in an extension study or a non -interventional 
study, if available.  
INVESTIGATIONAL MEDI CINAL PRODUCTS  
The investigational medicinal products (IMPs) for this study are atezolizumab and 
bevacizumab/placebo.  Cisplatin and gemcitabine are considere d non -IMPs.  
TEST PRODUCTS (INVES TIGATIONAL DRUGS)  
Atezolizumab will be administered by [CONTACT_22671] a fixed dose of 1200  mg every 3  weeks 
(Q3W) on Day 1 of each 21 -day cycle until unacceptable toxicity or loss of clinical benefit as 
determined by [CONTACT_169839], and clinical status.  
Bevacizumab (Arm A) at a dose of 15 mg/kg or matching placebo (Arm B) will be administered 
after atezolizumab by [CONTACT_95077] 1 of each 21 -day cycle.  There will be a minimum 
5-minute gap between administration of atezolizumab and bevacizumab/placebo.  
NON -INVESTIGATIONAL MEDICINAL PRODUCTS  
Cisplatin will be administered by [CONTACT_22671] a dose of 25 mg/m2 followed by [CONTACT_169840] 
a dose of 1000 mg/m2 on Days  [ADDRESS_198214] tumor 
assessment at which they were known to be progression -free with radiographic evidence as of 
the clinical cutoff date.  Patients with no postbaseline tumor assessment will be censored at the 
date of randomization.  
A stratified Cox proportional -hazards model will be used to estimate the PFS HR and its  95% 
CI.  A stratified two -sided log -rank test will be used to compare the investigator -assessed PFS 
between Arm A and Arm B at the two -sided significance level of 0.05.  The stratification factors 
for these stratified analyses are location of primary tumor (iCCA vs. eCCA vs. GBC), metastatic 
disease (yes vs. no), and geographic region (Asia vs. rest of the world).  However, if at least 
one stratum has fewer than [ADDRESS_198215] number of events will be combined with other levels of the same 
stratification factor for the stratified analysis.  The final set of stratification factors used in the 
primary endpoint analysis wi ll be applied to all other endpoints where stratified analyses are 
performed.  The  stratification information will be obtained from the IxRS at the time of 
randomization.  Results from an unstratified analysis will also be provided.  The Kaplan -Meier 
metho d will be used to estimate median PFS for each treatment arm.  The Brookmeyer -Crowley 
methodology will be used to calculate the 95% CI for the median PFS of each treatment arm.  
To assess the homogeneity of the treatment effect with respect to the primary e fficacy endpoint 
of PFS, forest plots (including the estimated HRs) for clinically relevant subgroups will be 
provided.  
To assess the robustness of the primary PFS analysis, a sensitivity analysis will be performed 
by [CONTACT_169841] -cancer therapy prior 
to occurrence of radiographic progression.  These patients will be censored at the last tumor 
assessment before start of the new treatment, regardless of progression or death afterwards.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
24/Protocol GO42661 , Version [ADDRESS_198216] 
of atezolizumab with bevacizumab in combination with CisGem (Arm A) on PFS relative to 
atezolizumab in combination with CisGem (Arm B).  Point and CI estimates of the true 
underlying HR of comparing PFS between Arm A and Arm B will be calculated.  A total of 
approximately 150 patients will be randomized at a 1:1 randomization ratio to either Arm  A or 
Arm B.  It is assumed that the median duration  of PFS in the control arm (Arm B) is 9  months.  
Operating characteristics (statistical power  based on a two -sided significance level of 0.05 and 
expected total number of events) at the time of the final PFS analysis will occur when 
approximately [ADDRESS_198217] been observed.  The planned sample size of 150  patients, 
targeting approximately 90  PFS events at the time of the final PFS analysis, is considered to 
provide sufficient data and precision for the purpose of estimation of the HR point estimate an d 
its 95% CI.  
INTERIM ANALYSES  
One interim analysis of PFS and objective response rate will be performed at the time when 
[ADDRESS_198218] full access t o unblinded data at the time of analysis.  Access to treatment assignment 
information will follow the Sponsor's standard procedures and will not be given to the Sponsor 
until the first interim analysis within this study is being conducted.  
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
25/Protocol GO42661 , Version [ADDRESS_198219] computed tomography  (scan)  
DCR  disease control rate  
DOR  duration of response  
EC Ethics Committee  
eCCA  extrahepatic cholangiocarcinoma  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
EGD  esophagogastroduodenoscopy  
EORTC  European Organisation for Research and Treatment of Cancer  
Fc fragment crystallizable  
FDA (U.S.) Food and Drug Administration  
FFPE  formalin -fixed, paraffin -embedded  
GBC  gallbladder cancer  
GHS/QoL  Global Health Status/Quality of Life  
GI gastrointestinal  
HBcAb  hepatitis B core antibody  
HBsAb  hepatitis B surface antibody  
HBsAg  hepatitis B surface antigen  
HBV hepatitis B virus  
HCC  hepatocellular carcinoma  
HCV  hepatitis C virus  
HIPAA  Health Insurance Portability and Accountability Act  
HLH hemophagocytic lymphohistiocytosis  
HR hazard ratio  
iCCA  intrahepatic cholangiocarcinoma  
ICH International Council for Harmonisation  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
26/Protocol GO42661 , Version [ADDRESS_198220]  
IND Investigational New Drug (Application)  
IRB Institutional Review Board  
IRF independent review facility  
IRR infusion -related reaction  
LMWH  low molecular weight heparin  
ITT intent -to-treat 
IxRS  interactive voice or Web-based response system  
MAS  macrophage activation syndrome  
MDSC  myeloid -derived suppressor cell  
MRI magnetic resonance imaging  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for 
Adverse Events  
NSAID  non-steroidal anti -inflammatory  
NSCLC  nonsmall -cell lung cancer  
ORR  objective response rate  
OS overall survival  
PFS progression -free survival  
PGI-CI Patient -Reported Global Impression of Change and 
Its Importance  
PGI-S Patient -Reported Global Impression of Severity  
PK pharmacokinetic s 
PR partial response  
PRO  patient -reported outcome  
PRO -CTCAE  Patient -Reported Outcome Common Terminology Criteria for 
Adverse Events  
Q3W  every [ADDRESS_198221]  Response Evaluation Criteria in Solid Tumors  
SARS -CoV-2 severe acute respi[INVESTIGATOR_6507] 2  
SD stable disease  
T3 free triiodothyronine  
T4 free thyroxine  
TAM  tumor -associated macrophage  
TME  tumor microenvironment  
Treg regulatory T -cell 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
27/Protocol GO42661 , Version [ADDRESS_198222] upper limit of normal  
VEGF  vascular endothelial growth factor  
WES  whole exome sequencing  
  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
28/Protocol GO42661 , Version [ADDRESS_198223] cancers (BTC s) represent a heterogeneous  group of epi[INVESTIGATOR_169784].  Biliary tract cancers include  cholangiocarcinoma (CCA) as 
well as gallbladder cancer (GBC) and ampul la of Vater cancer.  Classification of CCA is  
based on the anatomical site of origin and can be subdivided into intrahepatic CCA 
(iCCA) , arising from the liver , and extrahepatic CCA (eCCA) , arising from the 
extrahepatic bile ducts.  Extrahepatic CCA can be  further segmented into  perihilar and 
distal subtypes.  
Cholangiocarcinoma  currently account s for approximately 15% of all  primary liver 
cancers and approximately 3% of gastrointestinal  (GI) malignancies 
(Banales  et al. 2020) .  Globally, the incidence and mortality rates of BTC show 
substantial geographical variation, presumably reflecting differences in geographical risk 
factors and possibly genetic determinants.  The incidence of CCA is manifold higher in 
Asia compared with Western countries.  Both the incidence and mortality of CCA are 
increasing, primarily because of a global rise in iCCA.  The incidence of GBC is highest 
in Asian countries, as well as countries in Latin America.  
At the time of diagnosis , 70%90% of patients w ith BTC present with unresectable 
locally advanced or metastatic disease.  Cholangiocar cinomas  are usually asymptomatic 
in early stages and  are therefore  often diagnosed when the disease is already in 
advanced stages , resulting in a dismal prognosis.  
A silent early presentation , coupled with a highly aggressive nature and refractoriness to 
chemotherapy , contribute to a poor prognosis.  Even for patients with resectable 
disease, postoperative recurrence in  60% of cases is reported within the first or second 
year following surgery (Jung et al . 2012) regardless of adjuvant treatment.  
Unresectable, recurrent , or metastatic BTCs are collectively termed advanced BTC . 
1.[ADDRESS_198224] of care f or advanced BTC is the combination of cisplatin 
and gemcitabine (hereafter referred to as CisGem ) based on the results of the 
ABC-02 Phase III study (Valle et al. 2010).  Compared with single -agent gemcitabine, 
CisGem  conferred a statistically significant overall survival ( OS) advantage ( hazard ratio 
[HR]: 0.64; 95% CI : 0.52 to 0.80; p 0.001 ; median OS 11.7 vs. 8.1  months ).  In addition, 
CisGem  also significantly improved progression -free survival ( PFS) and disease control 
rate (DCR).  These data have been  conﬁrmed in subsequent randomized studies  
(Okusaka et al. 2010; Sakai et al. 2018; Morizane et al. 2019) . 
The limited benefit of first -line treatment with CisGem  highlights the need for more 
effective agents and treatment combinations to improve patient outcomes.  
Comprehensive genomic profiling has identified several potentially actionable oncogenic 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
29/Protocol GO42661 , Version 6 alterations in patients with CCA, notably FGFR2  and IDH, leading to the development of 
molecularly  targeted agents in biomarker -selected patients ( Lamarca et al. 2020 ).  
However, FGFR2  and IDH mutations are largely confined to  20% patients with iCCA  
and are far less common in eCCA or GBC  BTC malignancies.  Therefore, there remains  
a significant  unmet need for more effective treatments for advanced BTC . 
1.2.[ADDRESS_198225] Cancer  
Vascular endothelial growth factor ( VEGF ), a primary growth factor regulating 
angiogenesis, is over-expressed  in 45 %75% of BTCs.  Vascular endothelial growth 
factor  expression is associated with the presence of metastases in iCCA; poorer 
prognosis in eCCA , and increased microvascular density in both CCA and GBC.  
These  observations have made VEGF -driven angiog enesis a logical target in BTC.  
Despi[INVESTIGATOR_169785], a series of randomized 
Phase II trials in which anti -VEGF agents were added to first -line chemot herapy have 
failed to demonstrate improved clinical benefit.  The ABC -[ADDRESS_198226]  
of adding cediranib (an oral VEGFR1, VEGFR2, and VEGFR3 tyrosine  kinase inhibitor, 
with additional activity against PDGF receptors and c -KIT) to CisGem  on PFS in patients 
with advanced BTC (Valle et al. 2015).  The study failed to meet its primary PFS 
endpoint ( HR: 0.93; 80% CI: 0.74 to 1.19; p   0.72), although the objective response rate 
(ORR ), a secondary endpoint,  was significantly incr eased in the cediranib arm 
(44%  vs. 19%; p  0.0036).  Study I3O -MC-JSBF evaluated the addition of ramucirumab 
(a VEGFR2 antibody) to CisGem  in patients with advanced BTC.  The addition of 
ramucirumab to CisGem  did not improve the primary endpoint of PFS (HR : 1.123, 
p  0.4821), or OS or ORR , both secondary endpoints (Valle et al . 2020) .  Gemcitabine 
combined with sorafenib (a multikinase inhibitor targeting proliferative and angiogenic 
pathways) failed to improve PFS compared with gemcitabine alone 
(Moehler  et al. 2014).  
Bevacizumab -based chemotherapy combinations have been studied in patients with 
advanced BTC in a series of single -arm Phase II studies.  The combination of 
bevacizumab with gemcitabine/oxaliplatin resulted in a n ORR  of 40%, a median PFS of 
7 months,  and a median OS of 12.7  months  (Zhu et al. 2010) .  The combination of 
bevacizumab, gemcitabine , and capecitabine led to an ORR of 24%, a median PFS of 
8.1 months , and a median OS of 10.2 months (Iyer et al . 2018).   In both studies, the 
addition of bevaciz umab to chemotherapy did not improve outcomes in patients with 
advanced BTC , compared with historical controls.  Both studies concluded that the 
respective bevacizumab combinations were  associated with  manageable toxicity.  
1.2.[ADDRESS_198227] Cancer  
Cancer immunotherapy (CIT) with antibodies targeting the PD -1/PD -L1 axis has 
changed the standard of care in multiple cancers, including hepatocellular carcinoma 
(HCC) .  Cancer immunotherapy  approaches have garnered significant interest in BTC , 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
30/Protocol GO42661 , Version 6 given their etiologic association with inflammation as well as relatively high levels of 
expression of PD -L1.  However, the role of PD -1/PD -L1 inhibition in BTC remains to be 
established and existing clinical data are limited to small single -arm studies a nd 
sub-analyses of basket trials.  To date, the efficacy of single -agent antiPD-1/PD -L1 
antibodies has been disappointing and, in most cases, reported ORRs are 
10% (Kelley  et al. 2020).  In the largest study published to date (KEYNOTE -158), the 
ORR was 5 .8% in 104 patients with advanced , previ ously treated BTC 
(Bang  et al. 2019).  Currently, the role of antiPD-L1 antibodies in BTC is limited to 
patients with deficient mismatch repair and microsatellite instability high, which 
represent   5% of all patien ts (Lamarca  et al. 2020a).  
Relatedly, antiPD-[ADDRESS_198228] failed to improve OS in 
unresectable HCC, and a retrospective series indicate that liver metastases are less 
responsive to PD -1 inhibition compared with other anatomic sit es (Tumeh  et al. 2017; 
Yau et al. 2019; Finn et al. 2020 ).  These observations point to the highly 
immunosuppressed nature of the liver tumor microenvironment ( TME ) in the setting of 
primary or secondary hepatic tumors.  
Given the apparent limitations of antiPD-L1 antibody monotherapy in BTC, there is 
strong interest in developi[INVESTIGATOR_169786] -suppressive mechanisms and promote anti-cancer  immunity.  
Cancers harness several mechanisms of immune escape to restrain or evade antitumor 
immune responses, including modulation of the TME to create an immunosuppressive 
milieu that d ictates responsiveness to CIT.  
In most BTCs, the TME is frequently characterized by [CONTACT_169842] T -cell infiltration 
and overexpress ion of immunosuppressive cell types such as tumor -associated 
macrophages (TAMs), myeloid -derived suppressor cells (MDSCs), regulatory T -cells 
(Tregs), and immature dendritic cells.  These TME components are believed to be 
essential in restraining anti -canc er immunity and fostering BTC progression through 
various mechanisms such as angiogenesis (Loeuillard et al. 2019; Fabris et al. 2020).  
Infiltration of immunosuppressive cells such as TAMs and MDSCs is associated with 
poor patient outcomes.  
PD-L1 blockade , in combination with agents targeting immune suppressive mechanisms 
within the TME , is a rational approach, including with both chemotherapy and anti -VEGF 
drugs , to promote a more immune -permissive TME.  
1.3 BACKGROUND ON ATEZOLIZUMAB  
Atezolizumab  is a human ized IgG1 monoclonal antibody that targets PD -L1 and inhibits 
the interaction between PD -L1 and  its receptors, PD -1 and B7 -1 (also known as CD80) , 
both of which function as inhibitory receptors expressed on T  cells.  Therapeutic 
blockade of PD -L1 binding by [CONTACT_169843] —F. Hoffmann -La [COMPANY_002] Ltd  
31/Protocol GO42661 , Version 6 and quality of tumor -specific T -cell respon ses, resulting in improved anti -tumor activity  
(Fehrenbacher et al. 2016; Rosenberg et al. 2016) .  Atezolizumab  has minimal  binding  
to fragment crystallizable ( Fc) receptors, thus eliminating d etectable F c-effector function  
and associated antibody -mediated cl earance of activated effector T  cells.  
Atezolizumab shows anti -tumor activity in both nonclin ical models and patients with 
cancer and is being investigated a s a potential therapy in a wide variety of malignancies.  
Atezolizumab is being studied as a single agent treatment in the advanced cancer and 
adjuvant therapy settings, as well as in combination with chemotherapy, targeted 
therapy, and CIT. 
Atezolizumab i s approved for the treatment of urothelial carcinoma , nonsmall -cell lung 
cancer  (NSCLC) , small -cell lung cancer , triple -negative breast  cancer , hepatocellular 
carcinoma, and melanoma . 
See the Atezolizumab Investigator's Brochure for details on nonclinical and clinical 
studies.  
1.[ADDRESS_198229] granted marketing approval in the [LOCATION_002] on 
26 February  2004 in combination with IV 5 fluorouraci l-based chemotherapy for the 
first-line treatment of patients with metastatic carcinoma of the colon or  rectum.  
Bevacizumab is approved in over 100 countries for one or more of the following 
indications:  breast cancer, NSCLC, renal cell cancer, glioblastoma multiforme, cervical 
cancer, epi[INVESTIGATOR_76296], primary peritoneal cancer, and fallopi[INVESTIGATOR_169787].  
See the Bevacizumab Investigator's Brochure for details on nonclinical and 
clinical  studies.  
1.5 STUDY RATIONALE AND BENEFIT RISK ASSESSMENT  
1.5.1  Rationale for Combining Chemotherapy with AntiPD-1/PD-L1 
Antibodies  
Chemotherapy can induce a number of positive immunomodulatory effects in the TME , 
such as induction of immunogenic cell death and/or depleting immunosuppressive cells 
(Galluzzi et al . 2015 ; Heinhuis et al . 2019 ), providing a rationale to combine with 
antiPD-1/PD -L1 antibodies .  Multiple cli nical studies have demonstrated that 
chemotherapy, including CisGem , can be effectively and safely combined with 
antiPD-1/PD-L1 antibodies in patients with c ancer (Galsky et al. 2020).  
The immunomodulatory effects of chemotherapy differ according to the type of drug 
used ( Wu and Waxman  2018 ).  Both cisplatin and gemcitabine have been shown to 
downregulate immune suppressive cells in the TME but are ineffective in inducing 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
32/Protocol GO42661 , Version 6 immunogenic cell death (Hato et al . 2014;  Galluzi et al . 2017 ).  This latter observation 
may limit the immune -potentiating effect of CisGem . 
To date, antiPD-L1 antibodies in combination with CisGem have been studied in small 
single -arm studies  in BTC (Ueno et al. 2019; Feng et al.  2020) .  Despi[INVESTIGATOR_169788] r ates, PFS and OS in these non -randomized studies were  disappointing , 
relative to the data for CisGem  alone from randomized studies .  This observation may 
suggest that additional treatment modalities may be required to further amplify the 
immune response.  
1.5.2  Rationale for Combined I nhibition of PD -L1 and VEGF  
Many immune -suppressive components of the BTC TME are thought to be regulated by 
[CONTACT_12270], providing a therapeutic rationale to explore dual blockade of PD -L1 and VEGF 
pathways in order to promote anti -cancer immunity.  Excessive levels of VEGF within the 
TME can induce tumor -associated immunosuppression either directly or indirectly by 
[CONTACT_3553]  4 princip al mechanisms:  1) inhibition of dendritic cell maturation and antigen 
presentation; 2) inhibition of cytotoxic T -cell proliferation, trafficking , and infiltration; 
3) promotion of an aberrant tumor vasculature ; and 4) recruitment and proliferation of 
MDSCs , Tregs , and pro -tumor M2 -TAMs ( Fukumura  et al.  2018 ).  Therefore, 
T cellmediated cancer -cell killin g by [CONTACT_4002] -L1 blockade could be enhanced through the 
reversal of VEGF -mediated immunosuppression mechanisms by [CONTACT_169844]-VEGF  therapy.   Combination treatment with anti PD-L1 and anti -angiogenic agents 
is now a standard of care in renal cell carcino ma (RCC) , NSCLC , and HCC , based on 
the results of Phase III studies.  
Combined PD -L1 and VEGF inhibition with atezolizumab and bevacizumab in pati ents 
with HCC was studied in 2  randomized studies.  In Arm F of Study  GO30140, 
119 patients with unresectable HCC were randomly assigned in a 1:1 ratio to receive 
either atezolizumab alone or atezolizumab in combination w ith bevacizumab.  
A statistically and clinically significant improvement in independent review facility 
(IRF)-assessed  PFS per Response Evaluation Criteria in Solid Tumors, Version  1.1 
(RECIST v1.1 ) was observed in the combination arm versus atezolizumab monotherapy 
(HR0.55; 80% CI : 0.40 to 0.74; p   0·0108)  (Lee et al. 2020) .  Study YO40245 
(IMbrave150 ) was a randomized Phase III study in which 501 patients with unresecta ble 
HCC were randomly assigned in a 2:1 ratio to receive either atezolizumab plus 
bevacizumab or sorafenib.  Combination treatment with atezolizumab plus bevacizumab 
resulted in a statis tically and clinically significant improvement in OS (HR: 0.58; 
95% CI: 0.42 to 0.79; p   0.0006) , PFS (HR0.59; 95% CI: 0.47 to 0.76; p 0.0001) , and 
ORR  (27% vs. 12%; p  0.0001) compared with sorafenib (Finn et al. 2020 ).  In 
a post-hoc analysis of Study  GO30140, the PFS benefit of atezolizumab and 
bevacizumab compared with atezolizumab alone was enhanced in patients with HCC 
harboring myeloid, Treg , and VEGFR2 immunosuppressive gene signatures (Zhu et al . 
2020).  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
33/Protocol GO42661 , Version 6 The effectiveness of combined PD -1/PD-L1 and VEGF inhibition in BTC is yet to be 
established , with available data limited to small Phase I studies  (Arkenau et al. 2018; 
Lin et al. 2018 ). 
1.5.3  Rationale for Combin ing AntiPD-L1, Anti-VEGF , and 
Chemotherapy  
The highly immunosuppressed nature of the TME in BTC , coupled with the limited 
clinical activity of PD -[ADDRESS_198230] immunomodulatory effects, is one such approach.  This combination has 
yet to be evaluated in BTC.  
Published Phase III data in other tumor types such as NSCLC support the rationale  for 
the combination of platinum -based chemotherapy, atezolizumab and bevacizumab  in 
BTC.  In patients with metastatic non -squamous NSCLC , the addition  of atezolizumab to 
bevacizumab plus chemotherapy significantly improved PFS and OS compared with 
bevaciz umab plus chemotherapy  (Socinski et al. 2018) .  Importantly, i n a pre-specified  
analysis of patients with baseline liver metastases,  atezolizumab  plus bevacizumab  and 
chemotherapy significantly improved OS and PFS in patients with liver metastases.  
Conver sely, neither atezolizumab plus chemotherapy nor bevacizumab combined with 
chemotherapy prolong ed OS or PFS in patients with liver metastases (Reck et al. 2019).   
This finding  indicates that the dual targeting of PD -L1 and VEGF with a chemotherapy 
backbone  may be needed to induce clinically meaningful antitumor immunity in hepatic 
tumors.  These data provide clinical proof  of principle to evaluate the atezolizumab, 
bevacizumab , and CisGem  combination regimen in BTC.  
On the basis of the compelling rationale described above and expected clinical benefit 
with the combination of atezolizumab, bevacizumab, and CisGem  and the well -defined 
safety profile of each approved drug as single agent and in combination , the Sponsor 
believes that the potential benefits of the combination outweigh its risks in the treatment 
of advanced -stage BTC, which remains an incurable disease with a high unmet medical 
need.  
The overall benefit risk ratio for atezolizumab in combination bevacizumab and CisGem 
is expected to be acceptable in this setting.  
1.5.4  Benefit -Risk Assessment during the COVID -19 Pandemic  
In the setting of the coronavirus disease 2019 (COVID -19) pandemic, patients with 
comorbidities, including those with cancer, are considered a mor e vulnerable population, 
with the potential for more severe clinical outcomes from severe acute respi[INVESTIGATOR_11520]  2 (SARS -CoV-2) infection .  However, it is unclear whether or how 
systemic cancer therapi[INVESTIGATOR_19335], targeted thera py, or immunotherapy 
impact the incidence or severity of SARS -CoV-2 infection . 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
34/Protocol GO42661 , Version 6 A possible consequence of inhibiting the PD -1/PD -L1 pathway may be the modulation of 
the host immune response to acute infection, which may result in immunopathology or 
dysregulated immune system defenses.  In nonclinical models, PD -1/PD -L1 blockade 
appears to be associated with serious exacerbation of inflammation in the setting of 
acute (as opposed to chronic) viral infection with lymphocytic cho riomeningitis virus 
(Clone 13; Frebel  et al. 2012).  However, there are insufficient and inconsi stent clinical 
data to assess if the outcome from SARS -CoV-2 infection  is altered by [CONTACT_169845]. 
Severe SARS -CoV-2 infection  appears t o be associated with a cytokine release 
syndrome (CRS) in volving the inflammatory cytokines IL -6, IL-10, IL -2, and interferon - 
(Merad  and Martin  2020).  While it is not known , there may be a potential for 
an increased  risk of an enhanced inflammatory response if a patient develops acute 
SARS -CoV-[ADDRESS_198231] the efficacy and safety of COVID -19 vaccination (S ociety 
for Immunotherapy of Cancer [SITC ] 2020) . 
Per recommendations of the National Comprehensive Cancer Network  (NCCN) 
COVID -19 Vaccination Advisory Committee, COVID -19 vaccination is recommended for 
all patients with cancer receiving active therapy (inc luding immune checkpoint inhibitors), 
with the understanding that there are limited safety and efficacy data in such patients 
(NCCN  2021).  Given the lack of clinical data, currently no recommendations can be 
made regarding the optimal sequence of COVID -19 vaccination in patients who are 
receiving cancer immunotherapy ( SITC 2020).  For patients enrolling in this study and 
receiving atezolizumab treatment, a decision to administer the vaccine to a patient 
should be made on an individual basis by [CONTACT_169846].  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
35/Protocol GO42661 , Version 6 In alignment with clinical practice procedures, factors to consider when making the 
individualized decision for patients receiving atezolizumab treatment to receive 
COVID -19 vaccination include the following:  the ris k of SARS -CoV-[ADDRESS_198232] be given in accordance with the approved or 
authorized vacci ne label.  Receipt of the COVID -19 vaccine is considered a concomitant 
medication and should be documented as such (see Section  4.4.1 ). 
2. OBJECTIVES  AND ENDPOINTS  
This study will evaluate the efficacy and safety of atezolizumab with bevacizumab in 
combination with CisGem , compared with atezolizumab in combination with CisGem , in 
patients with advanced BTC (i.e., iCCA, eCCA, or GBC) who have not received prior 
systemic therapy .  Specific objectives and corresponding endpoints for the study are 
outlined in Table  1. 
In this protocol, study treatment  refers to the combination of treatments assigned 
to patients as part of this study .  Patients will receive one of the following combination s 
of treatments (see  Section  3.1 for details):  
 Atezolizumab   Bevacizumab   chemotherapy ( CisGem ), followed by 
[CONTACT_120422]   Bevacizumab  
 Atezolizumab   Placebo   chemotherapy ( CisGem ), followed by 
[CONTACT_120422]   Placebo  
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
36/Protocol GO42661 , Version 6 Table  1 Objectives and Corresponding Endpoints  
Primary Efficacy Objective  Corresponding Endpoint  
 To evaluate the efficacy of 
Atezo   Bev   CisGem compared 
with Atezo   PBO   CisGem   PFS, defined as the time from randomization to the first 
occurrence of disease progression as determined by 
[CONTACT_3143] v1.1 or death 
from any cause (whichever occurs first)  
Secondary Efficacy Objective  Corresponding Endpoints  
 To evaluate the efficacy of 
Atezo   Bev   CisGem compared 
with Atezo   PBO   CisGem   OS, defined as the time from randomization to death 
from any cause  
 Confirmed ORR, defined as the proportion of patients 
with a CR or PR on two consecutive occasions 
 [ADDRESS_198233] v1.1  
 DOR , defined as the time  from the first occurrence of 
a confirmed objective respon se to disease progression 
as determined by [CONTACT_3142]  v1.1 or death from any cause 
(whichever  occurs first)  
 DCR, defined as the proportion of patients with a CR or 
a PR on two consecutive occasions   [ADDRESS_198234]  v1.1 
 TTCD in patient -reported physical functioning, role 
functioning, and quality of life, as measured by [CONTACT_169825] -C30 and/or 
EORTC IL77, and defi ned as the time from 
randomization to the first clinically meaningful 
deterioration that is either maintained for 
two consecutive assessments or followed by [CONTACT_120418] 3 weeks  
Exploratory Efficacy Objective  Corresponding Endpoints  
 To evaluate the efficacy of 
Atez   Bev   CisGem compared 
with Atezo   PBO   CisGem   PFS rates a t specified timepoints (e.g., 6  months and 
12 months), defined as  the probability that a  patient  will 
be alive without experiencing disease progression , as 
determine d by [CONTACT_941] i nvestigator according to 
RECIST  v1.1,  at specified timepoints  
 OS rates at specific timepoints (e.g., 6  months and 
12 months), defined as the probability that a patient will 
be alive at specified timepoints  
 Mean scores and changes in mean scores from 
baseline in all scales of the EORTC QLQ -C30, EORTC 
IL77, and EORTC QLQ -BIL21  
 Proportion of responses on the PGI -CI and PGI -S 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
37/Protocol GO42661 , Version 6 Table  1 Objectives and Corresponding Endpoints  (cont.)  
Safety Objective  Corresponding Endpoints  
 To evaluate the safety of 
Atezo   Bev   CisGem compared 
with Atezo   PBO   CisGem   Incidence and severity of adverse events, with severity 
determined according to NCI  CTCAE v5.0  
 Change from baseline in targeted vital signs  
 Change from baseline in targeted clinical laboratory 
test results  
Exploratory Safety Objective  Corresponding Endpoint s 
 To evaluate the treatment -related 
tolerability of Atezo   Bev   CisGem 
compared with 
Atezo   PBO   CisGem from the 
patient perspective   Frequency, severity, interference, and/or presence of 
select symptomatic treatment toxicities, as determined 
through use of the PRO -CTCAE  
 Change from baseline in select symptomatic treatment 
toxicities, as determined by [CONTACT_169847] -CTCAE  
 Overall troublesomeness with treatment, as determined 
by [CONTACT_169848] e ffects single item of the 
EORTC  QLQ -BIL21  
Pharmacokinetic Objective  Corresponding Endpoint  
 To characterize the 
pharmacokinetics of atezolizumab  
when given in combination with 
bevacizumab  and/or CisGem   Serum concentration of atezolizumab at specified 
timepoints  
Immunogenicity Objective  Corresponding Endpoint  
 To evaluate the immune response 
to atezolizumab   Prevalence of ADAs to atezolizumab at baseline and 
incidence of ADAs to atezolizumab during the study  
Exploratory Immunogenicity 
Objective  Corresponding Endpoint  
 To evaluate potential effects of 
ADAs   Relationship between ADA status and efficacy, safety, 
or PK endpoints  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
38/Protocol GO42661 , Version 6 Table  1 Objectives and Corresponding Endpoints (cont.)  
Exploratory Biomarker Objective  Corresponding Endpoint  
 To identify and/or evaluate biomarkers 
that are predictive of response to study 
treatment (i.e.,  predictive biomarkers), 
are early surrogates of efficacy, are 
associated with progression to a more 
severe disease state (i.e.,  prognostic 
biomarkers), are assoc iated with 
acquired resistance to study treatment, 
are associated with susceptibility to 
developi[INVESTIGATOR_169789] (i.e.,  safety biomarkers), 
can provide evidence of study treatment 
activity  (i.e., pharmacodynamic 
biomarkers), or can increase the 
knowledge and understanding of disease 
biology and drug safety   Relationship between biomarkers in blood, 
serum, plasma, and tumor tissue  and efficacy, 
safety, PK, immunogenicity, or other biomarker 
endpoints  
ADA   anti-drug antibody; Atezo   atezolizumab; Bev   bevacizumab; CisGem   cisplatin and 
gemcitabine;  CR   complete response; DCR   disease control rate; DOR   duration of response; 
EORTC   European Organisation for Research and Treatment of Cancer;  IL  Item Library; 
NCI CTCAE   National Cancer Institute Common Terminol ogy Criteria for Adverse Events ; 
ORR   objective response rate; OS   overall survival; PBO   placebo; PFS   progression -free 
survival; PGI-CI  Patient Global Impression of Change, Importance; PGI -S  Patient Global 
Impression of Severity; PK   pharmacokinetic;  PR   partial response; 
PRO -CTCAE   Patient -Reported Outcome Common Terminology C riteria for Adverse Events; 
QLQ -BIL21   Quality -of-Life Questionnaire for Cholangiocarc inoma and Cancer of the 
Gallbladder; RECIST   Response Eval uation Criteria in Solid Tumors ; SD   stable disease; 
TTCD   time to confirmed deterioration.  
 
3. STUDY DESIGN  
3.1 DESCRIPTION OF THE S TUDY  
This is a Phase  II, randomized, double -blind, placebo -controlled , multicenter  study 
designed to evaluate the efficacy and safety of atezolizumab with bevacizumab in 
combination with CisGem , compared with  atezolizumab in combination with CisGem , in 
patients with advanced BTC (i.e., iCCA, eCCA, or GBC ) who have not received prior 
systemic therapy.  
The study will enroll globally approximately 150 patients , who will be  randomized in 
a 1:1 ratio to one of two treatment arms .  The number of patients with either eCCA or 
GBC will  be capped at a maximum of  50% of the total number of patients enrolled.  
Treatment  will consist of a chemotherapy combination phase  followed by a CIT/ placebo 
phase  as outlined in  Table  2. 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
39/Protocol GO42661 , Version 6 Table  2 Study Treatment  
Treatment 
Arm Dose, Route, and Regimen  
(Drugs Listed in Order of Administration)  
Chemotherapy Combination Phase a 
Cycles 18 
(21-Day Cycles)  CIT/Placebo Phase  
Cycles 9 and Beyond  
(21-Day Cycles)  
Arm A  Atezo   Bev   CisGem  
 Atezolizumab 1200 mg IV on Day 1  
 Bevacizumab 15 mg/kg IV on Day 1  
 Cisplatin 25 mg/m2 IV on Days  1 and 8  
 Gemcitabine 1000 mg/m2 IV on Days  1 
and 8  Atezo   Bev 
 Atezolizumab 1200 mg IV on Day 1  
 Bevacizumab 15 mg/kg IV on Day 1  
Arm B  Atezo   PBO   CisGem  
 Atezolizumab 1200 mg IV on Day 1  
 Placebo IV on Day 1  
 Cisplatin 25 mg/m2 IV on Days  1 and 8  
 Gemcitabine 1000 mg/m2 IV on Days  1 
and 8  Atezo   PBO  
 Atezolizumab 1200 mg IV on Day  1 
 Placebo IV on Day 1  
Atezo   atezolizumab; Bev   bevacizumab; CisGem   cisplatin and gemcitabine; CIT   cancer 
immunotherapy; PBO   placebo.  
a Treatment during the chemotherapy combination phase will be administered on a [ADDRESS_198235].  
 
Randomization will be stratified according to the following stratification factors:  
 Location of primary tumor ( iCCA  vs. eCCA  vs. GBC ) 
 Metas tatic disease (yes vs. no) 
 Geographic region (Asia vs. rest of the world ) 
 
Patients who do not meet the criteria for participation in this study (screen failure) may 
qualify for 1 re-screening opportunity (for a total of 2 screenings per participant) at the 
investigator's discretion.  Patients are not required to re -sign the Informed  Consent  Form 
if they are re -screened within [ADDRESS_198236] reasons for screen failure in the 
screening log  (see Section  4.5.1 ). 
Patients will continue treatment as indicated in  Table  2 until unacceptab le toxicity or loss 
of clinical benefit , as determined by [CONTACT_169849] (e.g., symptomatic deterioration 
such as pain secondary to disease).  In the absence of unacc eptable toxicity, patients 
who meet the criteria for disease progression  (as assessed by [CONTACT_169850] —F. Hoffmann -La [COMPANY_002] Ltd  
40/Protocol GO42661 , Version [ADDRESS_198237]  v1.1; see Appendix  5) while receiving atezolizumab will be permitted to 
continue the study treatment if they meet all of the following criteria:  
 Evidence of clinical benefit, as determined by [CONTACT_169851] a review of 
all available data  
 Absence of symptoms and signs (including laboratory values, such as new or 
worsening hypercalcemia) indicating unequivocal progression of disease  
 Absence of decline in Eastern Cooperative Oncology Group ( ECOG ) Performan ce 
Status that can be attributed to disease progression  
 Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be managed by [CONTACT_990] -allowed medical interventions  
 
Patients who transiently withhold or permanently discontinue one component of their 
treatment (i.e., either atezolizumab, bevacizumab/placebo, or chemotherapy) because of 
toxicity may continue with the other components of study treatment, as long as the 
patients are experiencing clinical bene fit in the opi[INVESTIGATOR_871].  However, 
bevacizumab/placebo should not be continued as a single agent.  
Patients will undergo tumor assessments every 9 (  1) weeks following treatment 
initiation , as outlined in Section 4.5.[ADDRESS_198238].  
Patient -reported outcome (PRO) assessments will be completed before starting 
treatment , at specified timepoints during  treatment , and at treatment discontinuation . 
Safety assessments will include the incidence, nature, and severity of adverse events 
and laboratory abnormalities graded per the National Cancer Institute Common 
Terminology Criteria for Adverse Events  (NCI CT CAE) , Version 5.0.  Laboratory safety 
assessments will include the regular monitoring of hematology and blood chemistry.  
Serum samples will be collected to monitor the pharmacokinetics (PK) of atezolizumab 
when administered in combination with bevacizumab  and/or CisGem .  Patient samples, 
including archival of tumor tissues, as well as serum and plasma, will be collected for 
future exploratory biomarker assessments.  
An overview of the study design is presented in Figure  1.  A schedule of activities is 
provided in Appendix  1.

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
41/Protocol GO42661 , Version 6  
Figure  1 Study Schema  
 
CIT   cancer immunotherapy; eCCA   extrahepatic cholangiocarcinoma; ECOG PS   Eastern Cooperative Oncology Group Performance Status; 
GBC   gallbladder cancer; iCCA   intrahepatic cholangiocarcinoma; R  randomization; RECIST   Response Evaluation Criteria in Solid  Tumors ; 
ROW   rest of the world. 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
42/Protocol GO42661 , Version [ADDRESS_198239] 
patient to the end  of the study, is expected to be approximately 3 5 years.  
In addition, the Sponsor may decide to terminate the study at any time.  
If the Sponsor decides to terminate the study, patients who are still receiving study 
treatment or undergoing survival follow -up may be enro lled in an extension study or 
a non-interventional study, if available.  
3.3 RATIONALE FOR STUDY DESIGN  
3.3.1  Rationale for Atezolizumab  Dose and Schedule  
Atezolizumab will be administered at a fixed dose of 1200 mg every 3 weeks ( Q3W ) 
(1200 mg on Day 1  of each 21 -day cycle), which is an approved dosage for 
atezolizumab, as outlined in the prescribing information.  Anti -tumor activity has been 
observed across doses , ranging from 1 20 mg/kg Q3W.  In Study PCD4989g, the 
maximum tolerated dose of atezolizumab was not reached and no dose -limiting toxicities 
were observed at any dose.  The fixed dose of 1200 mg Q3W (equivalent to an average 
body weight based dose of 15  mg/kg Q3W) was sel ected on the basis of both 
nonclinical studies (Deng  et al. 2016) and available clinical PK, efficacy, and safety data 
(see the Atezolizumab Investigator's Brochure for details).  
3.3.2  Rationale for Bevacizumab Dose  and Schedule  
Bevacizumab will be administered at a dose of 15 mg /kg Q3W on Day 1 of each 21 -day 
cycle , which is the approved dosage for bevacizumab (Avastin local labels).  This dose 
schedule aligns with the atezolizumab dose schedule highlighted above and was the 
dose used in combination with atezoli zumab in the GO30140 , IMbrave150 , and 
IMpower [ADDRESS_198240] differently to other BTCs.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
43/Protocol GO42661 , Version [ADDRESS_198241] chemotherapy 
regimen  in combination with either atezolizumab plus bevacizumab  or atezolizumab plus 
placebo .  Despi[INVESTIGATOR_169790] -VEGF agents combined with chemotherapy in 
advanced BTC, VEGF remains a rational t arget given its multifaceted role in maintaining 
an immunosuppressive TME.  Immunotherapy with drugs targeting PD -1/PD -L1 has 
transformed cancer treatment, but this approach has not been well -studied in BTC.  
Preliminary data indicate limited clinical acti vity of single -agent antiPD-1/PD -L1 
antibodies, including atezolizumab, highlighting the need for combination regimens to 
augment anti -cancer immunity in patient s with BTC.  Biliary tract cancer  has an 
unfavorable TME that is dominated by [CONTACT_169852] e elements, many of which are 
known to be regulated by [CONTACT_12270].  Collectively, these observations provide a compelling 
rationale to study atezolizumab in combination with bevacizumab and chemotherapy in 
patients with advanced BTC.  
In this study , both treatment arms are considered experimental .  This randomized  
Phase  II study aims to assess the relative merits of both experimental regimens in order 
to inform the design of future studies in BTC.  
The study does not include a CisGem -only treatment ar m, given that this regimen has 
been well -characterized in previous  randomized clinical trials (see Section  1.5.3 ). 
3.3.5  Rationale for Contin ued Treatment of 
Atezolizumab/Bevacizumab and Atezolizumab/Placebo after 
Chemotherapy  
The ability to treat patients on a continuous basis with platinum -based chemotherapy 
regimens is limited because of the risk of cumulative toxicity.  In  BTC, CisGem  
administration is typi[INVESTIGATOR_169791] a maximum of [ADDRESS_198242] 
patients, clinical response is noted by 24 weeks (Furuse  et al. 2011).  
The toxicity profile and response for anti PD-1/PD -L1 agents differ from chemotherapy 
and permit longer treatment durations.  The incidence and nature of toxicities associated 
with immunotherapy is different from platinum -based chemotherapy regimens and 
PD-1/PD -L1 antibodies are generally considered to be more easily  tolerated than 
chemotherapi[INVESTIGATOR_014].  Th e combination of atezolizumab, bevacizumab, and 
carboplatin/paclitaxel was successfully evaluated by [CONTACT_169853]150 Phase III study.  This study protocol allowed for the 
continuation of atezolizumab, wit h or without bevacizumab, following the cessation of 
induction chemotherapy.  In this study, the rate of serious adverse events with 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
44/Protocol GO42661 , Version 6 atezolizumab either alone or in combination with bevacizumab during the maintenance 
phase were low and clinically manageabl e.  Furthermore, the median durations of 
treatment with atezolizumab and bevacizumab were longer than the duration of 
chemotherapy; 8.2  months for atezolizumab (range:   026 months), 6.7  months for 
bevacizumab (range:   026 months) , and 2.2 months for chem otherapy 
(range:   05 months; Socinski  et al. 2018).  The  patterns of response to either PD -1 or 
PD-L1 inhibitors are different than that of chemotherapi[INVESTIGATOR_014], with clinical responses 
occurring in a delayed fashion or converting from either stable disease (SD) to RECIST -
defined partial response (PR) or complete response (CR) or from PR to CR.  Delayed 
initial anti -tumor response or late conversion to CR may occur sometime after stoppi[INVESTIGATOR_169792] .  For these reasons, continued treatment with atezol izumab or 
atezolizumab plus bevacizumab/placebo following cessation of chemotherapy may be 
clinically beneficial to patients with BTC.  
3.3.6  Rationale for Progression -Free Survival as the Primary 
Endpoint  
In this study, the primary efficacy endpoint will be inve stigator -assessed PFS .  In BTC, 
PFS has been shown to strongly correlate with OS in a sys tematic review of data from 
104 trials and is considered to be an appropriate surrogate endpoint  of clinical benefit in 
BTC (Eckel and Schmid 2007 ).  In addition, PFS is not generally confounded by 
[CONTACT_70124][INVESTIGATOR_014].   Progression -free survival  has been used successfully as  
a surrogate endpoint  of benefit for advanced BTC to guide follow -on Phase  III studies 
(Valle et al . 2009) . 
3.3.7  Rationale for Stratif ication Factors  
Patients will be stratified according to anatomic subtype, presence of metastatic disease, 
and geographic region  in order to balance key prognostic variables between treatment 
arms : 
 Anatomic subtype :  Each anatomic subtype of BTC has a distinct epi[INVESTIGATOR_623], 
patho biology, and prognosis  (Rizvi et al . 2018).  For example, iCCA has a better 
prognosis than other BTC subtypes, whereas GBC has a poorer prognosis 
(Furu se et al. 2011 ).  Anatomic subtypes of BTC are also heterogeneous  with 
respect to genetic background and TME composition , which may impact response 
to immunotherapy  (Rizvi et al . 2018).  
 Extent of disease:   This study will enroll patients with either locally advanced tumors 
not amenable to surgical resection or metastatic disease.  The presence of distant 
metasta ses is a poor prognostic factor (Park et al . 2009 ; Kim et al . 2017 ). 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
45/Protocol GO42661 , Version 6  Geographic region :  Differenc es exist with respect to patient characteristics, 
treatment strategies, and clinical outcomes  between Eastern and Western patients 
with BTC  (Marcano -Bonilla et al . 2016; Olthof et al . 2019) .  The prevalence of risk 
factors such as fluke infestation and vir al hepatitis varies by [CONTACT_1617] , 
which may contribute to a differential response to immunotherapy ( Khan et al . 2019; 
Kelley  et al. 2020 ). 
 
3.3.[ADDRESS_198243] each been shown to 
occur after radiographic evidence of an apparent increase in tumor burden.  This initial 
increase in tumor burden caused by  [CONTACT_44859] -cell infiltration in the setting of a T -cell 
response has been termed pseudoprogression (Hales et al. 2010).  In Study  PCD4989g, 
evidence of tumor growth followed by a response was observed in several tumor types.   
In addition, in some responding patients with radiographic evidence of progression, 
biopsies of new lesions or areas of new growth in existing lesions revealed 
tumor -infiltrating  immune cell s and no viable cancer cells.  Because of the potential for 
a response after pseudoprogression, this study will allow all patients to continue 
treatment after apparent radiographic progression per RECIST v1.1, provided the 
benefitrisk ratio is determined  to be favorable by [CONTACT_093] ( for the criteria , see 
Section  3.1).  Patients should be discontinued in the event of  unacceptable toxicity or 
loss of clinical benefit , as determined by [CONTACT_093] , after an integrated assessment 
of radiographic and biochemical data, local biopsy results (if available),  and clinical 
status  (see Section  3.1 for details) . 
3.3.[ADDRESS_198244] that the expression of PD -L1 in tumors correlates with 
response to anti PD-1 and antiPD-L1 therapy (Topalian et al. 2012 ; Herbst et al. 2014 ; 
Borghaei et al. 2015; Fehrenbacher et al. 2016; Herbst et al. 2016 ; 
Rosenberg  et al. 2016 ).  In this study, archival or newly collected tumor tissue will be 
obtained  at baseline .  If archival tu mor tissue is not available , or is determined to be 
unsuitable for required testing, a pretreatment tumor biopsy is required, if deemed 
clinically feasible by [CONTACT_11168] .  Archival or baseline tumor specimens will be 
tested for PD -L1 expression retrospectively by a central laboratory.  In addition to the 
assessment of PD -L1 status, other exploratory biomarkers, such as potential predictive 
and prognostic biom arkers related to the clinical benefit of atezolizumab, bevacizumab, 
CisGem , and combinations  of these therapi[INVESTIGATOR_014];  or tumor immunobiology, mechanisms of 
resistance, or tumor type may be analyzed.  
Tissue samples  will be collected for DNA extraction to enable  whole exome sequencing 
(WES) to identify variants that are predictive of response to study drug, are associated 
with progression to a more severe disease state, are associated with acquired 
resistance to study drug, are associated with susceptibility to d evelopi[INVESTIGATOR_68146], 
can lead to improved adverse event monitoring or investigation, or can increase the 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
46/Protocol GO42661 , Version 6 knowledge and understanding of disease biology and drug safety.  Genomics is 
increasingly informing researcher s’ understanding of disease pathobiology.  
WES  provide s a compreh ensive characterization of the exome, and, along with clinical 
data collected in this study, may increase the opportunity for developi[INVESTIGATOR_169793] a drug or develop adverse events.  Data will be 
analyzed in the context of this study but may also be explored in aggregate with data 
from other studies.  The availability of a  larger dataset will assist in identification and 
characterization of important biomarkers and pathways to support future drug 
development.  
Blood samples will be collected at baseline and during the study to evaluate changes in 
circulating biomarkers.  Cha nges in biomarkers , such as cytokines  associated with T-cell 
activation  and lymphocyte  subpopulations may provide evidence of biologic  activity of 
atezolizumab , bevacizumab, CisGem,  and combinations  in patients  with BTC .  
Correlations between these biomark ers and safety and efficacy endpoints  will be 
explored to identify blood -based biomarkers that might predict which patients are more 
likely to  benefit from the combination treatment.  
Exploratory research on safety biomarkers may be conducted to support future drug 
development.  Research may include further characterization of a safety biomarker or 
identification of new safety biomarkers that are associated with susceptibility to 
develo pi[INVESTIGATOR_169794] .  Adverse event reports will not be derived from safety biomarker data by 
[CONTACT_1034], and safety biomarker data will not be included in the formal safety analyses 
for th is study.  In addition, safety biomarker data will not inform decisions on patient 
management.  
3.3.[ADDRESS_198245] their daily functioning and health -related quality 
of life (Koeberle et al. 2008; Zabernigg et al. 2012).  Such concepts are best 
documented through PRO  instrument s, which uniquely and directly capture patients’ 
perspective of their disease , and ultimately provide clinicians with valuable information to 
support decision -making.  
Cancer treatments, particularly combination therapi[INVESTIGATOR_014], can also produce significant 
symptomatic adverse events , some of which  can overlap with disease -related 
symptoms .  Recent research has shown that clinicians may underreport the incidence 
and severity of symptoms experienced by [CONTACT_169854] 
(Fromme et al. 2004; Trotti et al. 2007; Pakhomov et al. 2008; Basch 2010; 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
47/Protocol GO42661 , Version 6 Quinten  et al. 2011; Atkinson  et al. 2012; Basch et al. 2014).  Collecting adverse event 
information directly from patients can provide a better understanding of treatment 
characteristics and their effects.  In order to  evaluate the tolerability of  the study 
treatments , patients will be asked to report on their experience related to four 
treatment -related symptoms selected from the validated PRO -Common Terminology 
Criteria for Adverse Events (PRO -CTCAE)  item bank (see  Appendix  11).  Because  there 
may be an overlap in these symptoms with those associated with advanced BTC, only 
symptoms that are uniquely associated with the study treatments were chosen fro m the 
PRO -CTCAE.  The 4 symptoms were identified as being salient to patients' experience 
with the study treatments , on the basis of known adverse drug reactions, mechanism of 
action, and recent work to identify common adverse events associated with 
immunotherapi[INVESTIGATOR_014] (King -Kallimanis et al. 2019; Hansen  et al. 2020).  
4. MATERIALS AND METHOD S 
4.[ADDRESS_198246] meet the following criteria for study entry:  
 Signed Informed Consent Form  
 Age  18 years at the time of signing the Informed Consent Form  
 Ability to comply with the study protocol  
 Considered to be eligible to receive platinum -based chemotherapy, in the 
investigator’s judgment  
 Documentation of recurrent/metastatic or locally advanced unresectable disease 
based on computed tomography (CT) or magnetic resonance imaging (MRI) scans  
(see Appendix  4) 
 Histologically or cytologically confirmed diagnosis of iCCA, eCCA, or GBC  
– For patients with recurrent BTC, histologic confirmation of BTC at the time of 
resection  is acceptable  
 No prior systemic therapy (including  systemic investigational agents) for advanced 
BTC 
– Prior chemotherapy or radiotherapy (with or without radio -sensitizing 
chemotherapy) in the neoadjuvant or adjuvant setting is permitted provided this 
is completed at least 6 months prior to Day 1 of Cycle 1 
– Prior treatment with gemcitabine administered as a radiation sensitizer in the 
neoadjuvant and adjuvant settings surrounding surgery, during and up to 
[ADDRESS_198247] returned 
to baseline , or Grade  1 or better  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
48/Protocol GO42661 , Version 6 – Previous use of herbal therapi[INVESTIGATOR_169795]-cancer activity included in the label is allowed, provided that these 
medications are discontinued prior to Day 1 of Cycle 1  
– The following prior interventions  are permitted , provided the patient has fully 
recovered:  
Surgery:  Non-curative resection with macroscopic residual disease or 
palliative by[CONTACT_4897] .  Patients who have previously undergone 
curative surgery must have evidence of non -resectable disease  requiring 
systemic chemotherapy.  
Photodynamic therapy:  Prior photodynamic therapy for localized disease 
with no evidence of metastatic disease or for localized disease to relieve 
biliary obstruction in the presence of metastatic disease , provided patient  
has clear evidence of disease progression requiring systemic 
chemotherapy . 
Palliative radiotherapy:  Palliative radiotherapy, provided that all adverse 
events have resolved and the patient has measurable disease outside the 
field of radiation.  
 At least on e measurable  untreated lesion  (per RECIST v1.1)  
 Adequate biliary drainage with no evidence of ongoing infection  
– If applicable, treatable and clinically  relevant biliary duct obstruction must be 
relieved by [CONTACT_169855]/stenting at least 2  weeks prior to 
Day 1 of Cycle  1 or by [CONTACT_169856]  1 of Cycle  1, and the patient has no active or suspected uncontrolled 
infection  
– Patients fitted with a biliary stent should be clinically stable and free of signs of 
infection and have total bilirubin  2upper limit of normal ( ULN) and AST/ALT 
 5ULN for  2 weeks prior to Day 1 of Cycle  1.  Patients with improving biliary 
function who meet all other inclusion criteria may be re -tested during the 
screening window.  
 Availability of a representative tumor specimen that is suitable for determination of 
PD-L1 status via central testing  
– A formalin -fixed, paraffin -embedded (FFPE) tumor specimen in a paraffin block 
(preferred) or at least  16 slides  contain ing unstained, freshly cut, serial sections  
should be submitted along with an associated  pathology report  within 4  weeks  
of randomization  
– If FFPE specimens described above are not available, any type of specimen  
(including fine -needle aspi[INVESTIGATOR_1516], cell pellet specimens [e.g., from pleural 
effusion], and lavage samples) are also acceptable.  This specimen should be 
accompanied by [CONTACT_40869] . 
If archival tissue is either insufficient or unavaila ble, a core -needle biopsy 
specimen should be collected during the screening period, if clinically 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
49/Protocol GO42661 , Version 6 feasible.  Trans -jugular biopsy tissue sample collections for patients who 
are at high risk of bleeding may be allowed.  
If archival tissue is either insuffici ent or unavailable and a fresh biopsy is 
not clinically feasible, the patient may still be eligible . 
 Negative HIV test at screening  with the following exception:  Patients with a positive 
HIV test at screening are eligible provided they are stable on anti -retroviral therapy, 
have a CD4 count  200/L, and have an undetectable viral load  
 Documented virology status of hepatitis, as confirmed by [CONTACT_169833]  B virus 
(HBV) or hepatitis C virus (HCV) tests  
– For patients with active HBV:  HBV DNA  500 IU/mL during screening, initiation 
of anti-HBV treatment at least 14  days prior to Day 1 of Cycle  1 and willingness 
to continue anti -HBV treatment during the study (per local standard of care  
[e.g., entecavir ]) 
– Patients with HCV, either with resolved infec tion (as evidenced by [CONTACT_169834]) or chronic infection (as evidenced by [CONTACT_83921]), are 
eligible  
 Eastern Cooperative Oncology Group  Performance Status of 0 or 1  
 Life expectancy of  3 months  
 Adequate hematologic and end -organ function, de fined by [CONTACT_123511], obtained within 7 days prior to Day 1 of Cycle 1 unless otherwise 
specified:  
– AST and ALT  2.5   ULN with the following exceptions:  
Patients with documented liver metastases:  AST and ALT  5  ULN. 
– Serum bilirubin  2  ULN 
– Albumin  28 g/L ( 2.8 g/dL)  
– Creatinine clearance  60 mL/min (calculated using the Cockcroft -Gault 
formula)  
– Hemoglobin  90 g/L ( 9 g/dL)  
Patients may be transfused to meet this criterion.  
– Platelet count  100   109/L ( 100,000/L) without transfusion  
– Lymphocyte count  0.5  109/L ( 500/L) 
– ANC   1.5   109/L (1500/L) without granulocyte colony -stimulating factor 
support  
– For patients not receiving therapeutic anticoagulation:  INR or aPTT  2  ULN 
– Proteinuria  2  on dipstick analysis (within 7 days prior to Day 1 of Cycle 1)  
Patients discovered to have   2  proteinuria on dipstick urinalysis at 
baseline should undergo a 24 -hour urine collection (or an alternative 
method such as protein:  creatinine ratio, per local guidance) and must 
demonstrate  1 g of protein in 24 hours.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
50/Protocol GO42661 , Version 6  For women of childbearing potential:  Agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive methods , and agreement to refrain 
from donating eggs  as defined below:  
– Women must remain abstinent or use contraceptive methods with a failure rate 
of  1% per year while they are receiving atezolizumab and bevacizumab and 
for [ADDRESS_198248] refrain from 
donating eggs during this same period.  
– A woman is considered to be of childbearing potential if she is postmenarchal, 
has not reached a postmenopausal state (  12 conti nuous months of 
amenorrhea with no identified cause other than menopause), and is not 
permanently infertile due to surgery (i.e., removal of ovaries, fallopi[INVESTIGATOR_2134], 
and/or uterus) or another cause as determined by [CONTACT_093] 
(e.g.,  Müllerian agenes is).  The definition of childbearing potential may be 
adapted for alignment with local guidelines or regulations.  
– Examples of contraceptive methods with a failure rate of  1% per year include 
bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit 
ovulation, hormone -releasing intrauterine devices, and copper intrauterine 
devices.  
– The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle  of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not adequate methods of contraception.  
If required per local guidelines or regulations, locally recognized adequate 
methods of co ntraception and information about the reliability of abstinence will 
be described in the local Informed Consent Form.  
 For men:  A greement to remain abstinent (refrain from heterosexual intercourse) or 
use a condom, and agreement to refrain from donating sp erm, as defined below:  
– With a female partner of childbearing potential or pregnant female partner, men 
must remain abstinent or use a condom during the treatment period and for 
[ADDRESS_198249] refrain from donating sperm during this 
same period.  
– The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not adequate methods of preventing drug 
exposure.  If  required per local guidelines or regulations, locally recognized 
adequate methods of contraception  and information about the reliability of 
abstinence will be described in the local Informed  Consent  Form.  
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
51/Protocol GO42661 , Version 6 4.1.2  Exclusion Criteria  
Patients who meet any of the following criteria will be excluded from study entry:  
 Recurrent disease  6 months after curative surgery or  6 months after the 
completion of adjuvant therapy (chemotherapy and/or radiation)  
 Prior local regional therapy such as radioembolization  
 Combined or mixed hepatocellular/ CCA  
 Clinically significant hepatic encephalopathy  within the 12  months prior to Day  1 of 
Cycle  1 
 National Cancer Institute Common Terminology Criteria for Adverse Events Grade  
 2 peripheral neuropathy  
 Prior bleeding event due to untreated or incompletely treated esophageal and/or 
gastric varices within 6 months prior to Day 1 of Cycle  1 
Patients at high risk of esophageal varices are required to undergo an 
esophagogastroduodenoscopy (EGD) during screening or must have 
undergone an EGD within 6 months of Day  1 of Cycle  1.  All size of varices 
(small to la rge) must be assessed and treated per local standard of care prior to 
Day [ADDRESS_198250] one of the following:  
– Presence or history of cirrhosis  
– Presence or history of portal hypertension  
– Presence or history of primary biliary cirrhosis, or primary sclerosing 
cholangitis  
– HBV or HCV infection  
– Evidence of gross vascular inva sion (portal vein, hepatic vein or collateral 
vessels)  
– Evidence of splenomegaly  
– Platelet count  120   109/L (120,000/ L) and albumin  36 g/L (3.6  g/dL)  
– Evidence of portal vein occlusion due to malignant invasion or constriction  
– Evidence of varices by [CONTACT_9661]  
 Active or history of autoimmune disease or immune deficiency, including, but not 
limited to :  myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus 
erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid 
antibo dy syndrome, granulomatosis with polyangiitis , Sjögren syndrome, Guillain -
Barré syndrome, or multiple sclerosis  (see Appendix  [ADDRESS_198251] of autoimmune diseases and immune deficiencies) , with the following 
exceptions:  
– Patients with a history of autoimmune -related hypothyroidism who are on 
thyroid -replacement hormone are eligible for the study  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
52/Protocol GO42661 , Version 6 – Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen 
are eligible for the study  
– Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with 
dermatologic manifestations only (e.g., patients with psoriatic arthritis are 
excluded)  are eligible for the study provided all of following conditions are met:  
Rash must cover  10% of body surface area.  
Disease is well -controlled at baseline and requires only low -potency topi[INVESTIGATOR_030].  
There is no occurrence of acute exacerbation s of the underlying condition 
requiring psoralen plus ultraviolet  A radiation, methotrexate, retinoids, 
biologic agents, oral calcineurin inhibitors, or high -potency or ora l 
corticosteroids within the 12  months prior to Day  1 of Cycle  1. 
 History of idiopat hic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis 
obliterans), drug -induced pneumonitis, or idiopathic pneumonitis, or evidence of 
active pneumonitis on screening chest CT scan  
 Significant cardiovascular disease (such as N ew York Heart Asso ciation Class  II or 
greater cardiac disease, myocardial infarction, or cerebrovascular acciden t) within 
3 months prior to Day  1 of Cycle  1, unstable arrhythmia, or unstable angina  
 History of malignancy other than BTC within 5 years prior to screening, with  the 
exception of malignancies with a negligible risk of metastasis or death (e.g., 5 -year 
OS rate  90%), such as adequately treated carcinoma in situ of the cervix, 
non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, 
or Stag e I uterine cancer  
 Symptomatic, untreated, or actively progressing CNS metastases  
Asymptomatic patients with treated CNS lesions are eligible, provided that all of 
the following criteria are met:  
– Measurable disease, per RECIST v1.1, must be present outside  the CNS.  
– The patient has no history of intracranial hemorrhage or spi[INVESTIGATOR_169796].  
– Metastases are limited to the cerebellum or t he supratentorial region 
(i.e., no metastases to the midbrain, pons, medulla, or spi[INVESTIGATOR_1831]).  
– There is no evidence of i nterim progression between completion of 
CNS -directed therapy and initiation of study treatment.  
– The patient has not undergone ste reotactic radiotherapy within 7  days prior 
to initi ation of study treatment, whole -brain  radiotherapy within 14  days 
prior t o initiation of study treatment , and neurosurgical resection within 
28 days prior to initiation of study treatment.  
– The patient has no ongoing requirement for corticosteroids as therapy for 
CNS disease.  Anticonvulsant therapy at a stable dose is permitted.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
53/Protocol GO42661 , Version 6 – Asymptomatic patients with CNS metastases newly detected at screening 
are eligible for the study after receiving radiotherapy or surgery, with no 
need to repeat the screening brain scan . 
 For patients with lung metastases, if one of the following criteria a pplies:  
– Large , central ly located pulmonary metastases  
– Clear tumor infiltration into the thoracic great vessels seen on imaging  
– Clear cavitation of pulmonary lesions seen on imaging  
 Active tuberculosis  
 Severe infection within 4 weeks prior to Day 1 of Cycle  1, including, but not limited 
to:  hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia , 
or any active infection that, in the opi[INVESTIGATOR_871], could impact patient 
safety  
 Treatment with therapeutic oral or IV antibio tics within 2 weeks prior to Day  1 of 
Cycle  1 
Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection 
or chronic obstructive pulmonary disease [COPD]  exacerbation) are eligible for 
the study , provided the signs of active infection have resolved  
 Prior allogeneic stem cell or solid organ transplantation  
 On the waiting list for liver transplantation  
 Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory fin ding that contraindicates the use of an investigational drug, may affect 
the interpretation of the results, or may render the patient at high risk from treatment 
complications  
 Pregnant or breastfeeding, or intending to become pregnant during the study or 
within 5  months after the final dose of atezolizumab or within 6  months after the final 
dose of bevacizumab  and/or  CisGem  
– Women of childbearing potential must have a negative serum pregnancy test 
result within 14 days prior to Day 1 of Cycle 1  
 Co-infection with HBV and HCV  
– Patients with a history of HCV infection but who are negative for HCV RNA by 
[CONTACT_169837]  
 Uncontrolled or symptomatic hypercalcemia (ionize d calcium   1.5 mmol/L, 
calcium   12 mg/dL, or corrected serum calcium  ULN)  
 History of severe allergic anaphylactic reactions to chimeric or humanized 
antibodies or fusion proteins  
 History of allergic reactions to cisplatin or other platinum -containing compounds  
 Known hypersensitivity to gemcitabine  
 Known hypersensitivity to Chinese hamster ovary cell products or to any component 
of the atezolizumab or bevacizumab formulations  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
54/Protocol GO42661 , Version 6  Treatment with a live, attenuated vacc ine within 4 weeks prior to Day  1 of Cycle  1 or 
anticipation of need for suc h a vaccine during atezolizumab treatment or within 
5 months after the final dose of atezolizumab  
 Treatment with investigational therapy within 4 weeks prior to Day 1 of Cycle  1 
 Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], 
including anti CTLA -4, antiPD-1, and anti PD-L1 therapeutic antibodies  
 Treatment with systemic immunostimulatory agents (including, but not limited to, 
interferon and IL-2) within 4 weeks or 5 drug -elimination half -lives (whichever is 
longer) prior to Day  1 of Cycle 1  
 Treatment with systemic immunosuppressive medication (including, but not limited 
to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antiTNF- agents) within 2 weeks prior to Day 1 of Cycle  1 or anticipation of need 
for systemic immunosuppressive medication during study treatment, with the 
following exceptions:  
– Patients who received acute, low -dose systemic immunosuppressant 
medication or a one -time pulse dose of systemic immunosuppressant 
medication (e.g., [ADDRESS_198252] allergy) are eligible 
for the study  
– Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids 
for COPD  or asthma, or low -dose  corticosteroids for orthostatic hypotension or 
adrenal insufficiency are eligible for the study  
 Inadequately controlled arterial hypertension (defined as systolic blood pressure 
[BP]  150 mmHg and/or diastolic BP  100 mmHg), based on an average of at le ast 
3 BP readings at 2 or more sessions  
– Anti-hypertensive therapy to achieve these parameters is allowed  
 History of hypertensive crisis or hypertensive encephalopathy  
 Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent 
peripheral arterial thrombosi s) within 6 months prior to Day  1 of Cycle  1 
 History of hemoptysis (  2.5 mL of bright red blood per epi[INVESTIGATOR_1865]) within 1  month prior 
to Day  1 of Cycle 1  
 Evidence of bleeding diathesis or significant coagulopathy (in the absence of  
therapeutic anticoagulation)  
 Current or recent (within 10 days of Day 1 of Cycle 1) use of aspi[INVESTIGATOR_248] (  325 mg/day) 
or current or recent treatment with dipyridamole , ticlopi[INVESTIGATOR_5325], clopi[INVESTIGATOR_7745], and 
cilostazol  
 Current or recent (within 10 days prior to Day 1 o f Cycle 1) use of full -dose oral or 
parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to 
prophylactic) purpose  
– Prophylactic anticoagulation for the patency of venous access devices is 
allowed provided the activity of the agent re sults in an INR  1.5ULN and 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
55/Protocol GO42661 , Version 6 aPTT is within normal limits (according to institutional standards) within 14  days 
prior to Day 1 of Cycle 1  
– Prophylactic use of low -molecular -weight heparin (i.e., 40  mg/day  enoxaparin) 
is allowed.  However, the use of direc t oral anticoagulant therapi[INVESTIGATOR_169797] (Pradaxa) and rivaroxaban (Xarelto) is not recommended due to 
bleeding risk  
 Core biopsy or other minor surgical procedure, excluding placement of a vascular 
access device, within 3 days prior to Day 1 of Cycle 1  
 History of abdominal or tracheoesophageal fistula, GI perforation, or intra -abdominal 
abscess within 6 months prior to Day 1 of Cycle 1  
 Evidence of abdominal free air that is not explained by [CONTACT_169857]  
 Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture  
 Major surgical proced ure within 4 weeks prior to Day  1 of Cycle  1 or anticipation of 
need for a major surgical procedure during the study  
 History of clinically significant and uncontr olled intra -abdominal inflammatory 
disease within 6 months prior to Day 1 of Cycle 1, including, but not limited to, peptic 
ulcer disease, diverticulitis, or colitis  
 Chronic daily treatment with a non -steroidal anti -inflammatory drug (NSAID)  
– Occasional use  of NSAIDs for the symptomatic relief of medical conditions such 
as headache or fever is allowed  
 Preexisting renal impairment , myelosuppression , or hearing impairment  
 
4.[ADDRESS_198253] been completed, and 
eligibility has been established for a patient, the study site will obtain the patient's 
identification number and treatment assignm ent from the interactive voice or Web-based 
response system (IxRS).  
Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms:  
 Arm A  (Atezolizumab   Bevacizumab   CisGem ) 
 Arm B ( Atezolizumab   Placebo   CisGem ) 
 
Randomization will occur through use of a permuted -block randomization method to 
ensure a balanced assignment to each treatment arm.  Randomization will be stratified 
through a n IxRS according to the stratification factors  outlined in  Section  3.1. 
4.2.1  Blinding  
Study site personnel and patients will be blinded to treatment assignment during the 
study.  The Sponsor and its agents will also be blinded to treatment assignment, with the 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
56/Protocol GO42661 , Version [ADDRESS_198254] interim 
analysis of PFS.  Investigators and patients will remain blinded to treatment assignment 
until the time of the final analysis of OS, except in cases for which  single -patient 
unblinding is necessary, as outlined below.  
If unblinding is  necessary for a medical emergency (e.g., in the case of a serious 
adverse event for which patient management might be affected by [CONTACT_123514]), the investigator will be able to break the treatment code by 
[CONTACT_123517].  The in vestigator is not required to contact [CONTACT_123516]; however, the treatment code should not be broken 
except in emergency situations.   The investigator should inform the Medical Monitor that 
the treatment code has  been broken.  
If the investigator wishes to know the identity of the study drug for any reason other than 
a medical emergency, he or she should  contact  [CONTACT_66324].  Unblinding 
may be permitted if an investigator is deciding whether a patient should withdraw from 
the study and initiate treatment with a proven therapy.  However, unblinding will not be 
permitted if an investigator is decid ing whether a patient should withdraw from the study 
and initiate treatment with an unproven therapy.  The investigator should document and 
provide an explanation for any non -emergency unblinding.  If the Medical Monitor agrees 
to patient unblinding, the i nvestigator will be able to break the treatment code by 
[CONTACT_123517].  
As per health authority reporting requirements, the Sponsor's Drug Safety representative 
will break the treatment code for all serious, unexpected suspected adverse reactions 
(see Section  5.7) that are considered by [CONTACT_123518].  The patient may continue to receive tre atment, and the investigator, patient, 
and Sponsor personnel, with the exception of the Drug Safety representative and 
personnel who must have access to patient treatment assignments to fulfill their roles 
(as defined above), will remain blinded to treatme nt assignment.  
4.[ADDRESS_198255] s (IMP s) for this study are atezolizumab  and 
bevacizumab /placebo .  Cisplatin and gemcitabin e are considered non -IMPs . 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
57/Protocol GO42661 , Version 6 4.3.1  Study Treatment  Form ulation s and Packaging  
[IP_ADDRESS]  Atezolizumab  
Atezolizumab  will be  supplied  by [CONTACT_169858] a sterile liquid in a single -use, 20 -mL 
glass vial.  The vial contains approximately 20  mL (1200 mg) of atezolizumab  solution.  
For information on the atezolizumab  formulation , see the pharmacy manual and the 
Atezolizumab Investigator's  Brochure.  
[IP_ADDRESS]  Bevacizumab and Placebo  
Bevacizumab will be supplied by [CONTACT_14547] a sterile liquid in single -use, 16 -mL, 
preservative -free glass vials that contain 400 mg of bevacizumab (25  mg/mL).  
For information on the formulation and handling of bevacizumab, see the pharmacy 
manual and the Bevacizumab Investigator's Brochure.  
Matching placebo will be provided by [CONTACT_1034].  Placebo will be supplied as a sterile 
liquid in single -use, 16 -mL, preservative -free glass vials that contain the vehicle without 
active ingredient.  Further details are provided in the pharmacy manual . 
[IP_ADDRESS]  Cisplatin and Gemcitabine  
For information on the formulation and packaging of CisGem , see the local prescribing 
information for these drugs . 
4.3.[ADDRESS_198256] following date, 
with subsequent dosing continuing on a 21 -day schedule, with one exception:  
If treatment was postponed for fewer than 3 days, the patient can resu me the original 
schedule.  
See the pharmacy manual for detailed instructions on drug preparation, storage, and 
administration.  
Details on treatment administration (e.g., dose and timing) should be noted on the 
Study  Drug Administration electronic Case Report Form (eCRF) .  Cases of accidental 
overdose or medication error, along with any associated adverse events, should be 
reported as described in Section [IP_ADDRESS] . 
Guidelines for treatment interruption or discontinuation for patients who experience 
adverse events are provided in Appendix  14 and Appendix  15. 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
58/Protocol GO42661 , Version 6 [IP_ADDRESS]  Atezolizumab  
Atezolizumab will be administered by [CONTACT_22671] a fixed dose of 1200  mg Q3W on 
Day 1 of each 21 -day cycle  until unacceptable toxicity or loss of clinical benefit as 
determine d by [CONTACT_169859], and clinical status (see Section  3.1 for details) . 
Administration of atezolizumab will be performed in a monitored setting where there is 
immediate access to trained personnel and adequate equipment  and medicine to 
manage potentially serious reactions.   For anaphylaxis precautions, see  Appendix  13.  
Atezolizumab infusions will be administered per the instructions outlined in  Table  3. 
Table  [ADDRESS_198257] Infusion  Subsequent Infusions  
 No premedication is permitted  prior to the 
atezolizumab infusion . 
 Vital signs ( pulse  rate, respi[INVESTIGATOR_697], 
blood pressure, and temperature) should  be 
measured  within 60 minutes prior to the 
infusion.  
 Atezolizumab should be infused over 
60 ( 15) minutes.  
 If clinically indicated, vital signs should be 
measured  every  15 ( 5) minutes  during the 
infusion and at 30  ( 10) minutes after the 
infusion . 
 Patients should  be informed about the 
possibility of delayed post -infusion 
symptoms and instructed to contact [CONTACT_123524].   If the patient experienced an 
infusion -related reaction with any previous 
infusion, premedication with 
antih istamines , antipyretics , and/or 
analgesics may be administered for 
subsequent doses  at the discretion of the 
investigator . 
 Vital signs should be measured  within 
60 minutes prior to the infusion.  
 Atezolizumab should be infused over 
30 ( 10) minutes if the previous infusion 
was tolerated without an infusion -related 
reaction, or 60 (  15) minutes if the patient 
experienced an infusion -related reaction 
with the previous infusion.  
 If the patient experienced an 
infusion -related reaction with the previous 
infusion or if clinically indicated, vital signs 
should be measured  during the infusion 
and at 30  ( 10) minutes after the infusion.  
 
Guidelines for medical management of infusion -related reactions (IRRs) are provided in 
Appendix  14. 
No dose modification for atezolizumab  is allowed.  
[IP_ADDRESS]  Bevacizumab and Placebo  
Bevacizumab (Arm A) at a dose of 15 mg/kg or matching placebo (Arm B) will be 
administered after atezolizumab by [CONTACT_95077] 1 of each 21 -day cycle.  
There  will be a minimum 5 -minut e gap between administration of atezolizumab and 
bevacizumab /placebo .  Treatment duration is described in Section  3.1. 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
59/Protocol GO42661 , Version 6 The dose of beva cizumab will be based on the patient's weight (in kilograms) measured 
 14 days prior to Day 1 of Cycle 1 and will remain the same throughout the study unless 
there is a weight change of  10% from the baseline body weight, in which case the 
bevacizumab dose should be modified.  
Administration of bevacizumab /placebo  will be performed in a monitored setting where 
there is immediate access to trained personnel and adequate equipment and medicine 
to manage potentially serious reactions.  For anaphylaxis preca utions, see Appendix  13.  
Bevacizumab /placebo  infusions will be administered per the instructions outlined in 
Table  4. 
Table  [ADDRESS_198258] and Subsequent Bevacizumab /Placebo  
Infusions  
First Infusion  Subsequent Infusions  
 No premedication is  permitted prior to the 
bevacizumab /placebo  infusion.  
 Vital signs (pulse rate, respi[INVESTIGATOR_697], 
blood pressure, and temperature) should 
be measured within 60 minutes prior to the 
infusion.  
 Bevacizumab /placebo  should be infused 
over 90  ( 15) minutes.  
 Vital signs should be  measured at the end 
of the infusion and 2 ( 1) hours after the 
infusion.  
 Patients should be informed about the 
possibility of delayed post -infusion 
symptoms and instructed to contact [CONTACT_123524].   If the patient experienced an 
infusion -related reaction with any 
previous infusion, premedication with 
antihistamines, antipyretics, and/or 
analgesics may be administered for 
subsequent doses at the discretion of the 
investigator.  
 Vital signs should be meas ured within 
60 minutes prior to the infusion.  
 Bevacizumab /placebo  should be infused 
over 60  ( 10) minutes if the previous 
infusion was tolerated without an 
infusion -related reaction, or 
90 ( 15) minutes if the patient 
experienced an infusion -related reaction 
with the previous infusion.  If the 
60-minute infusion was well -tolerated, 
bevacizumab /placebo  may be infused 
over 30  ( 15) minutes thereafter.  
 Vital signs should be  measured at the 
end of the infusion and 2 ( 1) hours after 
the infusion.  
 
Guidelines for medical management of IRRs are provided in Appendix  14. 
No dose modifications are permitted for bevacizumab/placebo aside from weight -based 
dose changes as outlined in the protocol.  
4.3.3  Chemotherapy (Cisplatin and Gemcitabine ) 
Cisplatin will be administered by [CONTACT_22671] a dose of 25 mg/m2 followed by 
[CONTACT_169840] a dose of 1000 mg/m2 on Days 1 and 8 of each 21 -day cycle.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
60/Protocol GO42661 , Version [ADDRESS_198259] of care for determining dose adjustments in 
the event of changes in patient weight.  Cisplatin will be administered after completion of 
the bevacizumab/placebo infusion, and gemcitabine will be administered after 
completion of the cisplatin infusion.  
Dose modification guidelines are provided in S ection  5.1.[ADDRESS_198260]  Handling and Accountability  
All IMPs required for completion of this study (atezolizumab and bevacizumab /placebo ) 
will be provided by [CONTACT_1034].  The study site (i.e.,  investigator or other authorized 
personnel [e.g., pharmacist  or mobile nurse ]) is responsible for maintaining records of 
IMP delivery to the site, IMP inventory at the site, IMP use by [CONTACT_6904], and 
disposition or return of unused IMP, thus enabling reconciliation of all IMP received,  and 
for ensuring that patients are provided with doses specified by [CONTACT_760].  
The study site should follow all instructions included with each shipment of IMP.  
The study site will acknowledge receipt of IMPs supplied by [CONTACT_169860].  Any damaged shipments will be 
replaced.  The investigator or designee must confirm that appropriate temperature 
conditions have been maintained during transit , either by [CONTACT_76972] (shipment 
arrival date an d time) or temperature monitoring , for all IMPs received and that any 
discrepancies have been reported and resolved before use of the IMPs.  All IMPs must 
be stored in a secure, environmentally controlled, and monitored (manual or automated) 
area in accord ance with the labeled storage conditions, with access limited to the 
investigator and authorized staff.  
Only patients enrolled in the study may receive IMPs, and only authorized staff may 
supply or administer IMPs.  
Investigational medicinal products  will e ither be disposed of at the study site according to 
the study site's institutional standard operating procedure or be returned to the Sponsor 
with the appropriate documentation.  The site's method of destroying Sponsor -supplied 
IMPs must be agreed to by [CONTACT_3433] e Sponsor.  The site must obtain written authorization from 
the Sponsor before any Sponsor -supplied IMP is destroyed, and IMP destruction must 
be documented on the appropriate form.  
Accurate records of all IMPs received at, dispensed from, returned to, and  disposed of by 
[CONTACT_169861].  
See the pharmacy manual and/or the applicable Investigator's Brochure for information 
on IMP handling, including preparation , storage, and accountability.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
61/Protocol GO42661 , Version 6 4.3.5  Continued Access to Atezolizumab  and Bevacizumab  
The Sponsor will offer continued access to [COMPANY_002]  IMPs (atezolizumab and 
bevacizumab ) free of charge to eligible patients in accordance with the [COMPANY_002] Global 
Policy on Continued Access to Investigational Medicinal Product , as outlined below.  
A patient will be eligible to receive [COMPANY_002] IMPs (atezolizumab and bevacizumab ) after 
completing the study if all of the following conditions are met:  
 The patient has a life -threatening or severe medical condition and requires 
continued [COMPANY_002] IMP treatment for his or her well -being  
 There are no appropriate alternative treatments available to the patient  
 The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them  
 
A patient will not be eligible to receive [COMPANY_002] IMPs (atezolizumab and bevacizumab ) 
after completing the study if any of the following conditions are met:  
 The [COMPANY_002] IMP is commercially marketed in the patient's country and is reasonably 
accessible to the pati ent (e.g., is covered by [CONTACT_102]'s insurance or wouldn't 
otherwise create a financial hardship for the patient)  
 The Sponsor has discontinued development of the IMP or data suggest that the IMP 
is not effective for BTC 
 The Sponsor has reasonable safety concerns regarding the IMP as treatment for 
BTC 
 Provision of the [COMPANY_002] IMP is not permitted under the laws and regulations of the 
patient's country  
 
The [COMPANY_002] Global Policy on Continued Access to Investigational Medicinal Product is 
available from the following website : 
https://www.roche.com/policy_continued_access_to_investigational_medicines.pdf  
4.4 CONCOMITANT THERAPY  
Concomitant therapy consists of  any medication (e.g., prescription drugs, 
over-the-counter drugs, vaccines, herbal or homeopathic reme dies, nutritional 
supp lements) used by a patient in addition to protocol -mandated treatment from 7 days 
prior to Day 1 Cycle  1 to the treatment discontinuation visit.  All such medications should 
be reported to the investigator and recorded on the Concomitant Medications eCRF.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
62/Protocol GO42661 , Version 6 4.4.1  Permitted Therapy  
Patients are permitted to use the following therapi[INVESTIGATOR_226]:  
 Oral contraceptives  with a failure rate of  1% per year (see Section  4.1.1 ) 
 Hormone -replacement therapy  
 Prophylactic use of low -dose anti -coagulation, unfractionated heparin, or low 
molecular weight heparin ( LMWH ) 
– The preferred choice for anti -coagulation treatment is LMWH as per  American 
Society of Clinical Oncology guidelines (Lyman et al. 201 3) 
 Vaccinations (such as  influenza , COVID -19) 
– Live, attenuated vaccines are not permitted (see Section  4.4.3 ) 
 Megestrol acetate admini stered as an appetite stimulant  
 Mineralocorticoids (e.g.,  fludrocortisone)  
 Corticosteroids  administered for COPD or asthma  
 Low-dose corticosteroids administered for orthostatic hypotension or adrenocortical 
insufficiency  
 Palliative radiotherapy (e.g., treatment of known bony metastases or symptomatic 
relief of pain)  7 days prior to Day 1 of Cy cle 1 of the chemotherapy combination 
phase and during the CIT/placebo phase, as outlined below:  
– Palliative radiotherapy is permitted, provided it does not interfere with the 
assessment of tumor target lesions (e.g., the lesion to be irradiated must not be  
the only site of measurable disease).  Treatment with atezolizumab may be 
continued during palliative radiotherapy.  Bevacizumab /placebo  must be held 
during palliative radiotherapy treatment.  Upon completion of palliative 
radiotherapy treatment, continua tion of bevacizumab /placebo  treatment may be 
allowed . 
 Radiotherapy to the brain as outlined below:  
– Patients whose extracranial tumor burden is stable or responding to study 
treatment and who are subsequently found to have 3 or fewer brain metastases 
may re ceive radiotherapy to the brain (either stereotactic radiosurgery or whole 
brain radiotherapy)  and continue on study treatment , provided that all of the 
following criteria are met : 
The patient has no evidence of progression or hemorrhage after completion 
of CNS -directed therapy.  
The patient has no ongoing requirement for corticosteroids as therapy for 
CNS disease.  
– Patients who require corticosteroid therapy for more than [ADDRESS_198261] be discontinued from study treatment  
– Anti-convulsant therapy, if required, is administered at a stable dose  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
63/Protocol GO42661 , Version 6 Note:  Treatment with atezolizumab and bevacizumab /placebo  should be 
withheld during CNS -directed radiation therapy.  
 Other local therapy (e.g.,  surgery, stereotactic radiosurgery, radio therapy, 
radiofrequency ablation) as outlined below:  
– Patients experiencing  a mixed response requiring local therapy f or control of 
3 or fewer lesions may still be eligible to continu e study treatment at the 
investigator’s discretion.  The Medical  Monitor i s available to advise as needed.  
Patients who receive local therapy directed at a target lesion will no longer be 
evaluable for radiographic response but will remain evaluable for progression.  
 Relief of b iliary tract obstruction during study treatment  
– In the event of the development of obstructive jaundice due to biliary tract 
obstruction, appropriate measures will be undertaken to diagnose (e.g., by 
[CONTACT_169862]/or CT scan) and relieve the obstruction (e.g., by [CONTACT_169863] [ERCP]/Percutaneous transhepatic 
cholangiography [PTC]   stent insertion/drainage) in accordance with institutional 
standards of care.  
– Protocol treatment should be deferred until the liver function tests have 
sufficiently resolved to permit safely restarting study treatment in the opi[INVESTIGATOR_13046].  
– Biliary tract obstruction by [CONTACT_169864].  
– Imaging will be performed at the planned time points according to the protocol.  
 On study tissue biopsie s 
– The following precautions should be considered by [CONTACT_169865]; they are not expected to supersede institutional guidelines  
– Bevacizumab/placebo should not be  administered until   3 days following 
the procedure and  evidence of adequate wound healing is observed.  
– For patients undergoing needle biopsies of deep -seated lesions (e.g., liver 
or renal ), hemoglobin, and hematocrit will be checked at the time of biopsy  
and prior to restarting bevacizumab/placebo, as clinically indicated.  
– Suggested post -biopsy hematocrit/hemoglobin thresholds include:  
For patients who have a  2 unit decrease in hemoglobin (g/dL) or a   6% 
decrease in hematocrit following the biopsy, bev acizumab may be restarted 
with appropriate clinical monitoring  
For patients who have a  2 but  3 unit decrease in hemoglobin (g/dL) or a 
 6% but  9% decrease in hematocrit, bevacizumab may be restarted at 
the discretion of the investigator  
Patients who  have a  3 unit decrease in hemoglobin (g/dL) or a   9% 
decrease in hematocrit should be evaluated (e.g., by [CONTACT_169866] —F. Hoffmann -La [COMPANY_002] Ltd  
64/Protocol GO42661 , Version 6 ultrasound), and bevacizumab may be restarted once the levels improve at 
the discretion of the investigator  
 
Premedication with antihistamines , antipyretic  medication s, and/or analgesics  may be 
administered for the second and subsequent atezolizumab infusions only, at the 
discretion of the investigator.  
Anti-emetic prophylaxis may be administered at the treating physician’s di scretion 
according to local practice.  
In general, investigators should manage a patient's care (including preexisting 
conditions) with supportive therapi[INVESTIGATOR_169798] (see Sections 4.4.2  and 4.4.3 ) as clinically  indicat ed, per local 
standard practice .  Patients who experience infusion -associated symptoms may be 
treated symptomatically with acetaminophen, ibuprofen, diphenhydramine, and/or 
H2-receptor antagonist s (e.g.,  famotidine, cimetidine) , or equivalent medications  per local 
standard practice.  Serious infusion -associated events manifested by [CONTACT_27926], 
hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or 
respi[INVESTIGATOR_169799] d 
(e.g.,  supplemental oxygen and 2-adrenergic agonists; see  Appendix  13). 
4.4.2  Cautionary Therapy  
[IP_ADDRESS]  Corticosteroids , Immunosuppressive Medicat ions, and T NF- 
Inhibitors  
Systemic corticosteroids , immunosuppressive medications,  and TNF - inhibitors may 
attenuate potential beneficial immunologic effects of treatment with atezolizumab.  
Therefore, in situations in which systemic corticosteroids , immunosuppressive 
medications,  or TNF - inhibitors would be routinely administered, alternatives, including 
antihistamines, should be considered.  If the alternatives are not feasible, systemic 
corticosteroids , immunosuppressive medications,  and TNF - inhibitors may be 
administered at the discretion of the investigator.  
Systemic corticosteroids  or immunosuppressive medications  are recommended, at the 
discretion of the investigator , for the treatment of specific adverse events when 
associated with atezolizum ab therapy  (see Section  5.1 and Appendix  15 for details).  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
65/Protocol GO42661 , Version 6 [IP_ADDRESS]  Herbal Therapi[INVESTIGATOR_169800], safety 
profiles, and potential drug drug interactions are generally unknown.  However, herbal 
therapi[INVESTIGATOR_169801] (see  Section  4.4.3 ) may be used 
during the study at the discretion of the investigator.  
4.4.3  Prohibited Therapy  
Any concomitant therapy intended for the treatment of cancer, whether health 
authority -approved or experimental, is prohibited for va rious time periods prior to Day  1 
of Cycle 1 (depending on the anticancer agent; see Section  4.1.2 ) and during study 
treatment until disease progression  is documented and patient h as discontinued study 
treatment .  This includes , but is not limited to , the followi ng: 
 Concomitant therapy intended for the treatment of cancer  (including, but not limited 
to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal 
therapy) , whether health authority approved or experimental , for various time 
periods prior  to starting study treatme nt, depending on the agent 
(see Section  4.1.2 ), and during study treatment , until disease progression is 
docum ented and the patient has discontinued study treatment , with the exception of 
palliative radiotherapy and local therapy under cer tain circumstances 
(see Section  4.4.1  for details ) 
 Concomitant use of herbal therapi[INVESTIGATOR_169802]-cancer  activity included in the label  
 Investigational therapy  within 4 weeks  prior to Day 1 of Cycle  1 and during study  
treatment  
 Live, attenuated vaccine s (e.g.,  FluMist) within 4  weeks prior to Day 1 of Cycle  1, 
during atezolizumab treatment , and for 5 months  after the final dose of atezolizumab  
 Systemic i mmunostimulatory  agents ( including , but not limited to , interferons and 
IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer ) prior to 
Day 1 of Cycle 1  and during study treatment  because these agents could potentially 
increase the risk of autoimmune conditions when given in combination with 
atezolizumab  
 Current use of full dose oral or parenteral anticoagulants or thrombolytic agents for 
therapeutic (as opposed to prophylactic) purposes or anti -platelet therapy are 
prohibited within 10 days prior to Day 1 of Cycle  1 and during study treatment  
– Local label recommended doses for prophylactic use of anticoagulants or 
thrombolytic therapi[INVESTIGATOR_33938].  
– Low-dose aspi[INVESTIGATOR_248] (  325 mg/day) is permitted.  Co administration of proton -pump  
inhibitors is strongly recommended  to reduce potential GI damage.  
– If a patient ex periences a venous thromboembolism event while still receiving 
study treatment, it may still be possible for the patient to continue study 
treatment  despi[INVESTIGATOR_169803] (see Section  4.1.2 ). 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
66/Protocol GO42661 , Version 6  Use of warfarin or warfarin -like products is not permitted (includes for prophylactic 
use) 
 Concomitant chronic use of NSAIDs while receiving study treatment is prohibited, 
with the excepti on of chronic low -dose aspi[INVESTIGATOR_248] (  325 mg/day).  However, for the 
symptomatic relief of medical conditions (e.g., headache, fever), sporadic or 
short -term intake of oral NSAIDs is allowed, when co administered with proton -pump  
inhibitors to reduce potential GI damage  
 
[IP_ADDRESS]  Prohibited and Cautionary Therapy for Gemcitabine -Treated 
Patients  
Gemcitabine is not indicated for use in combination with radi otherapy.  Patients should 
not receive gemcitabine within 7 days before or after radi otherapy.  Concurrent therapy 
(given together or  7 days apart) with gemcitabine and thoracic radiation has led to 
life-threatening mucositis, especially esophagitis and pneumonitis.  Excessive toxicity 
has not been observed when gemcitabine is administer ed more than 7  days before or 
after radiation.  Radiation recall has been reported in patients who receive gemcitabine 
after prior radiation . 
[IP_ADDRESS]  Prohibited and Cautionary Therapy for Cisplatin -Treated 
Patients  
Simultaneous use of myelosuppressive agents or ra diation will boost the effects of 
cisplatin's myelosuppressive activity.  The occurrence of nephrotoxicity caused by 
[CONTACT_169867], hydralazine, diazoxide, and propr anolol.  
Concomitant administration of ototoxic (e.g., aminoglycosides, loop diuretics) medicinal 
products will potentiate the toxic effect of cisplatin on auditory function . 
Simultaneous use of antihistamines, buclizine, cyclizine, loxapi[INVESTIGATOR_050], meclizine , 
phenothiazines, thioxanthenes, or trimethobenzamides may mask ototoxic symptoms 
(such as dizziness and tinnitus).  
In the event of the simultaneous use of oral anticoagulants, it is advisable to more  
frequently check the INR.  
4.5 STUDY ASSESSMENTS  
The schedule of activities to be performed during the study is provided in Appendix  1.  
The schedule of activities related to PRO  assessme nts is provided in Appendix  2.  
All activities should be performed an d documented for each patient.  
Patients will be closely monitored for  safety and tolerability throughout the study.  
Patients should be assessed for toxicity prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are acceptable.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
67/Protocol GO42661 , Version [ADDRESS_198262] be obtained before 
performing any  study -related procedures  (including screening evaluations) .  
Informed  Consent Forms for enrolled patients and for patients who are not subsequently 
enrolled will be mai ntained at the study site.  
All screening evaluations must be completed and reviewed to confirm that patients meet 
all eligibility criteria before enrollment .  The investigator will maintain a detailed record of 
all patients screened and , to document  eligib ility or record reasons for screening failure, 
as applicable.  Patients who do not initially meet all eligibility criteria for participation in 
this study (screen failure) may qualify for one re-screening opportunity (for a total of two 
screenings per pati ent) at the discretion of the  investigator.  Patients are not requ ired to 
re-sign the Informed Consent Form if  they are re -screened within [ADDRESS_198263] reasons for 
screen failure in the screening log . 
4.5.2  Medical History , Baseline Conditions, Concomitant Medication,  
and Demographic Data  
Medical history , including  clinically significant diseases, surgeries, cancer history 
(including prior cancer therapi[INVESTIGATOR_26649]), reproductive status, smoking 
history , and use of alcohol  and drugs of abuse , will be recorded  at baseline .  In addition, 
all medications (e.g.,  prescription drugs, over -the-counter drugs, vaccines, herbal or 
homeopathic remedies, nutritional supplement s) used by [CONTACT_25701] 7  days prior 
to Day 1 of Cycle 1  will be recorded.   At the time of each follow -up physical examination, 
an interval med ical history should be obtained and any changes in medications and 
allergies should be recorded.  
Demographic data will include age, sex, and self -reported race/ethnicity.  
4.5.[ADDRESS_198264] abnormalities observed at baseline on the 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
68/Protocol GO42661 , Version [ADDRESS_198265] 
new or worsened clinically significant abnormalities on the Adverse Event eCRF.  
Vital signs are to be measure d before, during, and after infusions as outlined in Table  5, 
and at other specified timepoints as outlined in the schedule of activities 
(see Appendix  1). 
Table  [ADDRESS_198266] Infusion  Subsequent Infusions  
Atezolizumab   Within 60 minutes prior to the 
atezolizumab infusion  
 Record patient's vital signs during or 
after the i nfusion if clinically indicated   Within 60 minutes prior to the 
atezolizumab infusion  
 Record patient's vital signs during or 
after the infusion if clinically 
indicated  
Bevacizumab/ 
placebo   Within 60 minutes prior to the 
bevacizumab /placebo  infusion   Within 60 minutes prior to the 
bevacizumab /placebo  infusion  
 At the end of infusion and 
2 ( 1) hours after the infusion   At the end of infusion and 
2 ( 1) hours after the infusion  
 
4.5.5  Tumor and Response Evaluations  
Patients will undergo tumor assessments at baseline and every 9 ( 1) weeks thereafter, 
regardless of dose delays,  until radiographic disease progression per RECIST v1.1  or 
(for patients who continue atezolizumab plus bevacizumab or placebo , after radiographic 
disease progression) loss of clinical benefit , as determined by [CONTACT_093]  
(see Section  3.1 for details ).  Thus, tumor assessments are to continue according to 
schedule in patients who discontinue treatment for reasons ot her than disease 
progression or loss of clinical benefit, even if they start a new anti -cancer therapy.  At the 
investigator's discretion, tumor assessments may be repeated at any time if progressi ve 
disease is suspected . 
All measurable and evaluable lesions should be assessed and documented at 
screening.   Tumor assessments performed as standard of care prior to obtaining 
informed consent and within [ADDRESS_198267] scans (with oral or IV contrast) or MRI  scan s of 
the chest, abdomen, and pelvis .  A spi[INVESTIGATOR_70058] a requirement.   If a CT scan with contrast is contraindicated ( e.g., in patients with 
impaired renal clearan ce), a non -contrast CT scan of the chest may be performed and 
MRI scan s of the abdomen and pelvis should be performed.   A CT scan with contrast or 
MRI scan of the head must be done at screening to evaluate CNS metastasis in all 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
69/Protocol GO42661 , Version 6 patients  (MRI scan must be p erformed if CT scan  is contraindicated) .  An MRI scan of 
the head  is required to confirm or refute the diagnosis of CNS metastases at baseline in 
the event of an equivocal CT scan.   Bone scans and CT scans of  the neck should also 
be performed if clinically  indicated.  At the investigator's discretion, other methods 
of assessment of measurable disease as per RECIST v1.[ADDRESS_198268] scan for tumor assessment is performed in a positron emission tomography 
(PET)/CT scanner, the CT acquisition must be consistent with the standards for 
a full-contrast diagnostic CT scan.  
All measurable and evaluable lesions identified at baseline should be re -assessed at 
each subsequent tumor evaluation.   The same radiographic procedures used to assess 
disease sites at s creening should be used for subsequent tumor assessments (e.g., the 
same contrast protocol for CT  scans).  
Objective response at a single timepoint will be determined by [CONTACT_76677] v1.1 ( see Appendix  5).  Assessments should be performed by [CONTACT_169868], if possible, to ensure internal consistency across visits.  
4.5.6  Laboratory , Biomarker, and Other Biological Samples  
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis:  
 Hematology:  RBC count, hemoglobin, hematocrit, WBC count with differential 
(neutrophils, lymphocytes, eosinophils, monocytes,  basophils), and platelet count  
 Chemistry panel (serum or plasma):  bicarbon ate or total carbon dioxide 
(if considered standard of care for the region), magnesium, sodium, potassium, 
chloride, glucose, BUN or urea, creatinine, total  protein, albumin, phosphate , 
calcium, total bilirubin, ALP, ALT, AST, and LDH 
 Coagulation:  INR and aPTT  
 Thyroid -function testing:  thyroid -stimulating hormone, free triiodothyronine  (T3) 
(or total T3 for sites where free T3 is not performed) , and free thyroxine  (also known  
as T4) 
 HIV serology  
 HBV serology:  hepatitis B surface antigen (HBsAg), hepatitis B surface antibody, 
total hepatitis B core antibody (HBcAb), and HBV DNA  
If a patient has a positive HBsAg test and/or a positive total HBcAb test at 
screening, an HBV DNA t est and a quantitative HBsAg test must also be 
performed during screening to determine if the patient has an HBV infection, as 
well as at Cycles [ADDRESS_198269] is not available, a qualitative HB sAg followed by a quantitative HBV 
DNA can be performed as an alternative.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
70/Protocol GO42661 , Version 6  HCV serology:  HCV antibody and (if HCV antibody test is positive) HCV RNA  
If a patient has a positive HCV antibody test at screening, an HCV RNA test must 
also be performed to determine if the patient has an HCV infection.  
 C-reactive protein  
 CA19 -9 
 Pregnancy test  
All women of childbearing potential will have a serum pregnancy test at 
screening.  Urine pregnancy tests will be performed at specified subsequent 
visits.  If  a urine pregnancy test is positive, it must be confirmed by a serum 
pregnancy test.  
A woman is considered to be of childbearing potential if she is postmenarchal, 
has not reached a postmenopausal state (  12 continuous months of amenorrhea 
with no identified cause  other than menopause), and is not permanently infertile 
due to surgery (i.e., removal of ovaries, fallopi[INVESTIGATOR_2134], and/or uterus) or another 
cause as determined by [CONTACT_093] (e.g.,  Müllerian agenesis).  
 Urinalysis (pH, specific gravity, glucose, pro tein, ketones, and  blood); dipstick 
permitted  
 
The following samples will be sent to  one or several central laboratories or to the 
Sponsor  or a designee for analysis:  
 Serum samples for atezolizumab PK analysis through use of a validated assay  
 Serum samples  for assessment of anti-drug antibodies ( ADAs ) to atezolizumab 
through use of a validated assay  
 Blood, serum, plasma , and peripheral blood mononuclear cell ( PBMC ) samples for 
exploratory research on biomarkers  and biomarker assay development  
 Whole metagenomics  sequencing and comprehensive analysis of the microbiome 
will be perfo rmed on stool samples  for exploratory microbiome research  
 A representative tumor specimen that is suitable for determination of PD -L1 status 
via central testing  
A FFPE tumor specimen in a paraffin block (preferred) or at least 16 slides 
containing unstained, freshly cut, serial sections should be submitted along with 
an assoc iated pathology report within 4  weeks of randomization  
If FFPE specimens described above are not availa ble, any type of specimen 
(including fine -needle aspi[INVESTIGATOR_1516], cell pellet specimens [e.g., from pleural 
effusion], and lavage samples) are also acceptable.  This specimen should be 
accompanied by [CONTACT_40869].  
If archival tissue is either  insufficient or unavailable, a core -needle biopsy 
specimen should be collected during the screening period, if clinically 
feasible.  Transjugular biopsy tissue sample collections for patients who 
are at high risk of bleeding may be allowed.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
71/Protocol GO42661 , Version [ADDRESS_198270] contain a minimum of 50  viable tumor cells that preserve cellular 
context and tissue architecture regardless of needle gauge or retrieval method .  
Samples collected via resection, core-needle biopsy  (at least 3 cores , embedded 
in a single paraffin block ), or excisional, incisi onal, punch, or forceps biopsy are 
acceptable . 
If archival tumor tissue is unavailable  or is determined to be unsuitable for 
required testing , a pretreatment tumor biopsy is required , if clinically feasible .  
A pretreatment tumor biopsy may also be performed if a patient' s archival tissue 
test results do not meet eligibility criteria.  
 
Exploratory biomarker research may include, but will not be limited to, analysis of genes 
or gene signatures associated with tumor immunobiology, PD -L1, immune cell 
subpopulation s, T cellreceptor repertoire, or cytokines associated with T -cell activation .  
Research may involve extraction of DNA, cell -free DNA, or RNA; analysis of mutations, 
single nucleotide polymorphisms, and other genomic variants; and genomic profiling 
through use of next -generation sequencing of a comprehensive panel of genes.  
DNA  extracted from blood may be compared with DNA extracted from tissue to identify 
somatic variants by [CONTACT_169869].  
Next-generation sequencing methods will include WES of tissue and blood samples, but 
WES of blood samples will be performed only at participating sites (see Section  4.5.9 ). 
Screening blood and tumor  tissue  samples, including those collected from patients who 
do not enroll in the study, may be used for future research and/or development of 
disease -related tests or tools.  
For sampling procedures, storage conditions, and shipm ent instructions, see the 
laboratory manual.  
Biological samples will be destroyed no later than the time of completion of the final 
Clinical Study Report, with the following exceptions:  
 Plasma  and/or  Serum samples collected for PK or immunogenicity analysi s may be 
needed for additional immunogenicity characterization and for PK or immunogenicity 
assay  development and  validation ; therefore, these samples  will be destroyed no 
later than 5 years after the final Clinical Study Report  has been completed  
 Blood, plasma, serum , PBMC,  and tumor tissue samples  collected for biomarker 
research will be destroyed no later than [ADDRESS_198271] ( IRB)/Ethics Committee ( EC)-approved Informed 
Consent Form and applicable laws (e.g.,  health authority requirements)  
 For enrolled patients, remaining archival tissue blocks will be returned to the site 
upon request or no later than the time of  final closure of the study database, 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
72/Protocol GO42661 , Version [ADDRESS_198272] review, sign, and date all ECG 
tracings.  Paper copi[INVESTIGATOR_26650]'s permanent 
study file at the site.  Any morphologic waveform changes or o ther ECG abnormalities 
must be documented on the eCRF.  
4.5.8  Clinical Outcome Assessments  
Patient -reported outcome  instruments will be completed t o more fully characterize the 
clinical profile of Atezolizumab   Bevacizumab   CisGem  compared with 
Atezo lizumab   Placebo   CisGem .  Patient -reported outcome  data will be 
collected  through use of the following instruments:  
 European Organisation for Research and Treatment of Cancer (EORTC) 
quality -of-life questionnaire  (QLQ -C30) 
 European Organisation for Research and T reatment of Cancer  quality -of-life 
questionnaire for cholangiocarcinoma and cancer of the gallbladder (QLQ -BIL21 ) 
 Selected items from the EORTC Item Library (IL ) 77 
 Patient Global Impression of Change  and its Importance  (PGI-CI) 
 Patient Global  Impression of Severity (PGI -S) 
 Patient -Reported Outcome Common Terminology Criteria for Adverse Events 
(PRO -CTCAE)  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
73/Protocol GO42661 , Version 6  
[IP_ADDRESS]  Data Collection Methods for Clinical Outcome Assessments  
Patient -reported outcome  instruments will be completed  at home or the clinic at sp ecified 
timepoints during the study (see schedule of activities in  Appendix  2).  Instruments will 
be administered before the patient recei ves any information on disease status, prior to 
the performance of non -PRO assessments, and prior to the administration of study 
treatment, unless otherwise specified.  
Patient -reported outcome  instruments, translated into the local language as appropriate,  
will be completed during clinic visits through use of an electronic device provided by [CONTACT_169870] .  The device will be pre -programmed to enable the appropriate 
instruments to be administered in the correct order at each specified timepoint.   The 
electronic device and instructions for completing the instrument s electronically will be 
provided by [CONTACT_7893].  The data will be transmitted to a centralized database 
maintained by [CONTACT_40893].  The data will be available for a ccess by 
[CONTACT_108897].   In circumstances when the electronic device is not 
available (e.g.,  device failure or due to supply issues),  a backup data collection method 
(e.g., web backup) will be used .  Cycle s 15 Day  15 PRO  assessments will be 
completed at home via telephone interview with patient responses collected on the 
device (or web backup) by [CONTACT_6624] . 
Patients should be given the following instructions for completing PRO instruments at 
home:  
 Patients should complete  the instruments in a quiet area with minimal distractions 
and disruptions  
 Patients should answer questions to the best of their ability; ther e are no right or 
wrong answers  
 Patients should not obtain advice or help from others (e.g., family members or 
friends) when completing the instruments  
 
During clinic visits, PRO instruments should be administered as outlined below:  
 Patients' health status should not be discussed prior t o administration of the 
instruments  
 Sites must administer the official version of each instrument, as provided by [CONTACT_429].  Instruments must not be copi[INVESTIGATOR_169804]  
 Sites should allow sufficient time for patients to complete the instruments, es timated 
to be 20 minutes at each specified visit  
 Sites should administer the instruments in a quiet area with minimal distractions and 
disruptions  
 Patients should be instructed to answer questions to the best of their ability; ther e 
are no right or wrong a nswers  
 Site staff should not interpret or explain questions, but may read questions verbatim 
upon request  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
74/Protocol GO42661 , Version 6  Patients should not obtain advice or help from others (e.g., family members or 
friends) when completing the instruments  
 
[IP_ADDRESS]  Description of Clinical Outcome Assessment Instruments  
EORTC QLQ -C30 
The EORTC QLQ -C30 is a valid ated and reliable self -report ed measure 
(Aaronson  et al. 1993; Fayers et al. 2001) ; see Appendix  6).  It consists of 30  questions 
that assess 5 aspects of patient functioning (physical, emotional, role, cognitive, 
and social), Global Health Status and Quality of Life (GHS/ QoL), and 9 symptoms  
(fatigue, nausea and vomiting, pain , dyspnea, insomnia, appetite loss, constipation, 
diarrhea, and financial difficulties) with a recall period of the previous week.  The 
functioning and symptoms items are scored on a 4 -point scale that ranges from not at 
all to very much,  and the GHS/QoL  items are scored on a 7 -point scale that ranges 
from very poor  to excellent.  
EORTC QLQ -BIL21  
The EORTC QLQ -BIL21 is a validated and reliable self-report ed measure that serves as 
a modular supplement to the QLQ -C30 for use in patients w ith CCA and cancer of the 
gallbladder (Kaupp -Roberts et al. 2016; see Appendix  7).  It consists of 21  questions that  
assess 8 symptom s (eating, jaun dice, tiredness, pain, anxiety, treatment side  effects, 
difficulties with draining bags/tube, and concerns regarding weight l oss) with a recall 
period of the previous week .  The scoring  for the QLQ -BIL21 follows that of the 
QLQ -C30.  
EORTC IL77  
The EORTC IL77 is a reduced version of the QLQ -C30 that was created specifically for 
this study from the EORTC Quality of Life Group I IL (https://www.eortc.be/itemlibrary/ ).  
It consists of 12 questions  that assess  2 aspects of patient functioning (physical and 
role), GHS/QoL, and 2 symptoms ( nausea and vomiting , and appetite loss)  with a recall 
period of the previous week (see Appendix  8).  The scoring for the IL77 follows  that of  
the QLQ -C30.  
PGI-CI 
The PGI -CI is a 2-item, self -reported measure used to assess patients’ impression about 
changes to their overall health because of their cancer and the associated importance 
compared with when they began the study (see  Appendix  9).  In the first item, the  PGI-CI 
utilizes a 7 -point response scale that  ranges from very much worse  to very much 
improved (adapted  from Guy et al. 1976).  In the second item, the PGI -CI utilizes 
a 3-point response scale (yes, no, and not applicable ) for patients to indicate if the 
change  they experienced (and reported in the first item) was important to them . 
PGI-S 
The PGI-S is a 1-item, self -reported measure used to assess patients ’ impression about 
how severely their overall health has been impacted because of their cancer during the 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
75/Protocol GO42661 , Version 6 preceding week  (see Appendix  10).  The  PGI-S utilizes a 5 -point response scale that  
ranges from very severe  to none (adapted from Guy et al. 1976).  
PRO -CTCAE  
The PRO -CTCAE is a validated item bank that is used to characterize the presence, 
frequency of occurrence, severity, and/or degree of interference with daily function of 
78 patient -reportable symptomatic treatment toxic ities (Basch et al. 2014; 
Dueck  et al. 2015).  The PRO -CTCAE contains 124 questions that are  rated either 
dichotomously (for determination of presence vs. absence) or on a 5 -point Likert scale 
(for determination of frequency of occurrence, severity, and interference with daily 
function).  Treatment toxicities can occur with observable signs (e.g. , vomiting) or 
non-observable symptoms (e.g., nausea).  The standard PRO -CTCAE recall period is 
the previous [ADDRESS_198273] applicable to the current treatments has been 
selected for this study (see  Appendix  11).  Symptoms have been selected on the basis 
of known adverse drug reactions , mechanism of action of the treatments under 
investigation, and recent work to identify common adverse events associ ated with 
immunotherapi[INVESTIGATOR_014] (King -Kallimanis et al. 2019; Hansen et al. 2020).  
4.5.9  Blood Samples for Whole Exome Sequencing (Patients at 
Participating Sites)  
At participating sites, blood samples  will be collected for DNA extraction to enable WES 
to identify var iants that are predictive of response to study drug, are associated with 
progression to a more severe disease state, are associated with acqu ired resistance to 
study drug, are associated with susceptibility to developi[INVESTIGATOR_68146], can lead to 
improve d adverse event monitoring or investigation, or can increase the knowledge and 
understanding of disease biology and drug safety.  DNA extracted from blood may be 
compared with DNA extracted from tissue to identify somatic variants by [CONTACT_169871] e variants from somatic variants.  The samples may be sent to one or more 
laboratories for analysis . 
Collection and submission of blood samples for WES is contingent upon the review and 
approval of the exploratory research by [CONTACT_25733]'s IRB or EC and, if applicable, an 
appropriate regulatory body.  If a site has not been granted approval for WES, this 
section of the protocol (Section  4.5.9 ) will not be applicable at that site.  
Genomics is increasingly informing researcher's understanding of disease pathobiology.  
WES  provide s a comprehensive characterization of the exome, and, along with clinical 
data collected in this study, may increase the opportunity for developi[INVESTIGATOR_169805] a drug or develop adverse events.  Data will be 
analyzed in the context of this study but may also be explored in aggregate with data 
from other studies.  The availability of a larger dataset will assist in identification and 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
76/Protocol GO42661 , Version 6 characterization of important biomarkers and pathways to support future drug 
development.  
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.  
Blood samples collected for WES are to be stored no later than 5  years  after the final 
Clinical Study Report has been completed.  However, the storage period will be in 
accordance with the IRB/EC -approved Informed Consent Form and applicable laws 
(e.g.,  health authority requirements).  
See Section  4.5.6  for details on use of samples after patient withdrawal, confidentiality 
standards for data, and availability of data from biomarker analyses.  
4.5.10  Optional Tumor Biopsies  
Consenting patients will undergo optional tumor biopsies at 24 weeks after treatment 
initiation , at disease progression , and may undergo additional on -treatment biopsies at 
any other time at the investigator's discretion  (if deemed clinically fea sible by [CONTACT_1275]) .  Samples collected via resection, core -needle biopsy (at least 3 cores 
preferred), or excisional, incisional, punch, or forceps biopsy are preferred.  
The Informed Consent Form will contain a separate section that addresses optio nal 
biopsies.  A separate, specific signature  [CONTACT_22862] a  patient's 
agreement to undergo optional biopsies.  The investigator should document whether or 
not the patient has given consent to participate and (if applicable) the date(s) of consent, 
by [CONTACT_169872].  
Samples may be used for exploratory biomarker research as described in Section  4.5.6 .  
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.  See Section  4.5.6  for details on duration of sample storage, use of 
samples after patient withdrawal, confidentiality standards for data, and availability o f 
data from biomarker analyses.  
4.5.11  Optional Stool Samples  
Patients will b e given the option of consenting to prov ide stool samples.  Optional stool 
samples will be collected at baseline and one additional timepoi nt between Cycle  2 and 
Cycle  3. 
The Informed Consent Form will contain a separate section that ad dresses optional sto ol 
samples.  A separate, specific signature [CONTACT_22862] a patient's 
agreement to provide optional stool samples.   The investigator should document 
whether or not the patient has given consent to participate and (if applicable) the date(s) 
of consent, by [CONTACT_169873].  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
77/Protocol GO42661 , Version 6 The gut microbiome has been shown to be a key determinant in immune regulation in 
cancer, in part by [CONTACT_169874] T -cell driven anti -tumor resp onses (Routy et al. 2018).  
For example , antibiotic treatment is associated with poor survival outcomes to anti PD-1 
therapy in NSCLC, RCC, and urothelial carcinoma (Elkrief et al. 2019).  Conversely, the 
risk of colitis with CITs may be predicted based on a patient’s pretreatment microbiome 
(Dubin et al. 2016; Chaput et al. 2017).  Thus, heterogeneity in microbiome composition 
across patients may be a key driver of safety events in addition to efficacy.  Whereas  gut 
bacteria have been implicated in the development of liver cancer, their impact on the 
efficacy of CIT is still unknown.  
This study will examine whether a patient’s microbi ome can determine response to a  CIT 
combination, and conversely, whether a CIT combination can alter the microbiome to 
such an extent that on -treatment changes to t he microbiome could be early predictors of 
adverse events, including colitis.  Analyzing the microbiome in BTC may provide the 
opportunity to discover systemic effects on distal cancers.  
Samples may be used for exploratory biomarker research as described i n Section  4.5.[ADDRESS_198274] permanently discontinue study treatment  (atezolizumab , 
bevacizumab /placebo , and chemotherapy ) if they experience any of the following:  
 Intolerable toxicity related to study treatment , including development of an 
immune -mediated adverse event determined by [CONTACT_70150]'s potential response to therapy and  severity of the event  
 Any medical condition that may jeopardize the patient's safet y if he or she continues 
study treatment  
 Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the patient  
 Use of another non -protocol anti -cancer therapy  
 Pregnancy  
 Loss of clinical benefit , as determined by [CONTACT_34462] , after an integrated 
assessment of radiographic and biochemical data, local biopsy results (if available), 
and clinical status (e.g., symptomatic deterioration such  as pain secondary to 
disease; see Section  3.1 for details)  
 
If one component of study treatment is transiently withheld or permanently discontinued 
because of tolerability concerns, the patient may continue with the other components of 
study treatment until loss of clinical benefit, as long as the patients are expe riencing 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
78/Protocol GO42661 , Version 6 clinical benefit in the opi[INVESTIGATOR_871] .  However, bevacizumab/place bo should 
not be continued as a  single agent.  
The primary reason for study treatment  discontinuation should be documented on the 
appropriate eCRF.   Patients who discon tinue study treatment prematurely will not be 
replaced.  
Patients will return to the clinic for a treatment discontinuation visit  30 days  after the 
final dose of study treatment .  The visit at which response assessment shows 
progressive disease may be use d as the t reatment discontinuation visit.   Patients who 
discontinue study treatment for any reason other than progressive disease or loss of 
clinical benefit will continue to under go tumor response assessments as outlined in the 
schedule of activities (see Appendix  1). 
After treatment discontinuation, information on survival follow -up and new ant i-cancer 
therapy will be collected via telephone calls, patient medical records, and/or clinic visits 
approximately every 3 months  until death  (unless the patient withdraws consent or the 
Sponsor terminates the study).  
4.5.[ADDRESS_198275] the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for patient discontinuation from the study may include, but are not limited to, 
the following:  
 Patient withdrawal of consent  
 Study termination or site closure  
 Loss to follow -up 
 Patient non -compliance, defined as failure to comply with protocol requirements as 
determined by [CONTACT_169875] a reason for patient discontinuation from the 
study.  The primary reason for discontinuation from the study should be documented on 
the appropriate eCRF.  If a patient requests to be withdrawn from the study, this requ est 
must be documented in the source documents and signed by [CONTACT_093].  Patients 
who withdraw from the study will not be replaced.  
If a patient withdraws from the study, the study staff may use a public information source 
(e.g.,  county records) to obtain in formation about survival status . 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
79/Protocol GO42661 , Version 6 4.5.14  Study Discontinuation  
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:  
 The incidence or severity of adverse events in th is or other studies indicates 
a potential health hazard to patients  
 Patie nt enrollment is unsatisfactory  
 
The Sponsor will notify the investigator if the Sponsor dec ides to discontinue the study.  
4.5.15  Site Discontinuation  
The Sponsor has the right t o close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:  
 Excessively slow recruitment  
 Poor protocol adherence  
 Inaccurate or incomplete data recording  
 Non-compliance with the International Council for Harmo nisation  (ICH) guideline for 
Good Clinical Practice  
 No study activity (i.e., all patients have completed the study and all obligations have 
been fulfilled)  
 
5. ASSESSMENT OF SAFETY  
5.1 SAFETY PLAN  
The safety plan for patients in this study is based on clinical ex perience with 
atezolizumab  and bevacizumab  in completed and ongoing studies.  The anticipated 
important safety risks are outlined below  (see Section s 5.1.1 , 5.1.2 , 5.1.3 , and 5.1.4 ). 
Measures will be taken to ensure the safety of patients participating in this study, 
including the use of stringent inclusion and exclusion criteria and close monitoring of 
patients during the study.  Administration of atezolizumab  and bevacizumab /placebo  will 
be performed in a monitored setting in which  there is immediate access to trained 
personnel and adequate equipment and medicine to manage potentially serious 
reactions.  Guidelines for managing patients who experience anticipated adverse events, 
including criteria for treatment interruption or discontinuat ion, are provided in 
Appendix  14, and Appendix  15.  See Sections 5.2, 5.3, 5.4, 5.5, and  5.6 for details on 
safety reporting (e.g.,  adverse events, pregnancies) for this study.  
Patients with active infection are excluded from study participatio n.  In the setting of 
a pandemic or epi[INVESTIGATOR_901], screening for active infections (including SARS -CoV-2) prior to 
and during study participation should be considered according to local or institutional 
guidelines or guidelines of applicable professional societies (e.g., American Soci ety of 
Clinical Oncology  or European Society for Medical Oncology ). 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
80/Protocol GO42661 , Version 6 Severe SARS -CoV-2 infection  appears to be associated with a CRS involving the 
inflammatory cytokines IL -6, IL-10, IL -2, and IFN - (Merad and Martin 2020 ).  If a patient 
develops suspected CRS during the study, a differential diagnosis should include 
SARS -CoV-2 infection , which should be confirmed or refuted through assessment of 
exposure history, appropriate laboratory testing, and clinical or radiologic evaluations per 
investigator judgmen t.  If a diagnosis of SARS -CoV-2 infection  is confirmed, the disease 
should be managed as per local or institutional guidelines.  
5.1.1  Risks Associated with Atezolizumab  
Atezolizumab has been associated with risks such as the following:  IRRs and 
immune -mediated  hepatitis, pneumonitis, colitis, pancreatitis, diabetes mellitus, 
hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, Guillain -Barré  
syndrome, myasthenic syndrome or myasthenia gravis,  facial paresis, myelitis, 
meningoencephalitis, myoca rditis, pericardial disorders, nephritis, myositis , and severe 
cutaneous adverse reactions .  In addition, immune -mediated  reactions may involv e any 
organ system and lead  to hemophagocytic lymphohistiocytosis  (HLH) .  Refer to 
Appendix  15 of the protocol and Section  6 of the Atezolizumab Investigator's Brochure 
for a detailed description of anticipated safety ris ks for atezolizumab.  
5.1.2  Risks Associated with Bevacizumab  
Bevacizumab has been associated with risks such as the following:   GI perforations, 
hemorrhage, arterial thromboembolic events, fistulae, wound -healing complications, 
hypertension, venous th romboembolism, and proteinuria.  
See Appendix  14 of the protocol and  Section  6 of the Bevacizumab  Investigator's 
Brochure for a detailed de scription of anticipated safety risks for bevacizumab . 
5.1.[ADDRESS_198276] been associated with each agent separately (e.g.,  hemorrhage, 
hypothyroidism, and GI  toxicity) may be ambiguous w hen the agents are administered 
together.  It is theoretically possible that allergic or inflammatory adverse events 
associated with bevacizumab could be exacerbated by [CONTACT_109839].  
5.1.4  Risks Associated with Cisplatin  or Gemc itabine  
For adverse reactions, warnings, and precautions for CisGem , see the local prescribing 
information.  See Section  5.1.5  for dose modifications and Appendix  14 for management 
of risks associated w ith CisGem . 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
81/Protocol GO42661 , Version [ADDRESS_198277] with these recommendations , however treatment with 
sargramostim is not allowed . 
Table  6 Dose -Modification Levels  for Cisplatin and Gemcitabine 
Treatment  Starting 
Dose  Dose  
Level  1 Dose  
Level  2 Dose  
Level  3 Dose  
Level 4 
Cisplatin a 25 mg/m2 20 mg/m2 15 mg/m2 Discontinue   
Gemcitabine b 1000 mg/m2 800 mg/m2 600 mg/m2 Discontinue   
a No dose re -escalation of cisplatin is allowed after a dose reduction to a lower dose level. 
b Dose re -escalations  are only permitted for the Day [ADDRESS_198278], regardless of causal attribution.  An adverse event can 
therefore be any of the following:  
 Any unfavorable and unintended sign (including an abnormal laboratory finding ), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product  
 Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a k nown condition) (see Sections  [IP_ADDRESS]  
and [IP_ADDRESS]  for more information)  
 Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
82/Protocol GO42661 , Version 6  Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study treatment  
 Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment o f study treatment (e.g.,  screening invasive 
procedures such as biopsies)  
 
5.2.2  Serious Adverse Events (Immediately Reportable to the 
Sponsor ) 
A serious adverse event is any adverse event that meets any of the following criteria:  
 Is fatal (i.e., the adverse event actually causes or leads to death)  
 Is life-threatening (i.e.,  the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)  
This does not include any adverse event that , had it occurred in a more severe 
form or wa s allowed to continue , might have caused death.  
 Requires or prolongs inpatient hosp italization (see Section  [IP_ADDRESS] ) 
 Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient's ability to conduct normal life 
functions)  
 Is a congenital anomaly/birth defect in a neonate/infant born to a mother expos ed to 
study treatment  
 Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)  
 
The terms severe and serious are not synony mous.  Severity refers to the intensity 
of an adverse event ( e.g., rated as mild, moderate,  or severe, or according to 
NCI CTCAE; see Section  5.3.3 ); the event itself may be of relatively minor medical 
significance (such as severe headache without any further findings).  
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.  
Serious adverse events are required to be reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the event; see Section  5.4.2  for 
reporting instructions).  
5.2.[ADDRESS_198279] (Immediately Reportable to 
the Sponsor ) 
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no mo re than 24 hours after learning of the event; 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
83/Protocol GO42661 , Version 6 see Section  5.4.2  for reporting instructions).  Adverse events of special interest for thi s 
study are as follows : 
 Cases of potential drug -induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
[CONTACT_25742]'s Law (see Section  [IP_ADDRESS] ) 
 Suspected transmission of an infectious agent by [CONTACT_104841] , as defined 
below  
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate  an infection 
in a patient exposed  to a medicinal product.  This term applies only when 
a contamination of study treatment  is suspected.  
 Systemic lupus erythematosus  
 Events suggestive of hypersensitivity, IRRs , CRS , HLH, and  MAS  
 Nephritis  
 Ocular toxicities (e.g., uveitis, retinitis , optic neuritis ) 
 Grade  2 cardiac disorders  
 Vasculitis  
 Autoimmune hemolytic anemia  
 Severe cutaneous reactions (e.g., Stevens -Johnson syndrome, dermatitis bullous, 
toxic epi[INVESTIGATOR_194])  
 Grade   3 hypertension  
 Grade   3 proteinuria  
 Any grade GI perforation,  abscess, or fistula  
 Grade  2 non -GI fistula or abscess  
 Grade   3 wound -healing complication  
 Hemorrhage  
– Any grade CNS bleeding  
– Grade  2 hemoptysis  
– Other Grade   3 hemorrhagic event  
 Any arterial thromboembolic event  
 Grade   3 venous thromboembolic event  
 Any grade posterior reversible encephalopathy syndrome  
 Grade   3 congestive heart failure  
 Myelitis  
 Facial paresis  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
84/Protocol GO42661 , Version 6  
5.3 METHODS AND TIMING F OR CAPTURING AND ASS ESSING 
SAFETY  PARAMETERS  
The investigator is responsible for ensuring that all adverse events (see Se ction  5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to  the Sponsor in 
accordance with instructions provided in this section and in Sections 5.4, 5.5, and 5.6. 
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section  5.2.2  for seriousness criteria), severity 
(see Section  5.3.3 ), and causality (see Section  5.3.4 ). 
5.3.[ADDRESS_198280].  
All adverse events, whether reported by [CONTACT_25743],  will be 
recorded in the patient's medical record and on the Adverse Event eCRF.  
After informed consent has been obtained but prior to initiation of study treatment , only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section  5.4.2  for instructions for reporting serious adverse events).  
After initiation of study treatment  on Day [ADDRESS_198281]. 
Instructions for reporting adverse events that occur after the adverse event reporting 
period  are provided in Section 5.6. 
5.3.2  Eliciting Adverse Event Information  
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event in formation at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:  
How have you felt since your last clinic visit?  
Have you had any new or changed health problems since you were last here?  
 
5.3.3  Assessment of Severit y of Adverse Events  
The adverse event severity grading scale for the NCI CTCAE (v 5.0) will be used for 
assessing adverse event severity.  Table  7 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
85/Protocol GO42661 , Version 6 Table  7 Adverse Event Severity Grading Scale  for Events Not Sp ecifically 
Listed in NCI CTCAE  
Grade  Severity  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
or intervention not indicated  
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a 
3 Severe or medically significant, but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; or 
limiting  self-care activities of daily living b, c 
4 Life-threatening consequences or urgent intervention indicated d 
5 Death related to adverse event d 
NCI CTCAE   National Cancer Institute Common Terminology Criteria for Adverse Events.  
Note:  Based on the most recent version of NCI CTCAE (v 5.0), which can be found at:   
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
a Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.  
b Examples of sel f-care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by [CONTACT_25744].  
c If an event is assessed as a significant medical event,  it must be re ported as a serious 
adverse event (see Section  5.4.2  for reporting instructions), per the definition of serious 
adverse event in Section  5.2.[ADDRESS_198282] be reported as serious adverse events (see Section  5.4.2  for 
reporting instructions),  per the definition of serious adverse event in Section  5.2.2 . 
 
5.3.4  Assessment of Causality of Adverse Events  
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to study treatment , indicating yes or no 
accordingly.  The following guidance should be taken into consideration  
(see also Table  8): 
 Temporal relationship of event onset to the initiation of study treatment  
 Course of the event, with special consideration of the effects  of dose reduction, 
discontinuation of study treatment , or reintroduction of study treatment  
(as applicable)  
 Known association of the event with study treatment  or with similar treatments  
 Known association of the event with the disease under study  
 Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event  
 Presence of non treatment -related factors that a re known to be associated with the 
occurrence of the event  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
86/Protocol GO42661 , Version 6  
Table  8 Causal Attribution Guidance  
Is the adverse event suspected to be caused by [CONTACT_169876], 
evidence, science -based rationales, and clinical j udgment?  
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of study treatment , and the adverse event cannot be readily explained by 
[CONTACT_102]'s  clinical state, intercurrent illness, or concomitant t herapi[INVESTIGATOR_014]; and/or the 
adverse event follows a known pattern of response to study treatment ; and/or the 
adverse event abates or resolves upon discontinuation of study treatment  or dose 
reduction and, if  applicable, reappears upon re -challenge.  
NO An adverse  event will be considered related, unless it fulfills the criteria specified below . 
Evidence exists that the adverse event has an etiology other than study treatment  
(e.g.,  preexisting medical condition, underlying disease, intercurrent illness, 
or concomi tant medication); and/or the adverse event has no plausible temporal 
relationship to administration of study treatment  (e.g., cancer diagnosed [ADDRESS_198283] dose of study treatment ). 
 
For patients receiving combination therapy, causality will be assessed individually for 
each protocol -mandated therapy.  
5.3.[ADDRESS_198284] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations . 
Only 1 adverse event term should be recorded in the event field on the 
Adverse  Event  eCRF.  
[IP_ADDRESS]  Infusion -Related Reactions  and Cytokine  Release Syndrome  
There may be significant overlap in signs and symptoms of IRRs and CRS.  While IRRs 
occur during or within  24 hours after treatment administration, time to onset of CRS may 
vary.  Differential diagnosis should be applied, particularly for late -onset CRS ( occurring  
more than 24 hours after treatment administration), to rule out other etiologies such as 
delayed hypersensitivity reactions, sepsis or infections, HLH, tumor lysis syndrome, 
early disease progression, or other manifestations of systemic inflammation.  
Adverse events that occur during or within 24 hours after study treatment administration 
and are judge d to be related to study treatment infusion should be captured on the 
Adverse Event eCRF as a diagnosis (e.g., infusion -related reaction  or cytokine  
release syndrome ).  Avoid ambiguous terms such as systemic reaction.   Cases of 
late-onset CRS should be reported as cytokine  release syndrome  on the 
Adverse  Event eCRF.  Associated signs and symptoms of an IRR should be recorded on 
the dedicated I nfusion -Related Reaction eCRF.  
If a patient experiences both a local and systemic reaction to a single administration  of 
study treatment, each reaction should be recorded separately on the 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
87/Protocol GO42661 , Version 6 Adverse  Event  eCRF, with associated signs and symptoms of an IRR also recorded 
separately on the dedicated Infusion -Related Reaction eCRF.  
In recognition of the challenge s in clinically distinguishing between IRRs and CRS, 
consolidated guidelines  for medical management of IRRs and CRS are provided in 
Appendix  14. 
[IP_ADDRESS]  Diagnosis versus Signs and Symptoms  
A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than 
jaundice, asterixis, and elevated transaminas es).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or syndrome 
at the time of reporting, each individual event should be recorded on the 
Adverse  Event  eCRF.  If a diagnosis is subsequently est ablished, all previously reported 
adverse events based on signs and symptoms should be nullified and replaced by [CONTACT_169877], with a starting date that 
corresponds to the starting date of the first symptom of the eventual diagnosis.  
[IP_ADDRESS]  Adverse Events That Are  Secondary to Other Events  
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or ser ious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:  
 If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting  should be reported on the eCRF  
 If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF  
 If a severe GI hemorrhage leads to renal failure, both events should be reported 
separately on the eCRF  
 If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF  
 If neutropenia is accompanied by a n infection, both events should be reported 
separately on the eCRF  
 
All adver se events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.  
[IP_ADDRESS]  Persistent or Recurrent Adverse Events  
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
88/Protocol GO42661 , Version [ADDRESS_198285] extreme severity should also be recorded on the 
Adverse  Event  eCRF.  If the event becomes serious, it should be reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning that the event became 
serious; see Section  5.4.2  for reporting instructions).  The Adverse Event eCRF should 
be updated by  [CONTACT_25748] non-serious to serious, providing the date 
that the event became serious, and completing all data fields related to serious adverse 
events.  
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an advers e event should be recorded as 
a separate event on the Adverse Event eCRF.  
[IP_ADDRESS]  Abnormal Laboratory Values  
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must  be reported as an adverse event if it meets any of the following cri teria:  
 Is accompanied by [CONTACT_4659]  
 Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)  
 Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy  
 Is clinically significant in the investigator's judgment  
Note:  For oncology trials, certain abnormal values may not qualify as 
adverse  events.  
 
It is the investigator's responsibility to review all laboratory findings.  Medic al and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.  
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g.,  ALP and bilirubin 5 ULN associated with chole stasis ), only the diagnosis 
(i.e., chole stasis ) should be recorded on the Adverse Event eCRF.  
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on  the A dverse Event eCRF, along with 
a descriptor indicating whether  the test result is above or below the normal range 
(e.g.,  elevated potassium,  as opposed to abnormal potassium ).  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an  elevated serum 
potassium level of 7.0 mEq/L should be recorded as hyper kalemia. 
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section  [IP_ADDRESS]  for 
details on recording persistent adverse events).  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
89/Protocol GO42661 , Version 6 [IP_ADDRESS]  Abnormal Vital Sign Values  
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must  
be reported as an adverse event if it meets any of the following criteria:  
 Is accompanied by [CONTACT_4659]  
 Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)  
 Results in a medical intervention or a change in concomitant therapy  
 Is clinically significant in the investigator's judgment  
 
It is the investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.  
If a clinically significant vital sign abnormality is a sign of a  disease or syndrome 
(e.g.,  high BP), only the diagnosis (i.e.,  hypertension) should be recorded on the 
Adverse Event eCRF.  
Observations of the same clinically  significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section  [IP_ADDRESS]  for 
details on recording persistent adverse events).  
[IP_ADDRESS]  Abnormal Liver Function Tests  
The finding of an elevated ALT or AST (  3ULN) in combination with either an elevated 
total bilirubin (  2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by [CONTACT_25742]'s Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:  
 Treatment -emergent ALT or AST  3ULN in co mbination with total bilirubin 
 2ULN 
 Treatment -emergent ALT or AST  3ULN in combination with clinical jaundice  
 
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see  Section  [IP_ADDRESS] ) 
and reported to the Sponsor immediately (i.e., no more than 24  hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest 
(see Section  5.4.2 ). 
[IP_ADDRESS]  Deaths  
For this protocol, mortality is a n efficacy endpoint.  Deaths that occur during the 
protocol -specified adverse event reporting period (see Section  5.3.1 ) that are attributed 
by [CONTACT_169878].  All other deaths  that occur during the 
adverse event reporting period , regardless of relationship to study treat ment , must be 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
90/Protocol GO42661 , Version 6 recorded on the Adverse Event eCRF and immediately reported to the Sponsor 
(see Section  5.4.2 ). 
Death should be considered  an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of d eath is unknown and cannot be ascertained at the time of 
reporting, unexplained death  should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), unexplained death  should 
be replaced by [CONTACT_25749].   The term sudden death  should not be 
used unless combined with the presumed cause of death (e.g., sudden cardiac death ). 
Deaths that occur after the adverse event reporting period should be reporte d as 
described in Section 5.6. 
[IP_ADDRESS]  Preexisting Medical Conditions  
A preexisting medical condition is one that is present at the screening  visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.  
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of  the condition wo rsens during the study.  
When  recording such events on the  Adverse Event eCRF, it is important to convey the 
concept that the preexisting condition has changed by [CONTACT_9672] 
(e.g.,  more frequent headaches ). 
[IP_ADDRESS]  Lack of Efficacy or Worse ning of Biliary Tract Cancer  
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should not be recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  In most cases, the expected pattern of 
progression will be based on RECIST  v1.1.  In rare cases, the determination of clinical 
progression will be based on symp tomatic deterioration.  However, every effort should 
be made to document progression through use of  objective criteria.  If there is any 
uncertainty as to whether an event is due to disease progression, it should be reported 
as an adverse event.  
[IP_ADDRESS]  Hospi[INVESTIGATOR_169806]  (i.e., inpatient  admission to a hospi[INVESTIGATOR_307])  
or prolonged hospi[INVESTIGATOR_25676] a serious adverse 
event (per the definition of serious adverse event in Section  5.2.2 ), except as outlined 
below.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
91/Protocol GO42661 , Version 6 An event that leads to hospi[INVESTIGATOR_169807] a serious adverse event:  
 Hospi[INVESTIGATOR_25678]  
 Planned hospi[INVESTIGATOR_33402] (e.g., for study treatment  
administration or performance of an efficacy measurement for the study)  
 Hospi[INVESTIGATOR_5186] n for a preexisting condition, provided that all of the following criteria 
are met:  
The hospi[INVESTIGATOR_169808] e disease  
The patient has not experienced  an adverse event  
 Hospi[INVESTIGATOR_169809] a serious adverse event, but should be reported as an adverse event 
instead:  
 Hospi[INVESTIGATOR_25682]  
 
[IP_ADDRESS]  Cases of Accidental Overdose or Medication Error  
Accidental overdose and medication error (hereafter collectively referred to as 
special  situations ), are defined as follows:  
 Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose  
 Medication error:  accidental deviation  in the administration of a drug  
In some cases, a medication error may be intercepted prior to administration of 
the drug.  
 
Special situations are not in themselves adverse events, but may result in adverse 
events.  Each adverse event associated with a spe cial situation should be recorded 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria  or qualifies as an adverse event of special interest , the event should 
be reported to the Sponsor immediately (i.e.,  no more than 24  hours after learning of the 
event; see Section  5.4.2 ).  For  atezolizumab and bevacizumab  (or matching placebo ), 
adverse events associated with special situations should be recorded as described 
below for each situation:  
 Accidental overdose:  Enter the adverse event term.  Check the 
Accidental  overdose and Medication error  boxes.  
 Medication error that does not qualify as  an overdose:  Enter the adverse event 
term.  Check the Medication error  box. 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
92/Protocol GO42661 , Version 6  Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the Accidental overdose  and Medication error  boxes.  
 
In addition, all special situatio ns associated with atezolizumab and bevacizumab  
(or matching placebo) , regardless of whether they result in an adverse event, should be 
recorded on the Adverse Event eCRF as described below:  
 Accidental overdose:  Enter the drug name [INVESTIGATOR_1238] accidental overdos e as the event 
term.  Check the Accidental overdose  and Medication error  boxes.  
 Medication error that does not qualify as an overdose:  Enter the name [CONTACT_26865] a description of the error (e.g., wrong dose administered, wrong 
dosing  schedule, incorrect route of administration, wrong drug, expi[INVESTIGATOR_26669]) as the event term.  Check the Medication error  box. 
 Medication error that qualifies as an overdose:  Enter the drug name [INVESTIGATOR_1238] 
accidental overdose  as the event term.  Ch eck the Accidental overdose  and 
Medication error  boxes.  Enter a description of the error in the additional case 
details.  
 Intercepted medication error:  Enter the drug name [INVESTIGATOR_1238] intercepted medication 
error as the event term.  Check the Medication error box.  Enter a description of 
the error in the additional case details.  
 
As an example, an accidental overdose that resulted in a headache would require 
2 entries on the Adverse Event eCRF, 1 entry to report the accidental overdose and 
1 entry to report the headache.  The Accidental overdose  and Medication error  
boxes would need to be checked for both entries.  
[IP_ADDRESS]  Patient -Reported  Outcome Data  
Adverse event reports will not be derived from PR O-CTCAE data by [CONTACT_1034].  
In addition, the S ponsor will make no attempt to reconcile patient reports of 
treatment -related symptoms (via the PRO -CTCAE) with investigator reports of adverse 
events.  Sites are not expected to review the PRO -CTCAE data for adverse events.  
[IP_ADDRESS]  Safety Biomarker Data  
Adverse e vent reports will not be derived from safety biomarker data by [CONTACT_1034], 
and safety biomarker data will not be included in the formal safety analyses for this 
study.  In addition, safety biomarker data will not inform decisions on patient 
management.  
5.[ADDRESS_198286] report 
such events to the Sp onsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_198287] 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
93/Protocol GO42661 , Version [ADDRESS_198288] report to the Sponsor within 24 hours after learning 
of the e vent, regardless of relationship to study treatment : 
 Serious adverse events  (defined in Section  5.2.2 ; see Section  5.4.2  for details on 
reporting requirements)  
 Adverse event s of special interest  (defined in Section  5.2.3 ; see Section  5.4.2  for 
details on reporting requirements)  
 Pregnancies  (see Section  5.4.3  for details on reporting requirements ) 
 
For serious adverse events and adverse events of special interest, the investigator must 
report new significant follow -up information to the Sponsor immediately (i.e., no more 
than 24 hours after becoming aware of the informatio n).  New significant information 
includes the following:  
 New signs or symptoms or a change in the diagnosis  
 Significant new diagnostic test results  
 Change in causality based on new information  
 Change in the event 's outcome, including recovery  
 Additional na rrative information on the clinical course of the event  
 
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.  
5.4.[ADDRESS_198289] Informati on for Sites in North, South America and Europe  
Medical Monitor/ [COMPANY_002] Medical Responsible }:  M.D., Ph.D.  (Primary)  
Telephone No.:  
Mobile Telephone No.:    [PHONE_3693]  
 
Medical Monitor /Emergency Medical Contact:   [CONTACT_169879].D. (Secondary)  
Mobile Telephone No.:  
 
To ensure the safety of study patients, an Emergency Medical Call Center will be 
available [ADDRESS_198290]  
[IP_ADDRESS]  Events That Occur  prior to  Study Treatment  Initiation  
After informed consent has been obtained but prior to initiation of study treat ment , only 
serious adverse events caused by a protocol -mandated intervention should be reported.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
94/Protocol GO42661 , Version 6 The paper Clinical Trial Adverse Event/Special Situations Form provided to investigators 
should be completed and submitted to the Sponsor  or its designee immediately (i.e., no 
more than 24 hours after learning of the event), either by [CONTACT_40882].  
[IP_ADDRESS]  Events That Occur after  Study Treatment  Initiatio n 
After initiation of study treatment  on Day [ADDRESS_198291] all case details that can be gathered immediately (i.e., 
within 24  hours after learning of the event) on the Adverse  Event eCRF and submit the 
report via the electronic data capture (EDC) system.  A  report will  be generated and sent 
to [COMPANY_002] Safety Risk Management by [CONTACT_27950].  
In the event that the EDC system is unavailable, the paper Clinical Trial Adverse 
Event/Special Situations Form provided to investigators should be completed and 
submitted to the Spo nsor or its designee immediately (i.e., no more than 24 hours after 
learning of the event), either by [CONTACT_77003] .  Once the EDC system is 
available, all inform ation will need to be entered and  submitted via the EDC system.  
Instructions for reporting serious adverse events that occur after the reporting period  are 
provided in Section 5.6. 
5.4.3  Reporting Requirements for Pregnancies  
[IP_ADDRESS]  Pregnancies in Female Patients  
Female patients of childbearing potential will be instructed through the Informed Consent 
Form to immediately inform the  investigator if they become pregnant during the study or 
within 5 months after the final dose of atezolizumab or 6 months after the final dose of 
bevacizumab  or chemotherapy ( CisGem ).  A paper Clinical Trial Pregnancy Reporting 
Form should be completed an d submitted to the Sponsor or its designee immediately 
(i.e., no more than 24 hours after learning of the pregnancy), either by [CONTACT_162492].  Pregnancy should n ot be recorded on the Adverse Event eCRF.  The 
investigator should discontinue study treatment  and counsel the patient, discussing the 
risks of the pregnancy and the possible effects on the fetus.  Monitoring of the patient 
should continue until conclusion  of the pregnancy.  Any serious adverse events 
associated with the pregnancy (e.g., an event in the fetus, an event in the mother during 
or after the pregnancy, or a congenital anomaly/birth defect in the child) should be 
reported on the Adverse Event eCRF .  In addition, the investigator will submit a Clinical 
Trial Pregnancy Reporting Form when updated information on the course and outcome 
of the pregnancy becomes available.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
95/Protocol GO42661 , Version 6 [IP_ADDRESS]  Pregnancies in Female Partners of Male Patients  
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
6 months  after the final dose of bevacizumab or chemotherapy ( CisGem ).  The 
investigator should report the pregnancy on the paper Clinical Trial Pregnancy Reporting 
Form and submit the form to the Sponsor or its designee immediately (i.e., no more than 
24 hours after learning of the pregnancy), either by [CONTACT_123565].  Attempts 
should be made to collect and report details of the course and outcome of any 
pregnancy in the partner of a male patient exposed to study treatment .  When permitted 
by [CONTACT_779] , the pregnant partner would  need to sign an Authorization for Use and 
Disclosure of Pregnancy Health Information to allow for follow -up on her pregnancy.  If 
the authorization has been signed, the investigator should  submit a Clinical Trial 
Pregnancy Repo rting Form with additional information on the pregnant partner and the 
course and outcome of the pregnancy as it becomes available.  An  investigator who is 
contact[CONTACT_169880], to support an informed 
decision in cooperation with the treating physician  and/or obstetrician.  
[IP_ADDRESS]  Abortions  
A spontaneous abortion should be classified as a serious adverse event (as  the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning  of 
the event; see Section  5.4.2 ). 
If a therapeutic or elective abortion was performed because of an underlying maternal or 
embryofetal toxicity, the toxicity should be classified as a serious adverse event, 
recorded on the A dverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section  5.4.2 ).  A therapeutic or 
elective abortion performed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.  
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting  Form.  
[IP_ADDRESS]  Congenital Anomalies /Birth Defects  
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
treatment  or the female partner of a male patient exposed to study treatment  should be 
classified as a serious adverse event,  recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section  5.4.2 ). 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
96/Protocol GO42661 , Version [ADDRESS_198292] to 
follow -up, or the patient withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study treatment  or trial -related 
procedures until a final outcome can be reported.  
During the stud y period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient's medical record to facilitate source data 
verification.  
All pregnancies reported during the study should be followed until pregnancy outc ome.  
5.5.[ADDRESS_198293], and pregnancies, the 
Sponsor or a designee may follow  up by [CONTACT_756], fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e .g., from hospi[INVESTIGATOR_123444], consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.  
5.[ADDRESS_198294] (defined as [ADDRESS_198295] ), all deaths, 
regardless of cause, should be rep orted through use of the Long -Term Survival 
Follow -Up eCRF . 
In addition, if the investigator becomes aware of a serious adverse event that is believed 
to be related to prior exposure to study treatment, the event should be reported through 
use of the Adver se Event eCRF.   However, if the EDC system is not available, the 
investigator should report these events directly to the Sponsor or its designee, either by 
[CONTACT_169881]/Special 
Situations Form using the fax number or email address provided to investigators.  
5.[ADDRESS_198296] experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
97/Protocol GO42661 , Version 6 To determine reporting requireme nts for single adverse event cases, the Sponsor will 
assess the expectedness of these events through use of the reference safety 
information in the documents listed below:  
Drug  Document  
Atezolizumab  Atezolizumab  Investigator's Brochure  
Bevacizumab  Bevacizumab  Investigator's Brochure  
 
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.  
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].  
6. STATISTICAL CONSIDERA TIONS AND ANALYSIS P LAN 
The statistical considerations and analy sis plan are summarized below.  
Efficacy  analyses  will be performed base d on the intent -to-treat (ITT) principle that all 
randomized patients, regardless of whether  they receive the assigned treatment or not, 
will be included for analyses with patients grouped according to the treatment assigned 
at randomization.  The ITT population  will be used for the efficacy endpoints , including 
ORR, PFS,  and OS.  Duration of response  (DOR) will be assessed in the 
DOR -evaluable populati on, a subset of  the ITT population  who achieve the best overall 
response as CR or PR.   The PRO analyse s of time to confirmed deterioration ( TTCD ) 
will be conducted  based on the ITT  population, and  the remaining PRO analyses will  be 
conducted in the PRO -evalua ble population,  which is a subset of  the ITT patients with 
a non-missing baseline PRO assessment  and at least [ADDRESS_198297] been observed.   The final OS 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
98/Protocol GO42661 , Version [ADDRESS_198298] of atezolizumab with bevacizumab in combination with CisGem  (Arm A) on PFS 
relative to atezolizumab in combination with CisGem  (Arm B) .  Point and CI estimates of 
the true underlying HR of comparing PFS between Arm A and Arm B  will be calculated .  
A total of approximately 150 patients will be randomized at a 1:1 randomization ratio to 
either Arm A or Arm B.  It is assumed that the median duration of PFS in the control arm  
(Arm  B) is 9 months.  Operating characteristics ( statistical power based on a two -sided 
significance level of 0.05 and expected total number of events)  at the time of the final 
PFS analysis  for true underlying HR values o f 0.55, 0.60, and 0.[ADDRESS_198299] 
been observed.  The planned  sample size of 150  patients , targeting  approximately 
90 PFS events  at the time of  the final PFS analysis , is considered to provide sufficient 
data and precision for the purpose of estimation of the HR point estimate and its 95% CI . 
Table  [ADDRESS_198300] Ratio Values  
 True Underlying HR  
0.55 0.60 0.70 
Expected number of 
events  90 90 90 
Power a 81% 68% 39% 
95% CI for true HR b (0.36, 0.83) (0.40, 0.91) (0.46, 1.06) 
HR   hazard ratio; PFS   progression -free survival.  
Note:  Operating characteristics are based on the following assumptions:  PFS event times are 
exponentially d istributed and median PFS in Arm B is 9 months.  
a Two-sided   0.05.  
b Confidence intervals  are based on the assumption that the PFS HR point estimate is equal to 
the true underlying value of the HR in each column. 
 
It should be noted that the study is underpowered for detection of minimal clinically 
meaningful differences under an assumed  true HR of 0.60 and above (see second and 
third column s of Table  9).  Therefore,  a clinically meaningful HR point estimate may not 
be statistically significant due to  a low power.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
99/Protocol GO42661 , Version [ADDRESS_198301] deviation s, medians and ranges.  Categorical 
variables will be summarized using count s and percentage s. 
6.3 SUMMARIES  OF DEMOGRAPHIC AND BASELINE 
CHARACTERISTICS  
Demographic and baseline characteristics (including age, sex, race/ethnicity, 
stratification factors, etc. ) will be summarized using means, standard deviations, 
medians, and ranges for continuous variables and counts and percentages for 
categorical variables, as appropriate.  Summaries will be presented overall and by 
[CONTACT_2939]. 
6.[ADDRESS_198302] tumor assessment  at which they were known to be progression -free with 
radiographic evidence as of the clinical cutoff date .  Patients with no postba seline  tumor 
assessment will be censored at the date of randomization.  
A stratified Cox proportional -hazards model will be used to estimate the PFS HR and 
its 95% CI.   A stratified two-sided log -rank test will be used to compare the 
investigator -assessed PFS between Arm A and Arm B  at the two -sided significance level 
of 0.05 .  The stratification factors for these stratified analyses are location of primary 
tumor ( iCCA vs. eCCA vs. GBC ), metastatic  disease (yes vs. no), and geographic region 
(Asia vs. rest of the world ).  However, i f at least one stratum has fewer  than [ADDRESS_198303] number of 
events  will be combined with other levels of the same stratification factor for the stratified 
analysis .  The final set of stratification factors used in the primary endpoint analysis will 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
100/Protocol GO42661 , Version 6 be applied to all other endpoints where stratified analyses are performed .  
The stratification information  will be obtained from the IxRS at the time o f randomization.  
Results from an unstratified analysis will also be provided.  The Kaplan -Meier method 
will be used to estimate median PFS for each treatment arm.  The B rookmeyer -Crowley 
methodology will be used to calculate the 95% CI for the median PFS  of each treatment 
arm. 
To assess the homogeneity of the treatment effect with respect to the primary efficacy 
endpoint of PFS, forest plots (including the estimated HRs) for clinically relevant 
subgroups will be provided.  
To assess the robustness of the pr imary PFS analysis, a sensitivity analysis will be 
performed by [CONTACT_169882]-cancer therapy prior to occurrence of radiographic progression.  These patients will 
be censored at the last tumor ass essment before start of the new treatment, regardless 
of progression or death afterwards.  
6.4.2  Secondary Efficacy Endpoints  
The secondary efficacy endpoints are OS, investigator -assessed confirmed ORR, DOR , 
and DCR, and TTCD  in patient -reported physical functioning, role functioning, and 
quality of life . 
[IP_ADDRESS]  Overall Survival  
Overall survival  is defined as the time from randomization to death from any cause .  
Data for p atients who are not reported as having died at the time of the clinical cutoff 
date will be censored at the date last known to be alive.  Data for patients who do not 
have postbaseline  information will be censore d at the date of randomization.  
The analysis methods for OS will be similar to those described for PFS. 
[IP_ADDRESS]  Confirmed Objective  Response Rate  
Confirmed ORR  is defined as the proportion of patients with a CR or PR on two 
consecutive occasions  [ADDRESS_198304] v1.1 .  Patients without any postbaseline  tumor assessments will be considered 
as non -responders.  
The confirmed ORR s for each treatment arm  will be calculated based on the 
ITT population , and the respective  95% CIs will be estimated using the Clopper -Pearson 
method.   The confirmed ORR s will be co mpared between Arm  A and Arm  B using the 
stratified Coch ran-Mantel -Haenszel test, and the ORR difference between these 2 arms 
will be also calculated with 95% CI  being computed using the normal approximation to 
the binomial distribution.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
101/Protocol GO42661 , Version 6 [IP_ADDRESS]  Duration of Respon se 
Duration of response  is defined as the time from the first occurrence of a confirmed 
objective response to disease progression as determined by [CONTACT_169883] v1.1 or death from any cause (whichever occurs first).  Data for patient s who 
are alive and who have not experienced disease progression at the time of the clinical 
cutoff date will be censored at the date of the last tumor assessment at which they wer e 
known to be progression -free. 
The DOR will be analyzed for the subset of ITT patients who have the best confirmed 
response as PR or CR.  The median DOR and its 95% CI for each treatment arm will be 
estimated by [CONTACT_169884]-Meier methodology.  
[IP_ADDRESS]  Disease Control Rate  
Disease control rate  is defined as the proportion of patient s with CR or PR on two 
consecutive occasion s  [ADDRESS_198305]  v1.1. 
The DCR for each treatment arm will be calculated based on the ITT population , with the 
respective  95% CIs being estimated  using the Clopper -Pearson method.  
[IP_ADDRESS]  Time to Confirmed Deterioration  
Time to confirmed deterioration  in patient -reported physical functioning, role functioning, 
and quality of life, as measured by [CONTACT_169885] -C30 and/or 
EORTC  IL77, is defined as the time from randomization to the first clinically meaningful 
deterioration that is either maintained for two consecutive assessments or followed by 
[CONTACT_120370] 3 weeks.  Clinically meaningful  deterioration will be defined 
using anchor -based analyses, details for which will be pre -specified in a separate 
statistical analysis plan.  
The TTCD analyses will be conducted in the ITT population, and the  analysis methods 
will be similar to those descri bed for PFS. 
6.4.3  Exploratory Efficacy Endpoints  
[IP_ADDRESS]  Exploratory Progression -Free Survival  
Progression -free survival  rates at specified time points (e.g., 6 and 12 months), defined 
as the probability that a patient  will be alive without experiencing disease progress ion, as 
determined by [CONTACT_3143] v1.1,  at specified timepoints.   
The PFS rates will be estimated using  the Kaplan -Meier methodology.  
[IP_ADDRESS]  Exploratory Overall  Survival  
Overall survival  rates at specific timepoints (e.g., 6 months and 12 months), defined as 
the probability that a patient will be alive at specified timepoints  will be estimated using  
the Kaplan -Meier methodology.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
102/Protocol GO42661 , Version 6 [IP_ADDRESS]  Exploratory Patient -Reported Outcome Endpoints  
Completion ra tes and reasons for missing data will be summarized for the 
EORTC  QLQ -C30, EORTC  QLQ -BIL21, EORTC  IL77, PGI -CI, and PGI -S at each 
treatment cycle by [CONTACT_169886].  
Visit mean summary and change from baseline analyses will be p erformed for all scales 
of the EORTC  QLQ -C30, EORTC  QLQ -BIL21, and EORTC IL77.  Summary statistics 
(e.g.,  number of patients, mean, standard deviation, median, minimum, maximum, 
95% CI) of linearly transformed scores (per the EORTC scoring manual) will be 
calculated at all assessment timepoints for each study arm.   These analyses will be 
performed in the PRO -evaluable population.  
Summary statistics (e.g. , number of patients, proportions) will be calc ulated for the 
PGI-CI and PGI -S in the PRO -evaluable population.  
6.[ADDRESS_198306] results, and changes in vital signs and ECGs.  
Study treatment exp osure (such as treatment duration, number of cycles , and dose  
intensit y) will be summarized with descriptive statistics.  
All verbatim adverse event terms will be mapped to Medical Dictionary for Regulatory 
Activities (MedDRA) thesaurus terms, and adverse e vent severity will be graded 
according to NCI CTCAE v 5.0.  All adverse events, serious adverse events, adverse 
events leading to death, adverse events of special interest, and adverse events leading 
to study treatment discontinuation that occur on or after  the first dose of study treatment 
or worsen after the first dose of study treatment for existing baseline conditions 
(i.e., treatment -emergent adverse events) will be summarized by [CONTACT_27940], 
appropriate thesaurus level, and severity grade.  For events of varying severity, the 
highest grade will be used in the summaries.  Deaths and cause of death will be 
summarized.  
Relevant laboratory, vital sign (pulse rate, respi[INVESTIGATOR_697], BP, pulse oximetry, 
and temperature), and ECG data will be displayed by [CONTACT_5586] , with grades  identified where 
appropriate.  Additionally, a shift table of selected laboratory tests will be used to 
summarize the baseline and maximum postbaseline  severity grade s.  Changes in vital 
signs and ECGs will be summarized.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
103/Protocol GO42661 , Version 6 6.5.2  Exploratory Analyses  of PRO -CTCAE Data  
Patient -reported outcome -CTCAE analyses will be descriptive, with a focus on 
characterizing the pattern of  symptomatic treatment toxicities over the course of the 
study.  Results from these exploratory analyses will be presented separate ly from the 
other safety analyses.  Patient -reported outcome -CTCAE data will be analyzed at the 
item level in line with current NCI CTCAE recommendations for  data handling 
(Basch  et al. 2014).  
Patient -reported outcome -CTCAE data will be summarized over tim e.  The proportion of 
missing data at each assessment timepoint will also be summarized to facilitate 
interpretation of data.  
The number and percentage of patients reporting each symptom and the change from 
baseline by [CONTACT_17203] ( presence, frequency of occu rrence, severity, interference) will be 
summarized at each assessment timepoint by [CONTACT_2939].  For items that are rated 
on a [ADDRESS_198307] 1 PK assessment.  
Samples will be collected for PK analyses and serum concentrations of atezolizuma b will 
be reported as individual values and summarized (mean, standard deviation, coefficient 
of variation, median, range, geometric mean, and geometric mean coefficient of 
variation) by [CONTACT_169887], when appropriate and as data allow.  Individ ual 
and median serum atezolizumab concentrations will be plotted for PK -evaluable patients 
by [CONTACT_4475].  
Atezolizumab concentration data may be pooled with data from other studies using an 
established population PK model to derive PK parameters such as clearance , volume of 
distribution, and area under the curve, as warranted by [CONTACT_26739].  Potential correlations 
of relevant PK parameters with dose, safety, efficacy, or biomarker outcomes may be 
explored . 
Additional PK and pharmacodynamic analyses will be conducted  as appropriate.  
6.[ADDRESS_198308] 
1 postbaseline ADA assessment.  Patients will be grouped according to treatment 
received.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
104/Protocol GO42661 , Version 6 The numbers and proportions of ADA -positive patients and ADA -negative patients at 
baseline (baseline prevalence) and after drug administration ( postbaseline  incidence) 
will be summarized for ADA -evaluable patients.  When determining postbaseline  
incidence, pa tients are considered to be ADA -positive if they are ADA -negative or have 
missing data at baseline but develop an ADA response following study drug exposure 
(treatment -induced ADA response), or if they are ADA -positive at baseline and the titer 
of one or more postbaseline  samples is at least 0.60 titer unit greater than the titer of the 
baseline sample (treatment -enhanced ADA response).  Patients are considered to be 
post-treatment  ADA-negative if they are ADA -negative or have missing data at baseline 
and all postbaseline  samples are negative, or if they are ADA -positive at baseline but do 
not have any postbaseline  samples with a titer that is at least 0.60  titer unit greater than 
the titer of the baseline sample ( treatment unaffected).  
The relationship between ADA status and safety, efficacy, PK, and biomarker endpoints 
may be analyzed and reported.  
6.[ADDRESS_198309] full access to unblinded data at the time of analysis.  Access to treatment 
assignment information will follow the Sponsor's standard procedures and will not be 
given to the Sponsor until the first interim analysis within this study is being conducted . 
6.9.[ADDRESS_198310] an optional interim 
analysis and the timing of the analysis will be documente d in the Sponsor 's trial master 
file prior to the conduct of the interim analysis.  The optional interim analysis will be 
performed and interpreted by [CONTACT_33482], who will have full access 
to unblinded data  at the time of analysis .  Acces s to treatment assignment information 
will follow the Sponsor 's standard procedures  and will not be given to the Sponsor until 
the first interim analysis within this study is being conducted . 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
105/Protocol GO42661 , Version [ADDRESS_198311] data clarification from the sites, which the sites 
will resolve electronically in the EDC system.  
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data .  Central laboratory data and any other 
externally generated electronic study data will be sent directly to the Sponsor, using the 
Sponsor's standard procedures to handle and process the electronic transfer of these 
data.  
Electronic Case Report Forms  and correction documentation will be maintained in the 
EDC system 's audit trail.  System backups for data stored by [CONTACT_169888] 's standard procedures.  
7.[ADDRESS_198312] be kept with the study records.  Acknowledgement of receipt 
of the data is required.  
7.3 ELECTRONIC PATIENT -REPORTED OUTCOME DATA  
An electronic device will be used to capture PRO  data when possible  
(see Section  [IP_ADDRESS] ).  The device is designed for entry of data in a  way that is 
attributable, secure, and accurate, in compliance with U.S. Food and Drug 
Administration (FDA) regulations for electronic records (21 CFR Part 11).  The data will 
be transmitted to a centralized database maintained by [CONTACT_169889]. 
The electronic data will be available for view access only, via a secure method.  
Only identified and trained users may view the data, and their actions will become part of 
the audit trail.  The  Sponsor will have view access only.  System backups for data stored 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
106/Protocol GO42661 , Version 6 by [CONTACT_169890] 's standard procedures.  
Once the study is complete, the data, audit trail, and trial and system documentation will 
be archived.  The investigator will re ceive patient data for the site in both human - and 
machine -readable formats that must be kept with the study records as source data.  
Acknowledgement of receipt of the data is required.  In addition, the Sponsor will receive 
all data in a machine -readable format.  
7.4 SOURCE DATA DOCUMENT ATION  
Study monitors will perform ongoing source data verification  and review  to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by [CONTACT_77038], complete, and ve rifiable from source  documents.  
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PROs , evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_169810], 
microfiche, photographic negatives, microfilm or magnetic med ia, X-rays, patient files, 
and records kept at pharmacies, laboratories, and medico -technical departments 
involved in a clinical trial.  
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Mon itoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.  
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section  7.6. 
To facilitate source data verification  and review , the investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and IRB/EC review.  The study  site must also 
allow inspection by [CONTACT_25756].  
7.5 USE OF COMPUTERIZED SYSTEMS  
When clinical observations are entered directly into a  study  site's computerized medical 
record system (i.e., in lieu of original hardcopy records), the electron ic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems  used in clinical research.  
An acceptable computerized data collection system allows preservatio n of the original 
entry of data.  If original data are modified, the system should maintain a viewable audit 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
107/Protocol GO42661 , Version [ADDRESS_198313] been 
reported or for the length of time required by [CONTACT_70173], 
whichever is longer.  
8. ETHICAL CONSIDERATION S 
8.1 COMPLIANCE WITH LAWS  AND REGULATIONS  
This study  will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice  and the principles of the Declaration of Helsinki, or the applicable laws 
and regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the [LOCATION_002] or under a 
U.S. Invest igational New Drug (IND ) Application will comply with FDA regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
European Economic Area  will comply with the E.U. Clinical Trial s Directive (2001/20/EC)  
or Clinical Trials Regulation (536/2014) and applicable local, regional, and national 
laws. 
8.2 INFORMED CONSENT  
The Sponsor 's sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a n Assent Form or Mobile Nursing  Informed Consent F orm, if  applicable) 
will be provided to each site.  If applicable, it will be provided in a certified translation of 
the local language.  The Sponsor or its designee must review and approve any proposed 
deviations from the Sponsor's sample Informed Consent  Forms or any alternate consent 
forms proposed by [CONTACT_779] (collectively, the Consent Forms ) before IRB/EC 
submission.  The final IRB/EC approved Consent Forms must be provided to the 
Sponsor for health authority submission purposes according to local re quirements.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
108/Protocol GO42661 , Version 6 If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optiona l procedure.  
Patients will be told that they are free to refuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature [CONTACT_33509] a patient's agreement to participate in optional procedu res.  Patients who 
decline to participate will not provide a separate signature.  
The Consent Forms must be signed and dated by [CONTACT_12718]'s legally 
authorized representative before his or her participation in the study.  The case history or  
clinical records for each patient shall document the informed consent process and that 
written informed consent was obtained prior to participation in the study.  
The Consent Forms should be revised whenever there are changes to study procedures 
or when ne w information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.  
If the Consent Forms are revised (thro ugh an am endment or an addendum) while 
a patient is participating in the study, the patient or a legally authorized representative 
must re -consent by [CONTACT_162499], in accordance with applicable laws and IRB/EC policy.  For any updated or 
revised Consent Forms, the case history or clinical records for each patient shall 
document the informed consent process and that written informed consent was obtained 
using the updated/revised Consent Forms for conti nued participation in the study.  
A copy of each signed Consent Form must be provided to the patient or the patient's 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient's study file or in the site file and mus t be available for verification by [CONTACT_33483].  
For sites in the [LOCATION_002], each Consent Form may also include patient authorization 
to allow use and disclosure of personal health informat ion in compliance with the 
U.S. Health Insurance Portability and Accountability Act  (HIPAA)  of 1996.  If the site 
utilizes a separate Authorization Form for patient authorization for use and disclosure of 
personal health information under the HIPAA regulations, the review, approval, 
and other processes o utlined above apply except that IRB review and approval may not 
be required per study site policies.  
8.[ADDRESS_198314] be submitted  to the IRB/EC by [CONTACT_11087] [INVESTIGATOR_25684]/EC before the study is 
initiated.  In  addition, any patient recruitment materials must b e approved by [CONTACT_1201]/EC.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
109/Protocol GO42661 , Version 6 The Principal Investigator i s responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordance with the 
requirements, policies, and procedures established by [CONTACT_1201]/EC.  Investigators are 
also responsible for promptly inf orming the IRB/EC of any protoc ol amendments 
(see Section  9.6). 
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety -related communications from the Sponsor .  Investigator s are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and 
archived in the site 's study file.  
8.[ADDRESS_198315] parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_4677], unless permitted or required by [CONTACT_2371].  
Medical information may be given to a patient's personal physician or other appropriate 
medical personnel responsi ble for the patient's welfare, for treatment purposes.  
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by [CONTACT_2371].   The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication 
(see Section  9.5). 
Data generated by [CONTACT_25757], Sponsor monitors, 
representatives, and collaborators, and  the IRB/EC for each study site, as a ppropriate.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
110/Protocol GO42661 , Version [ADDRESS_198316] (see Section  9.5). 
8.5 FINANCIAL DISCLOSURE  
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are res ponsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study ( see definition of end of 
study in Section  3.2). 
9. STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION  
9.[ADDRESS_198317] of 
the study to be fully documented, including, but n ot limited to, the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a co mplete record of all changes to 
data.  
9.[ADDRESS_198318] on patient safety and 
data integrity to the Sp onsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good  Clinical Practice guidelines and require 
reporting to health a uthorities.  As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.  
9.3 MANAGEMENT OF STUDY QUALITY  
The Sponsor will implement a system to manage the quality of the study, focusing on 
processes and data that are essential to ensuring patient sa fety and data integrity.  
Prior  to study initiation, the Sponsor will identify potential risks associated with critical 
trial processes and data and  will implement plans for evaluating and controlling these 
risks.  Risk evaluation and control will include the selection of risk -based parameters 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
111/Protocol GO42661 , Version 6 (e.g.,  adverse event rate, protocol deviation rate) and the establishment of quality 
tolerance limits for the se parameters prior to study initiation.  Detection of deviations 
from quality tolerance limits will trigger an evaluation to determine if action is needed.  
Details on the establishment and monitoring of quality tolerance limits will be provided in 
a Qual ity Tolerance Limit Management Plan.  
9.4 SITE INSPECTIONS  
Site visits will be conducted by [CONTACT_26833], patients ' medical records, and eCRFs.  The investigator will 
permit national and local health a uthorities; Sponsor monitors, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.  
9.5 ADMINISTRATIVE STRUC TURE  
This trial will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  The Sponsor 
will pr ovide clinical operations management, data management, and medical monitoring.  
Approximately 75 sites globally will participate to randomize approximately 150 patients.  
Screening and enrollme nt will occur through an IxRS.  
Central facilities will be used f or certain study assessments throughout the study 
(e.g.,  specified laboratory tests, biomarker analyses, and PK analyses ), as specified in 
Section  4.5.6 .  Accredited local laboratories will be used for routine monitoring; local 
laboratory ranges will be collected.  
9.6 DISSEMINATION OF DAT A AND PROTECTION OF TRADE 
SECRETS  
Regardless of the outcome of a trial, the Sponsor is dedicated to openly  providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries,  and in peer -reviewed journals.  The Sponsor will 
comply with all requirements for publication of study results.  Stud y data may be shared 
with others who are not participating in this study (see Section  8.4 for details) , and 
redacted Clinical Study R eports and /or other summaries of clinical study results may be 
available in health authority databases for public access, as required by [CONTACT_1295], 
and will be made available upon request.  For more information, see the [COMPANY_002] Global 
Policy on Sharin g of Clinical Study Information  at the following website:  
https://www.roche.com/innovation/process/clinical -trials/data -sharing/  
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involvin g an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
the respective Clinical S tudy Report .  In addition, for all clinical trials in patients involving 
an IMP for which a marketing authorization application has been filed or approved in any 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
112/Protocol GO42661 , Version [ADDRESS_198319] editorial and ethical practice, the Sponsor  will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_169891].  Any formal publication 
of the study in which contribution of Sponsor  personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_169892].  
Any in ventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor , except where agreed otherwise.  
9.7 PROTOCOL AMENDMENTS  
Any protocol amen dments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.  
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g.,  change in Medical Monitor or contact [CONTACT_3031]).  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
113/Protocol GO42661 , Version 6 10. REFERENCE S 
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research 
and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 1993;85:365 76. 
Arkenau HT, Martin -Liber al J, Calvo E, et al. Ramucirumab Plus Pembrolizumab in 
Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: 
Nonrandomized, Open -Label, Phase I Trial (JVDF ). Oncologist. 
2018;23:1407 e136.  
Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by 
[CONTACT_15098]. Qual Life Res 2012;21:1159 64. 
Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in 
mechanisms and management [published online ahead of print, 2020 Jun 30]. Nat  
Rev Gastroenterol Hepatol. 2020;10.1038/s41575 -020-0310 -z. 
doi:10.1038/s41575 -020-0310 -z. 
Bang Y -J, Ueno M, Malka D, et al. Pembrolizumab (pembro) for advanced biliary 
adenocarcinoma: Results from the KEYNOTE -028 (KN028) and KEYNOTE -158 
(KN158) basket stu dies. Journal of Clinical Oncology 2019;37 (Suppl 15) :4079.  
Basch E. The missing voice of patients in drug -safety reporting. N Engl J Med 
2010;362:865 9. 
Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s 
patient -reported outcomes version of the common terminology criteria for adverse 
events (PRO -CTCAE). J Natl Cancer Inst 2014;106:1 11. 
Borghaei H, Paz -Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced 
nonsquamous non small -cell lung cancer. N Engl J Med 2015;37 3;162739. 
Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response 
and colitis in metastatic melanoma patients treated with ipi[INVESTIGATOR_125]. Ann Oncol 
2017;28:1368 79. 
Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, 
pharmacodynamics, tissue distribution, and tumor penetration of anti -PD-L1 
monoclonal antibody, an immune checkpoint inhibitor. MAbs 2016;8:593 603. 
doi: 10.1080/19420862.2015.1136043. Epub: 26 February 2016.  
Dubin K, Callahan M, Ren B, et al. Intestinal microbiome analyses identify melanoma 
patients at risk for checkpoint -blockade -induced colitis. Nat Commun 
2016 ;7:[ZIP_CODE].  
Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US National 
Cancer In stitute’s patient -reported outcomes version of the Common Terminology 
Criteria for Adverse Events (PRO -CTCAE). JAMA Oncol 2015;1:1051 9. 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
114/Protocol GO42661 , Version [ADDRESS_198320] carcinoma: a pooled 
analysis of clinical trials. Br J Cancer  2007;96:896 –902. 
Elkrief A, Derosa L, Kroemer G, et al. The negative impact of antibiotics on outcomes in 
cancer patients treated with immunotherapy: a new independent prognostic factor? 
Ann Oncol 2019 ;30:15729. 
Fabris L, Perugorria M, Mertens J, et al. The tumour microenvironment and immune 
milieu of cholangiocarcinoma. Liver Int 2019;39 (Suppl 1):63 78. 
Fayers PM, Aaronson NK, Bjordal K, et al, on behalf of the EORTC Quality of Life 
Group. The EORTC QLQ -C30 Scoring Manual (3rd Edition). Published by: 
[CONTACT_67383], Brussels 2001.  
Fehrenbacher L, Spi[INVESTIGATOR_20116] A, Ballinger M, et al. Atezolizumab versus docetaxel for patients 
with previously treated non -small -cell lung cancer (POPLAR): a multicentre, 
open -label, phase 2  randomised controlled trial. Lancet 2016;387:1837 46. 
Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus 
gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract 
cancers: results from a phase II study. J of Cancer 2020;8:e000367.  
Finn RS, Qin S, Ikeda M,  et al. Atezolizumab plus nevacizumab in unresectable 
hepatocellular carcinoma . N Engl J Med 2020;382:1894 1905.  
Frebel H, Nindl V, Schuepbach RA, et al. Programmed death 1 protects from fatal 
circulatory failure during systemic virus infection of mice. J Exp Med 
2012;209:2485 –99. 
Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of 
chemotherapy adverse effects? A comparison with patient -reported symptoms 
from the Quality -of-Life Questionnaire C30. J Clin Oncol 2004;22:348 90. 
Fukumur a D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using 
antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 2018;  
15:32540. 
Furuse J, Okusaka T, Bridgewater J, et al. Lessons from the comparison of two 
randomized clinical tr ials using gemcitabine and cisplatin for advanced biliary tract 
cancer. Crit Rev Oncol Hematol 2011;80:31 9. 
Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy 
and targeted anticancer agents . Cancer Cell 2015;28:690 714. 
Galluzzi L, Buqué A, Kepp O, et al. Immunogenic cell death in cancer and infectious 
disease. Nat Rev Immunol 2017;17, 97 –111. 
Galsky M, Arranz Arija JA, Bamias A, et al. Atezolizumab with or without chemotherapy 
in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, 
placebo -controlled phase 3 trial. Lancet 2020;395:1547 57. 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
115/Protocol GO42661 , Version 6 Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: 
US Department of Heath,Education, and Welfare Public Health Service Alcohol, 
Drug Abuse, and Mental Health Administration, 1976.  
Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of 
immunotherapy agents. Ann Oncol 2010;21:1944 51. 
Hansen AR, Ala -Leppi[INVESTIGATOR_169811] K, McKillop C, et al. Development of the  Functional 
Assessment of Cancer Therapy -Immune Checkpoint Modulator (FACT -ICM): 
a toxicity subscale to measure quality of life in patients with cancer who are treated 
with ICMs. Cancer 2020;126:1550 58. 
Hato SV, Khong A, deVries IJM, et al. Pathways: the immunogenic effects of 
platinum -based chemotherapeutics. Clin Cancer Res  2014;20:2831 7. 
Hegde PS, Karanikas V, and Evers S. The where, the when, and the how of immune 
monitoring for cancer immunotherapi[INVESTIGATOR_169812] . Clin 
Cancer Res 2016 ;22:186574. 
Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by [CONTACT_169893] c hemotherapy in solid tumors . Ann Oncol 
2019;30:219 35. 
Herbst RS, Baas P, Kim D -W, et al. Pembrollizumab versus docetaxel for previously 
treated PD -L1-positive, advanced non -small -cell lung cancer (KEYNOTE -010):  
a randomised controlled trial. Lancet 2016;387;1540 50. 
Herbst RS, Soria JC, Kowanetz M et al. Predictive correl ates of response to the 
anti-PD-L1 antibody atezolizum ab in cancer patients. Nature 2014; 515: 5637. 
Iyer RV, Pokuri VK, Groman A, et al. a multicenter phase II study of gemcitabine, 
capecitabine, and bevacizumab for locally advanced or metastatic biliary tract 
cancer . Am J Clin Oncol. 2018;41:649 55. 
Jung SJ, Woo SM, Park HK, et al. Patterns of initial disease recurrence after resection of 
biliary tract cancer.  Oncology  2012;83:83 90. 
Kaupp -Roberts SD, Yadegarfar G, Friend E, et al. Validation of the EORTC QLQ -BIL21 
questionnaire for measuring quality of li fe in patients with cholangiocarcinoma and 
cancer of the gallbladder. Br J Cancer 2016;115:1032 8. 
Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapi[INVESTIGATOR_169813]. J Hepatol 2020;72:353 63. 
Khan SA, Tavolari S, Brandi G. C holangiocarcinoma: epi[INVESTIGATOR_6889]. 
Liver Int 2019;39 (Suppl 1 ):1931.  
Kim BJ, Hyung J, Yoo C, et al. Prognostic factors in patients with advanced biliary tract 
cancer treated with first -line gemcitabine plus cisplatin: retrospective analysis of 
740 patients. Cancer Chemother Pharmacol 2017;80:209 15. 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
116/Protocol GO42661 , Version 6 King-Kallimanis BL, Howie LJ, Roydhouse JK, et al. Patient reported outcomes in 
anti-PD-1/PD -L1 inhibitor immunotherapy registration trials: FDA analysis of data 
submitted and future directions. C lin Trials 2019;16:322 26. 
Koeberle D, Saletti P, Borner M, et al. Patient -reported outcomes of patients with 
advanced biliary tract cancers receiving g emcitabine plus capecitabine: 
a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin 
Oncol 2008;26:3702 8. 
Lamarca A, Barriuso J, McNamara MG, Valle JW . Molecular targeted therapi[INVESTIGATOR_014]: Ready  
for "prime time " in biliary tract cancer . J Hepatol  2020 a;73:17085. 
Lamarca A, Ross P, Wasan HS, et al. Advanced intrahepatic cholangi ocarcinoma: post 
hoc analysis of the ABC -01, -02, and -[ADDRESS_198321]  
2020 b;112:20010. 
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine 
release syndrome anad neurologic toxicity associated with immune ef fector cells. 
Bio Blood Marrow Transplant 2019;25:625 38. 
Lee MS , Ryoo B -Y, Hsu C -H, et al. Atezolizumab with or without bevacizumab in 
unresectable hepatocellular carcinoma (GO30140): an open -label, multicentre, 
phase 1b study. Lancet Oncol 2020;21:734 57. 
Lin J , Shi W, Zhao  S, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with 
advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation 
with next -generation sequencing  [abstract] . J Clin Oncol 2018 :abstract 500. 
Loeui llard E, Conboy C, Gores, G, et al. Immunobiology of cholangiocarcinoma. JHEP 
Rep 2019;1:297 311. 
Lyman G, Khorana A, Kuderer N, et al. Venous thromboembolism prophylaxis and 
treatment in patients with cancer: American Society of Clinical Oncology clinical  
practice guideline update. J Clin Oncol 2013;31:2189 204. 
Marcano -Bonilla L, Mohamed EA, Mounajjed T, Roberts LR. Biliary tract cancers: 
epi[INVESTIGATOR_623], molecular pathogenesis and genetic risk associations. Chin Clin 
Oncol. 2016;5(5):61.  
Merad M, Martin JC.  Pathological inflammation in patients with COVID -19: a key role for 
monocytes and macrophages. Nat Rev Immunol 2020;20:355 62. 
Moehler M, Maderer A, Schimanski C, et al. Gemcitabine plus sorafenib versus 
gemcitabine alone in advanced biliary tract cancer:  a double -blind 
placebo -controlled multicentre phase II AIO study with biomarker and serum 
programme. Eur J Cancer 2014;50:125 35. 
Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S -1 versus 
gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the 
FUGA -BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 
2019;30:1950 8. 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
117/Protocol GO42661 , Version 6 [NCCN] National Comprehensive Cancer Network. Recommendations of the NCCN 
COVID -19 Vaccination Advisory Committee [resource on th e Internet]. 2021 [cited: 
28 May 2021]. Available from: https://www.nccn.org/docs/default -source/covid -
19/2021_covid -19_vaccination_guidance_v2 -0.pdf?sfvrsn=b483da2b_2.  
Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with 
cisplatin in patients with biliary tract cancer: a comparative multicentre study in 
Japan. Br J Cancer 2010;103:469 74. 
Olthof PB, Miyasaka M, Koerkamp BG, et al. A comparison of treatment and outcomes 
of perihilar cholangiocarcinoma between Eastern and Western  centers. HPB 
(Oxford) 2019;21:345 51. 
Osorio JC, Arbour KC, Le DT, et al. Lesion -Level Response Dynamics to Programmed 
Cell Death Protein (PD -1) Blockade. Journ al of Clinical Oncology 
2019; 37:3546 -55. 
Park J, Kim MH, Kim KP, et al. Natural history and pro gnostic factors of advanced 
cholangiocarcinoma without surgery, c hemotherapy, or radiotherapy: a  large -scale 
observational study . Gut Liver  2009;3:298 305. 
Pakhomov SV, Jacobsen SJ, Chute CG, et al. Agreement between patient -reported 
symptoms and their documentation in the medical record. Am J Manag Care 
2008;14:530 9. 
Quinten C, Maringwa J, Gotay CC, et al. Patient self -reports of symptoms and clinician 
ratings as predictors of overall cancer survival. J Natl Cancer Inst 2011;103:185 8. 
Reck M, Mok TSK,  Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy 
in non -small -cell lung cancer (IMpower150): key subgroup analyses of patients 
with EGFR mutations or baseline liver metastases in a randomised, open -label 
phase 3 trial. Lancet Respir Med 201 9;7:387401. 
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma evolving 
concepts and therapeutic strategies. Nat Re v Clin Oncol  2018;15:[ADDRESS_198322] progressed following 
treatment with platinum -based chemotherapy: a  single -arm, multicentre, phase  2 
trial. Lancet 2016;387:1909 20. 
Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences eff icacy of 
PD-1-based immunotherapy against epi[INVESTIGATOR_220]. Science 2018 ;9:917. 
Sakai D, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, 
cisplatin plus S -1(GCS) versus gemcitabine, cisplatin (GC) for advanced biliary 
tract cancer (KHBO1401 -MITSUBA). Ann Oncol 2018;29 (Suppl 8);viii205 70. 
Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of 
metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288 301. 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
118/Protocol GO42661 , Version 6 [SITC] Society for Immunotherapy of Cancer. Society  for Immunotherapy of Cancer 
statement on SARS -CoV-2 vaccination and cancer immunotherapy [resource on 
the Internet]. Press release: 23 December 2020 [cited: 28 May 2021]. Available 
from: https://www.sitcancer.org/aboutsitc/press -releases/2020/sitc -stateme nt-sars-
cov-2-vaccination -cancer -immunotherapy.  
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of 
antiPD-1 antibody in cancer. N Engl J Med 2012;366:2443 54. 
Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new  method for 
summarising adverse events of cancer treatment by [CONTACT_169894]. Lancet Oncol 2007;8:613 24. 
Tumeh PC, Hellmann MD, Hamid O, et al. Liver metastasis and treatment outcome with 
anti-pd-1 monoclonal antibody in patients wit h melanoma and NSCLC . Cancer 
Immunol Res  2017 ;5:41724. 
Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin 
plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract 
cancer : a non -randomised, multicentre, open -label, phase 1 study . Lancet 
Gastroenterol Hepatol 2019;4:611 –21. 
Valle J W, Wasan H, Johnson  P, et al. Gemcitabine alone or in combination with cisplatin 
in patients with advanced or metastatic cholangiocarcinomas or other biliary tract 
tumours : a multicentre randomised phase II studyThe [LOCATION_006] ABC -01 Study. Br J 
Cancer 2009;101:621 7. 
Valle J W, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for 
biliary tract cancer . N Engl J Med 2010;362:1273 81. 
Valle JW, Wasan H,  Lopes A, et al. Cediranib or placebo in combination with cisplatin 
and gemcitabine chemotherapy for patients with advanced biliary tract cancer 
(ABC -03): a randomised phase 2 trial. Lancet Oncol. 2015;16:967 78. 
Valle JW, Bai L -Y, Orlova R. et al. Ramucir umab (RAM) or merestinib (MER) or placebo 
(PL) plus gemcitabine (GEM) and cisplatin (CIS) as first -line treatment for 
advanced or metastatic biliary tract cancer (BTC): A randomized, double -blind, 
phase II study  [abstract] . J Clin Oncol 2020;38 :abstract 477. 
Wu J, Waxman DJ. Immunogenic chemotherapy: Dose and schedule dependence and 
combination with immunotherapy. Cancer Lett 2018;419:210 21. 
Yau T, Park JW, Finn RS, et al. LBA38_PRCheckMate 459: A randomized, multi -center 
phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first -line (1L) treatment 
in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 
2019 ;30 (Suppl 5):v874 5. 
Zabernigg A, Giesinger JM, Pall G, et al. Quality of life across chemotherapy lines in 
patients with  cancers of the pancreas and biliary tract. BMC Cancer 2012;12:390.  
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
119/Protocol GO42661 , Version 6 Zhu A, Guan Y, Abbas A, et al. Genomic correlates of clinical benefits from atezolizumab 
combined with bevacizumab vs. atezolizumab alone in patients with advanced 
hepatocellular carcinoma  (HCC), in: AACR Annual Meeting).  
Zhu A, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, 
oxaliplatin, and bevacizumab in advanced biliary -tract cancers and correlation of 
changes in 18 -fluorodeoxyglucose PET with clinical outcome:  a pha se2 study. 
Lancet Oncol 2010;11:48 54. 
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
120/Protocol  GO42661 , Version 6 Appendix  1  
Schedule of Activities  
Day Screening a Treatment Cycles (21 -Day Cycles) b 
Treatment 
Discontinuation 
Visit c 
 30 Days after 
Final Dose  Follow -Up Chemotherapy 
Combination Phase  
(Cycles 1 8) CIT/Placebo 
Phase  
(Cycles 9 and 
Beyond)  
Days –28 
to –1 Day 1   Day 8  Day 1   
(Window)  ( 3 Days)  
Informed consent d x      
Baseline tumor tissue sample e x      
Demographic data  x      
Medical history, including cancer, and baseline 
conditions f x      
PRO assessments g  See Appendix  2  
Vital signs j x x  x x  
Weight  k x x k x k x k   
Height  x      
Complete physical examination l x      
Limited physical examination l  x m  x m x  
ECOG Performance Status  x x m  x m x  
ECG n x If clinically indicated   
EGD o x      
Hematology p x q x  x  x m x  
Chemistry profile (serum or plasma)  r x q x m  x m x  

Appendix 1: Schedule of Activities  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
121/Protocol GO42661 , Version 6 Day Screening a Treatment Cycles (21 -Day Cycles) b 
Treatment 
Discontinuation 
Visit c 
 30 Days after 
Final Dose  Follow -Up Chemotherapy 
Combination Phase  
(Cycles 1 8) CIT/Placebo 
Phase  
(Cycles 9 and 
Beyond)  
Days –28 
to –1 Day 1   Day 8  Day 1   
(Window)  ( 3 Days)  
Coagulation  tests:  INR and aPTT x q    x  
Pregnancy  test  s x x  x x  
TSH, free T3, and free T4 t x x t x  
CA 19 -9 x x  x x  
C-reactive protein   x  x x  
HIV, HBV, HCV serology u x      
Quantitative HBsAg, HBV DNA , HCV RNA v x   x x  
Urinalysis  w x x m  x m   
Atezolizumab IV infusion x  x  x   
Bevacizumab/placebo IV infusion x  x  x   
Cisplatin and gemcitabine IV infusions x  x x    
Concomitant medications y x x  x x  
Tumor assessment z, aa x z x aa 
Adverse events bb  x x x x x 
Serum sample  for ADA and PK assessment cc  See Appendix  3  
Blood samples for  biomarkers (central laboratory) cc  See Appendix  3 
Fresh tumor tissue biopsy sample (optional)   See Appendix  3  

Appendix 1: Schedule of Activities  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
122/Protocol GO42661 , Version 6 Day Screening a Treatment Cycles (21 -Day Cycles) b 
Treatment 
Discontinuation 
Visit c 
 30 Days after 
Final Dose  Follow -Up Chemotherapy 
Combination Phase  
(Cycles 1 8) CIT/Placebo 
Phase  
(Cycles 9 and 
Beyond)  
Days –28 
to –1 Day 1   Day 8  Day 1   
(Window)  ( 3 Days)  
Stool sample (optional)  x See Appendix  3    
Survival and anti -cancer therapy follow -up dd      x 

Appendix 1: Schedule of Activities  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
123/Protocol GO42661 , Version 6 ADA   anti-drug antibody; CIT   cancer immunotherapy; CT   computed tomography; ECOG   Eastern Cooperative Oncology Group; 
EGD   esophagogastroduodenoscopy; EORTC   European Organisation for Research and Treatment of Cancer; FFPE   formalin -fixed, 
paraffin -embedded; HBcAb   hepatitis B core antibody; HBsAb   hepatitis B surface antibody; HBsAg   hepatitis B surface antigen; HBV   hepatitis  B 
virus; HCV   hepatitis C virus; MRI   magnetic resonance imaging; PK   pharmacokinetic; PRO   patient -reported outcome; RECIST v1. 1  Response 
Evaluation Criteria in Solid Tumors, Version 1.1; T3   free triiodothyronine; T4   free thyroxine.  
Notes:  All assessments will be performed on the day of the specified visit unless a time window is specified.  On treatment days, all assessments 
should be performed prior to dosing, unless otherwise specified .  If scheduled dosing and study assessm ents are  precluded because of a  holiday, 
weekend, or other event, dosing may be postponed to the soonest following date, with subsequent dosing conti nuing on a  21-day schedule.  
If treatment was postponed for fewer than 3 days, the patient can resume the original schedule.   Screening local laboratory assessments 
obtained   [ADDRESS_198323]  of care tests or examinations performed  prior to obtaining informed consent and w ithin 28 days prior to Day  1 of Cycle  1 may 
be used; such tests do not need to be repeated for screening.  
b During the study treatment period, assessments scheduled on the days of study treatment infusions , should be performed before the in fusion 
unless ot herwise  noted.  
c Patients will be asked to return to the clinic no more than [ADDRESS_198324] be documented before any study -specific screening procedure is performed . 
e Representative tumor specimens in formalin fixed paraffin -embedded (FFPE) blocks (preferred) or at least 16 unstained slides  with an 
associated pathology report should be submitted within 4 weeks of randomization .  A patient with insufficient or unavailable archival tissue  or 
without a fresh biopsy sample  may be eligible .  See Section  4.1.1  for tissue sample requirements.  
f Medical history, including clinically significant diseases, surgeries, reproductive status, smoking history,  and use of alcohol, will be recorded at 
screening .  Cancer history includes stage, date of diagnosis, and prior ca ncer therapi[INVESTIGATOR_26649].  
g The  3-day window only applies to visit scheduling.  PROs should be administered before the patient receives any information on disease 
status, prior to the performance of non -PRO assessments and  prior to the administration of study treatment  ( 3-day win dow).  In scenarios 
where laboratory assessments (e.g., blood draws) are done at a different location than the one providing treatment or when th ey are done on a 
different day than study treatment administration, laboratory assessments can be completed bef ore the completion of PROs  ( 3 days)  as long as 
results have not been discussed with patients.  
j Vital signs include respi[INVESTIGATOR_697], pulse rate, systolic and diastolic blood pressure, and temperature .  Vital signs should be recorded as 
described in Section  4.5.4 . 
k The dose of bevacizumab /placebo  will be based on the patient's weight (in kilograms) measured  14 days prior to baseline (the initiation of 
study treatment)  and will remain the same throughout the study unless there is a weight change of  10% from baseline  body weight, in which 
case the bevacizumab dose should be modified.  Body weight will be re -baselined at the t ime of dose change, and dose modifications should 
occur if the patient’s weight changes  10% from the new baseline.   In general, sites should also follow their institutional guidelines and local 
standard of care for determining chemotherapy dose adjustments in the event of changes in patient weight.  

Appendix 1: Schedule of Activities  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
124/Protocol GO42661 , Version 6 l Complete and limited physical examinations are defined in Section  4.5.3 . 
m ECOG Performance Status, limited physical examination, local laboratory assessments, and PRO assessments may be obtained [ADDRESS_198325] undergone an EGD within 6  months 
of Day 1 of Cycle 1 .  Please refer to Section  4.1.2  for risk criteria.  
p Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, lymphocyte s, eosinophils, 
monocytes, basophils), and pla telet count.  
q At screening, patients must have adequate hematologic and end -organ function defined by [CONTACT_169895] 7 days  prior to 
Day 1 of Cycle  1, as described in Section  4.1.1 .  Screening local laboratory assessments obtained  [ADDRESS_198326] to be repeated for Cycle 1.  
r Chemistry panel (serum or plasma) includes bicarbonate or total carbon dioxide (if considered standard of care for the region), magnesium, 
sodium, potassium, chloride, glucose, BUN or urea, creatinine, total  protein, albumin, phosphate, calcium, total bilirubin, ALP, ALT, AST, and 
LDH. 
s All women of childbearing potential (including those who have had a tubal ligation) must have a serum pregnancy test performe d at screening 
and documented as negative within [ADDRESS_198327].  
t TSH, free T3 (or total T3 at sites where free T3 is not performed), and free T4 will be  collected at screening, on Day  1 of Cycle  1, and every 
fourth cycle thereafter (e.g., Cycl es 1, 5, 9, 13, and so forth).  
u During screening, patients will be tested for HIV, HBsAg, HBsAb, total HBcAb, and HCV antibody .  HBV DNA test must be performed during 
screening in patients who have positive  serology for HBsAg and/or positive serology for HBcAb.  If a patient has a positive HCV antibody test 
during screening, an HCV RNA test must also be performed . 
v If a patient tests positive for HBsAg and/or HBcAb, quantitative HBsAg and HBV DNA will be te sted during screening , Day  [ADDRESS_198328] is not available, a  qualitative HBsAg 
followed by [CONTACT_169896] .  Study treatment and procedures may proceed while HBV DNA is being 
proce ssed, but results should be reviewed by [CONTACT_169897].  If HBV DNA increases to  500 IU/mL, consultation 
with a hepatologist or gastroenterologist with specialty in HBV is recommended .  The Medical Monitor is available to advise as needed.  

Appendix 1: Schedule of Activities  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
125/Protocol GO42661 , Version [ADDRESS_198329] be  2   within [ADDRESS_198330]  2+ proteinuria on dipstick urinalysis at baseline should 
undergo a [ADDRESS_198331] demonstrate  1 g of protein in 24 hours.   Urinalysis/urine dipstick should be repeated before every 
cycle during treatment.  
x Atezolizumab will be adminis tered prior to bevacizumab/placebo.  Patients will receive atezolizumab by [CONTACT_104940] I V infusion every 21  days on 
Day 1 of each 21 -day cycle as indicated.  For atezolizumab, the initial dose will be delivered over 60 (  15) minutes.  Subsequent infusions will 
be delivered over 30 (  10) minutes if the previous infusion was tolerated without infusion -associated adverse events, or 60 (  15) minutes if the 
patient experienced an infusion -associated adverse event with the previous infusion .  Following atezolizumab, patients will receive 
bevacizumab/placebo by [CONTACT_169898] 21 days on Day 1 of each 21 -day cycle as indicated.  The initial dose of 
bevacizumab/placebo will be delivered over 90 (  15) minutes.  Subsequent infusion s will be delivered over 60 (  10) minutes if the previous 
continuous IV  infusion was tolerated without infusion -associated adverse events, or 90 (  15) minutes if the patient experienced an 
infusion -associated adverse event with the previous infusion.  Subsequent infusions will be delivered over 30 (  10) minutes if the previous 
infusion was tolerated without infusion -associated adverse events, or 60 (  15) minutes if the patient experienced an infusion -associated adverse 
event with the previous infusion .  During the chemotherapy combination phase, patients will receive cisplatin at a dose of 25 mg/m2 IV followed 
by [CONTACT_169840] a dose of 1000 mg/m2 by [CONTACT_169899] [ADDRESS_198332] etion of the bevacizumab/placebo infusion, and gemcitabine  will be administered after completion of the cisplatin  infusion.   Dosing of all 
study drugs will occur only if the clinical assessment and local laboratory test results are acceptable.  If a tumor assessment was performed, 
results must be reviewed by [CONTACT_169900].  
y Medication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeopathic remedies, nut ritional supplements) used by 
a patient in  addition to protocol -mandated treatment from  [ADDRESS_198333] scans (with oral or IV contrast) or MRI scans of the chest, abdomen, and pelvis.  A spi[INVESTIGATOR_169814] n of the chest 
may be obtained but is not a requirement.  If a CT scan with contrast is contraindicated (e.g., in  patients with impaired renal cle arance), 
a non-contrast CT scan of the chest may be performed and MRI scans of the abdomen and pelvis should be performed.  A CT scan with c ontrast 
or MRI scan of the head must be done at screening to evaluate CNS metastasi s in all patients (MRI scan must be performed if CT scan is 
contraindicated).  An MRI scan of the head is required to confirm or refute the diagnosis of CNS metastases at baseline in th e event of an 
equivocal CT scan.  Bone scans and CT scans of  the neck s hould also be performed if clinically indicated.  At the investigator's discretion, other 
methods of  assessment of measurable disease as per RECIST v1.1 may be used.  
Appendix 1: Schedule of Activities  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
126/Protocol GO42661 , Version 6 aa Patients will undergo tumor assessments at baseline  and every 9 ( 1) weeks thereafter,  regardless of dose delays, until radiographic disease 
progression per RECIST v1.1 or (for patients who continue atezolizumab plus bevacizumab or placebo, after radiographic diseas e progression) 
loss of clinical benefit as determined by [CONTACT_093] (s ee Section  3.1 for details).  Thus, tumor assessments are to continue according to 
schedule in patients who discontinue treatment for reasons other than disease progression or loss of clinical benefit, even  if they start new 
anti-cancer therapy.  At the investigator's discretion, tumor assessments may be repeated at any time if progressive disease is suspected.   All 
measurable and evaluable lesions should be re -assessed at each subsequent tumor evaluation.   The same radiographic procedures used to 
assess disease sites at screening should be used for subsequent tumor assessments (e.g., the same contrast protocol for CT  scans).  
bb After informed consent has been obtained , but prior to Day [ADDRESS_198334].  After this period, all deaths, regardless of cause, should be reported.  In addition, if the investigator becomes aware of 
a serious adverse event that is believed to be related to prior exposure to study treatment, the adverse event should be repo rted (see 
Section  5.6). 
cc See Appendix  3 for details of the PK, immunogenicity, and biomarker collection schedule.  Blood samples may be processed at sites  to obtain 
serum and plasma , as described in the laboratory manual . 
dd After t reatment discontinuation, information on survival follow -up and new anti -cancer therapy (including targeted therapy and immunotherapy) 
will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months until d eath (unless the patient 
withdraws consent or the Sponsor terminates the study).  If a patient requests to be withdrawn from follow -up, this request must be documented 
in the source documents and signed by [CONTACT_093].  If the patient withdraws from t he study, the study staff may use a public information 
source (e.g., county records) to obtain information about survival status . 
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
127/Protocol  GO42661 , Version 6 Appendix  2  
Schedule of Patient -Reported Outcome Assessments  
Day All Treatment Cycles (21 -Day Cycles) a 
Treatment Discontinuation 
Visit b 
 30 Days after  
Final Dose  Chemotherapy Combination Phase  CIT/Placebo Phase  
Cycles 12 Cycles 35 Cycles 
68 Cycles 9 and 
Beyond  
Day 1  Day 8  Day 15 c Day 1  Day 15 c Day 1  Day 1  
(Window)  ( 3 Days)  
EORTC QLQ -C30 x      x 
(Cycles 9 and 11 
only)  x 
EORTC IL77     x  x x 
(Odd cycles 
13    only)   
EORTC QLQ -BIL21  x   x  x x 
(Odd cycles 9    only)  x 
PGI-CI    x 
(Cycle  3 
only)   x 
(Cycle 6 
only)  x 
(Cycle 9 only)  x 
PGI-S x   x 
(Cycle  3 
only)   x 
(Cycle 6 
only)  x 
(Cycle 9 only)  x 
PRO -CTCAE  x x x c x x c x x 
(Odd cycles 9    only)  x 
Appendix 2 Schedule of Patient -Reported Outcome Assessments  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
128/Protocol GO42661 , Version 6 CIT   cancer immunotherapy; EORTC   European Organisation for Research and Treatment of Cancer; IL  item library; PGI-CI  Patient Global 
Impression of Change and its Importance; PGI -S  Patient Global Impression of Severity; PRO   patient -reported outcome; 
PRO -CTCAE   Patient -Reported Outcome Common Terminology Criteria for Adverse Events ; QLQ -BIL21   Quality -of-Life Questionnaire for 
Cholangiocarcinoma and Cancer of the Gallbladder . 
a All PRO assessments will be completed at the clinic , except for the Day 15 PRO -CTCAE which will be completed from home .  The  3-day 
window only applies to visit scheduling.  PROs should be administered before the patient receives any information on disease status, prior to the 
performance of non -PRO assessments, and prior to the administration of study treatment (  3-day window).  In scenarios where laboratory 
assessments (e.g., blood draws) are done at a different location than the one providing treatment or when they are done on a different day than 
study treatment administration, laboratory assessments can be completed before the  completion of PROs ( 3 days) as long as results have not 
been discussed with patients.  
b Patients will be asked to return to the clinic not more than 30  days after the final dose of  study treatment for a treatment discontinuation visit.  
c These PRO asses sments will be completed at home  via telephone call . 
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
129/Protocol  GO42661 , Version 6 Appendix  3  
Schedule of Pharmacokinetic, Immunogenicity, and 
Biomarker  Samples  
Visit  Timepoint  Sample Type  
 Screening and between 
Cycle 2 and Cycle 3  
(optional)    Stool sample (optional)  
 Day 1 of Cycle 1   Prior to any drug 
administration   Atezolizumab PK (serum)  
 Atezolizumab ADA 
(serum)  
 Blood biomarker (PBMC)  
 Serum biomarker  
 Plasma biomarker  
 Blood  (WES) a 
 30 ( 10) minutes after 
end of atezolizumab 
infusion   Atezolizumab PK (serum)  
 Day 1 of Cycles 2, 3, 4, 8, 
12, and 16   Prior to any drug 
administration   Atezolizumab PK (serum)  
 Atezolizumab ADA 
(serum)  
 Blood biomarker (PBMC)  
 Serum biomarker  
 Plasma biomarker  
 24 weeks after treatment 
initiation and at disease 
progression  
(optional)    Fresh tumor tissue biopsy 
sample (optional) b 
 Treatment discontinuation 
visit ( 30 days after final 
dose) c  At visit   Atezolizumab PK (serum)  
 Atezolizumab ADA 
(serum)  
 Blood biomarker (PBMC)  
 Serum biomarker  
 Plasma biomarker  
ADA   anti-drug antibody; PBMC   peripheral blood mononuclear cell; PK   pharmacokinetic ; 
WES   whole exome sequencing . 
a Blood sample for WES to be collected at Day 1 of Cycle 1, or as soon as possible after 
enrollment.  Collection for participating sites only.  
b For patients who consent to collection of optional biopsies, optional tumor biopsy samples 
may be collected by [CONTACT_169901] -needle or excisional or punch biopsy at the investigator’s discretion.  
Preferably, growing lesions should be selected.  
c If biomarker samples have been collected or will be collect ed at a visit within 7  days of the 
biopsy procedure date, an additional biomarker sample collection is not required  
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
130/Protocol  GO42661 , Version 6 Appendix  4  
Staging Criteria for Advanced Biliary Cancers  
BTC subtype  Locally advanced  Metastatic  
Extrahepatic  
(Biliary confluence 
involvement)   Bilateral extension to second -
order biliary radicles  
 Encasement or occlusion of 
hepatic artery (or bilateral 
involvement of hepatic arteries)  
 Encasement or occlusion of portal 
vein 
 Atrophy of one liver lobe with 
contralateral portal  branch or 
hepatic artery involvement  
 Extrahepatic adjacent local 
invasion (vessels or organs)   Multifocal masses within 
different liver segments  
 Metastatic lymph nodes 
beyond the 
hepatoduodenal ligament  
 Extrahepatic 
disseminated disease 
(e.g., lung, bone, 
peritoneum)  
Intrahepatic  
(Hepatic mass  
without biliary 
confluence 
involvement)   Hepatic artery involvement  
 Multifocal masses within the same 
liver segment  
 Extrahepatic adjacent local 
invasion (vessels or organs)  
Gallbladder   Large intrahepatic adjacent local 
invasion  
 Extrahepatic adjacent local 
invasion (vessels, bile ducts or 
organs)  
BTC   biliary tract cancer.  
 
REFERENCE  
Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without 
cetuximab in advanced biliary -tract cancer (BINGO): a randomised, open -label, 
non-comparative phase 2 trial. Lancet Oncol  2014;15:819828. 
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
131/Protocol  GO42661 , Version 6 Appendix  5  
Response  Evaluation Criteria in Solid Tumors , 
Version  1.1 (RECIST v1.1)  
Selected sections from the Response Evaluation Criteria in Solid Tumors, Version  1.1 
(RECIST v1.1)  (Eisenhauer et al. 2009) , are presented below, with slight modifications 
from the original pu blication and the addition of explanatory text as needed for clarity.1 
TUMOR MEASURABILITY  
At baseline, tumor lesions/lymph nodes will be categorized as measurable or 
non-measurable as described below.  All measurable and non -measurable lesions 
should be assessed at screening and at subsequent protocol -specified tumor 
assessment timepoints.  Additional assessments may be performed as clinically 
indicated for suspi[INVESTIGATOR_55519].  
DEFINITION OF  MEASURABLE LESIONS  
Tumor Lesions  
Tumor lesions must be accurately measured in at least one dimension (longest diameter 
in the plane of measurement is to be recorded) with a minimum size as follows:  
 10 mm by [CONTACT_20420] (CT) or magnetic resonance i maging (MRI) scan 
(CT/MRI scan slice thickness/interval  5 mm)  
 10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non -measurable)  
 [ADDRESS_198335] be 
 [ADDRESS_198336]  scan (CT scan slice thickness 
recommended to be  5 mm).  At  baseline and follow -up, only the short axis will be 
measured and follow ed.  Additional information on lymph node measurement is provided 
below (see Identification of Target and Non -Target Lesions  and Calculation of Sum of 
Diameters ). 
                                            
 
[ADDRESS_198337] been made.  

Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
132/Protocol GO42661 , Version 6 DEFINITION OF NON -MEASURABLE LESIONS  
Non-measurable tumor lesions encompass small lesions  (longest diameter  10 mm or 
pathological lymph nodes with short axis  10 mm but  15 mm) as well as truly 
non-measurable lesions.  Lesions considered truly non -measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
mass/abdominal organomegaly identified by [CONTACT_70187].  
SPECIAL CONSIDERATIO NS REGARDI NG LESION MEASURABIL ITY 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.  
Bone Lesions:  
 Technetium -99m bone scans, sodium fluoride positron emission tomography scans, 
and plain fi lms are not considered adequate imaging techniques for measuring bone 
lesions.  However, these techniques can be used to confirm the presence or 
disappearance of bone lesions.  
 Lytic bone lesions or mixed lytic -blastic lesions with identifiable soft tissue 
components  that can be evaluated by [CONTACT_12783] -sectional imaging techniques such as 
CT or MRI can be considered measurable lesions if the soft tissue component 
meets  the definition of measurability described above  
 Blastic bone lesions are non -measurable  
 
Cystic  Lesions:  
 Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered malignant lesions (neither measurable nor non -measurable) since they 
are, by [CONTACT_108], simple cysts  
 Cystic lesions thought to represent cystic met astases can be considered 
measurable lesions if they meet the definition of measurability described above.  
However, if non -cystic lesions are present in the same patient, these are preferred 
for selection as target lesions.  
 
Lesions with Prior Local Treat ment:  
 Tumor lesions situated in a previously irradiated area or in an area subjected to 
other loco -regional therapy are usually not considered measurable unless there has 
been demonstrated progression in the lesion  
 
Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
133/Protocol GO42661 , Version 6 METHODS FOR ASSESSIN G LESIONS  
All measur ements should be recorded in metric notation, using calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the 
treatment start and never more than 4 weeks before the beginning of the treatment.  
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during the study.  
Imaging -based evaluation should always be the preferred option.  
CLINICAL LESIONS  
Clinical lesions will only be  considered measurable when they are superficial and 
 10 mm in diameter as assessed using calipers (e.g., skin nodules).  For the case of 
skin lesions, documentation by [CONTACT_6775], including a ruler to estimate the size 
of the lesion, is suggested.  
CHEST X -RAY  
Chest CT is preferred over chest X -ray, particularly when progression is an important 
endpoint, since CT is more sensitive than X -ray, particularly in identifying new lesions.  
However, lesions on chest X -ray may be considered measurable if th ey are clearly 
defined and surrounded by [CONTACT_6776].  
CT AND MRI SCANS  
Computed tomography  is the best currently available and reproducible method to 
measure lesions selected for response assessment.  In this guideline, the definition of 
measurability of lesions on a CT scan is based on the assumption that CT slice 
thickness is  [ADDRESS_198338] slice thickness of  [ADDRESS_198339] or MRI (without IV contrast) will be used to evaluate the patient at 
baseline and during the study should be guided by [CONTACT_77056].  For patients who develop contraindications to 
contrast after baseline contrast CT is done, the decision as to whether non -contras t CT 
or MRI (enhanced or non -enhanced) will be performed should also be based on the 
tumor type and the anatomic location of the disease, and should be optimized to allow 
for comparison with the prior studies if possible.  Each case should be discussed wit h 
the radiologist to determine if substitution of these other approaches is possible and, 
if not, the patient should be considered not evaluable from that point forward .  Care must 
be taken in measurement of target lesions and interpretation of non -target disease or 
Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
134/Protocol GO42661 , Version [ADDRESS_198340] 
a different size using a new modality.  
ENDOSCOPY, LAPAROSCO PY, ULTRASOUND, TUMO R MARKERS, 
CYTOLOGY, HISTOLOGY  
Endoscopy, laparoscopy, ultrasound, tumor markers, cytolo gy, and histology cannot be 
used  for objective tumor evaluation.  
ASSESSMENT OF TUMOR BURDEN  
To assess objective response or future progression, it is necessary to estimate the 
overall tumor burden at baseline and use this as a comparator for subsequent 
measurements.  
IDENTIFICATION OF TA RGET AND NON -TARGET LESIONS  
When more than one measurable lesion is present a t baseline, all lesions up to 
a maximum of 5 lesions total (and a maximum of 2 lesions per organ) representative of 
all involved organs should be id entified as target lesions and will be recorded and 
measured at baseline.  This means that, for instan ces in which patients have only  1 or 
2 organ sites involved, a maximum of 2 lesions ( 1 site) and 4 lesions ( 2 sites), 
respectively, will be recorded.  Other lesions (albeit measurable) in those organs will be 
considered non -target lesions.  
Target lesions should be selected on the basis of their size (lesions with the longest 
diameter) and should be representative  of all involved organs, but in addition should lend 
themselves to reproducible  repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstance the next largest lesion  that can be measured reproducibly should be 
selected.  
Lymph nodes merit special mention since they are normal anatomical structures that 
may be visible by [CONTACT_33490].  As noted above, pathological 
nodes that are defined as measu rable and may be identified as target lesions must meet 
the criterion of a short axis of  [ADDRESS_198341] in which the image is obtained (for CT, 
this is almost always the axial plane; for MRI, the plane of acquisition may be axial, 
sagittal, or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20  mm   30 mm has a short axis of 20  mm and 
qualifies as a malignant, measur able node.  In this example, 20  mm should be recorded 
as the n ode measurement.  All other pathological nodes (those with short axis  10 mm 
Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
135/Protocol GO42661 , Version 6 but  15 mm) should be considered non -target lesions.  Nodes that have a short axis of 
 10 mm are considered non -pathological and should not be recorded or followed.  
All lesions  (or sites of disease) not selected as target lesions (measurable or 
non-measurable), including pathological lymph nodes, should be identified as non -target 
lesions and should also be recorded at baseline.  Measurements are not required.  It is 
possible to  record multiple non -target lesions involving the same organ as a single item 
on the Case Report Form (CRF) (e.g., multiple enlarged pelvic lymph nodes  or 
multiple liver metastases ). 
CALCULATION OF SUM O F DIAMETERS  
A sum of the diameters (longest diameter for no n-lymph node lesions, short axis for 
lymph node lesions) will be calculated for all target lesions at baseline and at each 
subsequent tumor assessment as a measure of tumor burden.  
Measuring Lymph Nodes  
Lymph nodes identified as target lesio ns should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the node regresses to  10 mm during the study.  Thus, when 
lymph nodes are included as target lesions, the sum of  diameters may not be zero even 
if CR criteria are met, since a normal lymph node is defined as having a short axis of 
 10 mm. 
Measuring Lesions That Become Too Small to Measure  
During the study, all target lesions (lymph node and no n-lymph node) recorded  at 
baseline should have their actual measurements recorded at each subsequent 
evaluation, even when very small (e.g., 2 mm).  However, sometimes lesions or lymph 
nodes that are recorded as target lesions at baseline become so faint on the CT scan 
that the  radiologist may not feel comfortable assigning an exact measurement and may 
report them as being too small to measure.  When this  occurs, it is important that a  value 
be recorded on the CRF, as follows:  
 If it is the opi[INVESTIGATOR_169815], the 
measurement should be recorded as 0 mm.  
 If the lesion is believed to be present and is faintly s een but too small to measure, 
a default value of 5 mm should be assigned and too small to measure  should be 
ticked.  (Note:  I t is less likely that this rule will be used for lymph nodes since they 
usually have a definable size when normal and are frequently surrounded by [CONTACT_169902]; however, if a lymph node is believed to be present 
and is faintly seen bu t too small t o measure, a default value of 5  mm should be 
assigned in this circumstance as well and too small to measure  should also be 
ticked).  
 
Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
136/Protocol GO42661 , Version [ADDRESS_198342] is able to provide an actual measurement, that 
should be recorded, even if it is  5 mm, and in that case too small to measure  should 
not be ticked.  
Measuring Lesions That Split or Coalesce on Treatment  
When no n-lymph node lesions fragment, the longest diameters of the fragmented 
portions should be added together to calculate the sum of diameters.  Similarly, as 
lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter m easurements of each individual lesion.  If the lesions have truly 
coalesced such that they are no longer separable, the vector of the longest diameter in 
this instance should be the maximum longest diameter for the coalesced lesion.  
EVALUATION OF NON -TARGE T LESIONS  
Measurements are not required for non -target lesions, except that malignant lymph node 
non-target lesions should be monitored for reduction to  10 mm in short axis.  
Non-target lesions should be noted at baseline and should be identified as present or 
absent and (in rare cases) may be noted as indicative of progression  at subsequent 
evaluations.  In addition, if a lymph node lesion shrinks to a non -malignant size 
(short  axis  10 mm), this should be captured on the CRF as part of the assessment of 
non-target lesions.  
RESPONSE CRITERIA  
CRITERIA FOR TARGET LESIONS  
Definitions of the criteria used to determine objective tumor response for target lesions 
are provided below:  
 Complete response:  Disappearance of all target lesions  
Any pathol ogical lymph nodes must have reduction in short axis to  10 mm.  
 Partial response :  At least a 30% decrease in the sum of diameters of all target 
lesions, taking as reference the baseline sum of diameters, in the absence of CR  
 Progressive disease (PD):  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum of diameters at prior timepoints  
(including baseline)  
In addition to the relative increase of 20%, the sum of diameters must also 
demonstrate an absolute increase of  5 mm.  
 Stable disease (SD):  Neither sufficient shrinkage to qualify for CR or PR nor 
sufficient increase to qualify for PD  
 
Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
137/Protocol GO42661 , Version 6 CRITERIA FOR NON -TARGET LESIONS  
Definitions of the criteria used to determine the tumor response for the group of 
non-target lesions are provided below.  While some non -target lesions may actually be 
measurable, they need not be measured and instead should be assessed only 
qualitatively at the timepoints specified in the schedule of activities.  
 Complete response :  Disappe arance of all non -target lesions and (if applicable) 
normalization of tumor marker level  
All lymph nodes must be non -pathological in size (  10 mm short axis).  
 Non-CR/Non -PD:  Persistence of one or more non -target lesions and/or 
(if applicable) maintenance  of tumor marker level above the normal limits  
 Progressive disease :  Unequivocal progression of existing non -target lesions  
 
SPECIAL NOTES ON ASS ESSMENT OF PROGRESSI ON OF NON -TARGET 
LESIONS  
Patients with Measurable and Non -Measurable Disease  
For patients w ith both measurable and non -measurable disease to achieve unequivocal 
progression on the basis of the non -target lesions, there must be an overall level of 
substantial worsening in non -target lesions in a magnitude that, even in the presence of 
SD or PR in  target lesions, the overall tumor burden has increased sufficiently to merit 
discontinuation of therapy.  A modest increase in the size of one or more non -target 
lesions is usually not sufficient to qualify for unequivocal progression status.  
The designa tion of overall progression solely on the basis of change in non -target 
lesions in the face of SD or PR in target lesions will therefore be extremely rare.  
NEW LESIONS  
The appearance of new malignant lesions denotes disease progression; therefore, some  
comments on detection of new lesions are important.  There are no specific criteria for 
the identification of new radiographic lesions; however, the finding of a new lesion 
should be  unequivocal, that is, not attributable to differences in scanning technique,  
change in imaging  modality, or findings thought to represent something other than tumor 
(for example, some  new bone lesions may be simply healing or flare of preexisting 
lesions).  This is  particularly important when the patient's baseline lesions show PR or 
CR.  For example, necrosis of a liver lesion may be reported on a CT scan report as 
a new cystic lesion, which it is not.  
A lesion identified during the study in an anatomical location that was not scanned at 
baseline is considered a new lesion and  will indicate disease progression.  
Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
138/Protocol GO42661 , Version [ADDRESS_198343] measurable disease at baseline.  
Table  1 Criteria for Overall Response at a Single Timepoint:  Patients 
with Target Lesions (with or without Non -Target Lesions)  
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not all evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or no  PD 
Any PD Yes or no  PD 
Any Any Yes PD 
CR   complete response; NE   not evaluable; PD   progressive disease; PR   partial response; 
SD   stable disease.  
 
MISSING ASSESSMENTS AND NOT -EVALUABLE DE SIGNATION  
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint.  If measurements are made on only a subset of target 
lesions at a timepoint, usually the case is also considered not evaluable at that 
timepoint, unless a convincing argument can be made that the contribution of the 
individual missing lesions would not change the assigned timepoint response.  This 
would be most likely to happen in the case of PD.  For example, if a patient had 
a baseline sum  of [ADDRESS_198344] achieved PD 
status, regardless of the contribution of the missing lesion.  

Appendix 5:  Response Evaluation Criteria in Solid Tumors , Version 1.1  (RECIST  v1.1) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
139/Protocol GO42661 , Version 6 SPECIAL NOTES ON RES PONSE ASSESSMENT  
Patient s with a global deterioration in health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
symptomatic deterioration.   Every effort should be made to document objective 
progr ession even after discontinuation of treatment.  Sym ptomatic deterioration is not 
a descriptor of an objective response; it is a reason for stoppi[INVESTIGATOR_12003].  
The objective response status of such patients is to be determined by [CONTACT_77058] -target lesions as shown in  Table  1. 
For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment.  If at the next scheduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progression was suspected.  
REFERENCE  
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228 47. 
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
140/Protocol  GO42661 , Version 6 Appendix  6  
European Organisation for the Research and Treatment of 
Cancer Quality -of-Life Questionnaire  (EORTC QLQ -C30) 
This document must not be reproduced.  The Sponsor will provide a copy of the 
document upon request.  
 
  

Appendix 6: European Organisation for Research and Treatment of Cancer Quality -of-Life 
Questionnaire ( EORTC QLQ -C30) 
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
141/Protocol GO42661 , Version 6  
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
142/Protocol  GO42661 , Version 6 Appendix  7  
European Organisation for Research and Treatment of Cancer 
Quality -of-Life Questionnaire for Cholangiocarcinoma and 
Cancer of the Gallbladder  (EORTC QLQ -BIL21 ) 
This document must not be reproduced.  The Sponsor will provide a copy of the 
document upon request.  
 
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
143/Protocol  GO42661 , Version 6 Appendix  8  
European Organisation for Research and Treat ment of Cancer 
Item Library 77 ( EORTC IL77 ) 
This document must not be reproduced.  The Sponsor will provide a copy of the 
document upon request.  
 
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
144/Protocol  GO42661 , Version 6 Appendix  9  
Patient Global Impression of Change and Its Importance ( PGI-CI) 
This document must not be reproduced.  The Sponsor will provide a copy of the 
document upon request.  
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
145/Protocol  GO42661 , Version 6 Appendix  10  
Patient  Global Impression of Severity ( PGI-S) 
This document must not be reproduced.  The Sponsor will provide a copy of the 
document upon request.  
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
146/Protocol  GO42661 , Version 6 Appendix  11  
Patient -Reported Outcome Common Terminolog y Criteria for 
Adverse Events  (PRO -CTCAE ) 
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
147/Protocol  GO42661 , Version 6 Appendix  12  
Preexisting Autoimmune Diseases  and Immune Deficienc ies 
Patients should be carefully questioned regarding th eir history of acquired or congenital 
immune deficiencies or autoimmune disease.  Patients with any history of immune 
deficiencies or autoimmune disease listed in the table below are excluded from 
participating in the study.  Possible exceptions to this ex clusion could be pati ents with 
a medical history of such entities as atopic disease or childhood arthralgias where the 
clinical suspi[INVESTIGATOR_33415].  Patients with a history of 
autoimmune -related hypothyroidism on a stable dose of thyroi d replacement hormone 
may be eligible for this study.  In addition, transient autoimmune manifestations of an 
acute infectious disease that resolved upon treatment of the infectious agent are not 
excluded (e.g.,  acute Lyme arthritis).  Caution should be us ed when considering 
atezolizumab for patients who have previously experienced a severe or life threatening 
skin adverse reaction or pericardial disorder while receiving another immunostimulatory 
anti-cancer agent.  The Medical Monitor is available to advise on any uncertainty over 
autoimmune exclusions.  
Autoimmune Diseases and Immune Deficiencies  
 Acute disseminated  
encephalomyelitis  
 Addison disease  
 Ankylosing spondylitis  
 Antiphospholipid antibody  
syndrome  
 Aplastic anemia  
 Autoimmune hemolytic anemia  
 Autoimmune hepatitis  
 Autoimmune  
hypoparathyroidism  
 Autoimmune hypophysitis  
 Autoimmune myocarditis   
 Autoimmune myelitis   
 Autoimmune oophoritis  
 Autoimmune orchitis  
 Autoimmune 
thrombocytopenic  purpura  
 Behçet disease  
 Bullous pemphigoid  
 Chronic fatigue syndrome  
 Chronic inflammatory  
demyelinating  polyneuropathy  
 Churg -Strauss syndrome  
 Crohn disease   Dermatomyositis  
 Diabetes mellitus type 1  
 Dysautonomia  
 Epi[INVESTIGATOR_169816] 
 Gestational pemphigoid  
 Giant cell arteritis  
 Goodpasture syndrome  
 Granulomatosis wit h 
polyangiitis  
 Graves disease  
 Guillain -Barré syndrome  
 Hashimoto disease  
 IgA nephropathy  
 Inflammatory bowel disease  
 Interstitial cystitis  
 Kawasaki disease  
 Lambert -Eaton myasthenia  
syndrome  
 Lupus erythematosus  
 Lyme disease , chronic  
 Meniere syndrome  
 Mooren ulcer  
 Morphea  
 Multiple sclerosis  
 Myasthenia gravis   Neuromyotonia  
 Opsoclonus myoclonus  
syndrome  
 Optic neuritis  
 Ord thyroiditis  
 Pemphigus  
 Pernicious anemia  
 Polyarteritis nodosa  
 Polyarthritis  
 Polyglandular autoimmune  
syndrome  
 Primary biliary cholangitis  
 Psoriasis  
 Reiter syndrome  
 Rheumatoid arthritis  
 Sarcoidosis  
 Scleroderma  
 Sjögren syndrome  
 Stiff-Person syndrome  
 Takayasu arteritis  
 Ulcerative colitis  
 Vitiligo  
 Vogt-Koyanagi -Harada 
disease  
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
148/Protocol  GO42661 , Version [ADDRESS_198345] operating procedures.  
REQUIRED EQUIPMENT A ND MEDICATION  
The following equipment and medication are needed in the event o f a suspected 
anaphylactic reaction during study treatment infusion:  
 Monitoring devices:  ECG monitor, blood pressure monitor, oxygen saturation 
monitor, and thermometer  
 Oxygen  
 Epi[INVESTIGATOR_33414], intramuscular, IV, and/or endotracheal administra tion 
in accordance with institutional guidelines  
 Antihistamines  
 Corticosteroids  
 Intravenous infusion solutions, tubing, catheters, and tape  
 
PROCEDURES  
In the event of a suspected anaphylactic reaction during study treatment  infusion, 
the following procedures should be performed:  
1. Stop the study treatment  infusion.  
2. Call for additional medical assistance.  
3. Maintain an adequate airway.  
4. Ensure that appropriate monitoring is in place, with continuous ECG and pulse 
oximetry monitori ng if possible.  
5. Administer antihistamines, epi[INVESTIGATOR_238], or other medications and IV fluids as 
required by [CONTACT_123589].  
6. Continue to observe the patient and document observations . 
 
 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
149/Protocol  GO42661 , Version 6 Appendix  14  
Overall  Guidelines for Management of Patients Who Experience 
Adverse  Events  
DOSE MODIFICATIONS  
There will be no dose modifications for atezolizumab .  No dose modifications are 
permitted for bevacizumab/placebo aside from weight -based dose changes as outlined 
in the protocol.  
Recommend ations on  dose  modification s for cisplatin and gemcitabine  (CisGem) are 
provided in the Safety Plan ( Section  5.1.5 ). 
TREATMENT INTERRUPTI ON 
Atezolizumab treatment may be temporarily suspended in patients experiencing toxicity 
considered to be related to stu dy treatment.  If corticosteroids are initiated for treatment 
of the toxicity, they must be tapered over  1 month to the equivalent of  10 mg/day oral 
prednisone before atezolizumab can be resumed.  If atezolizumab is withheld for 
 12 weeks after event onset, the patient will be discontinued from atezolizumab.  
However, atezolizumab may be withheld for  12 weeks to allow for patients to taper off 
corticosteroids prior to resuming treatment.  Atezolizumab can be r esumed after being 
withheld for   12 weeks if the patient is likely to derive clinical benefit.  The decision to 
re-challenge patients with atezolizumab should be based on the investigator's 
benefitrisk assessment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  Atezolizumab treatment may be suspended for reasons 
other than toxicity (e.g., surgical procedures).  The acceptable length of treatment 
interruption must be based on the investigator’s benefitrisk  assessment and in 
alignment with the protocol requirements for the duration of treatment and documented 
by [CONTACT_093].   The Medical Monitor is available to advise as needed . 
Bevacizumab /placebo  treatment may be temporarily suspended in patients experiencing 
toxicity considered to be related to study treatment.  If the event resolves to Grade  1, 
bevacizumab /placebo  may be restarted at the same dose level.  If bevacizumab /placebo  
is delayed due to toxicity for  [ADDRESS_198346] be permanently discontinued from bevacizumab /placebo .  
Bevacizumab /placebo  can be resumed after being withheld for  [ADDRESS_198347] been withheld for  42 days because of toxicity, the patient should be 
discontinued from gemcitabine o r cisplatin . 

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
150/Protocol GO42661 , Version 6 Atezolizumab, bevacizumab/placebo, gemcitabine, or cisplatin treatment may be 
suspended for reasons other than toxicity (e.g., surgical procedures).  The investigator 
will determine the acceptable length of treatment interruption.  If atezoliz umab, 
bevacizumab/placebo, gemcitabine, or cisplatin are transiently withheld or permanently 
discontinued, one or all of the other drugs can be continued as long as the patients are 
experiencing clinical benefit in the opi[INVESTIGATOR_871].  However , 
bevacizumab/placebo should not be continued as a single agent .  Recommend ations on  
CisGem  dose interruptions are provided in the Safety Plan ( Section  5.1.5 ). 
MANAGEMENT GUIDELINE S 
Guidelines for management of patients who experience specific adverse events are 
provided in Table  1.  See both Table  1 and Table  2 for adverse events that occur during 
the chemotherapy combinat ion phase.  See Table  2 for adverse events that occur during 
the cancer immunotherapy (CIT)/placebo phase . 
Specific adverse events associa ted with gemcitabine or cisplatin are provided below.  
For adverse events that are not listed herein, see guidelines in the applicable local 
prescribing information (if available) or Summary of Product Characteristics.  For cases 
in which management guidel ines are not covered in the protocol or prescribing 
information, patients should be managed as deemed clinically appropriate by [CONTACT_1275].  

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
151/Protocol GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab /Placebo  
with or without  Cisplatin and Gemcitabine  
Event  Action to Be Taken  
IRRs, anaphylaxis, and 
hypersensitivity reactions   Guidelines for management of IRRs for atezolizumab are 
provided in  Appendix  15. 
 Guidelines for management of IRRs for bevacizumab /placebo  
are provided below.  
 For anaphylaxis precautions, see  Appendix  13. 
 For hypersensitivity reactions and allergic reactions, 
permanently discontinue the causative agent.  
IRR to bevacizumab /placebo , 
Grade  1   Systemic intervention is not indicated.  Continue 
bevacizumab /placebo . 
IRR to bevacizumab /placebo , 
Grade 2   Reduce infusion rate to  50% or interrupt infusion at the 
discretion of the investigator per medical judgment.  
 If the infusion is interrupted, it may be resumed at  50% of the 
rate prior to the reaction after the patient's symptoms have 
adequately resolved and increased in 50% increments up to 
the full rate if well tolerated.  Infusions may be restarted at the 
full rate during the next cycle.  
IRR to bevacizumab /placebo , 
Grade 3 or 4   Stop infusion and per manently discontinue 
bevacizumab /placebo . 
 Administer aggressive symptomatic treatment (e.g., oral or IV 
antihistamine, antipyretic, glucocorticoids, epi[INVESTIGATOR_238], 
bronchodilators, oxygen) if clinically indicated.  

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
152/Protocol GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab/Placebo 
with or without Cisplatin and Gemcitabine  (cont.)  
Event  Action to Be Taken  
Gastrointestinal toxicity  
GI perforation, any grade   Withhold atezolizumab , gemcitabine, or cisplatin . 
 Permanently discontinue bevacizumab /placebo . 
 Initiate treatment per institutional guidelines.  
 If event improves, consider resuming atezolizumab. 
gemcitabine, or cisplatin  If not, permanently discontinue 
atezolizumab , gemcitabine , or cisplatin . a 
Bowel obstruction, Grade 2   Atezolizumab , gemcitabine, or cisplatin . may be continued 
at the discretion of the investigator.  
 Withhold bevacizumab /placebo  for partial obstruction 
requiring medical intervention.  
 Bevacizumab /placebo  may be restarted upon complete 
resolution of event.  
Bowel obstruction, Grade  3 
or 4  Atezolizumab , gemcitabine, or cisplatin  may be continued 
at the discretion of the investigator.  
 Withhold bevacizumab /placebo  until complete resolution.  
 If surgery is nece ssary, patient may restart 
bevacizumab /placebo  after full recovery from surgery and 
at the investigator's discretion.  
Posterior reversible encephalopathy syndrome  
Posterior reversible 
encephalopathy syndrome, 
any grade confirmed by 
[CONTACT_81789]   Withhold atezolizumab  and cisplatin .  Permanently 
discontinue bevacizumab /placebo  and gemcitabine . 
 If event improves, consider resuming atezolizumab  and 
cisplatin .  If not, permanently discontinue atezolizumab  
and cisplatin . a 
a Resumption of treatment may be considered if the investigator believes the patient is likely to 
derive clinical benefit.  
 
Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
153/Protocol GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab/Placebo 
with or without Cis platin and Gemcitabine  (cont.)  
Hypertension a 
General guidance   Treat with antihypertensive medication as needed.  
Hypertension, Grade 1   Continue atezolizumab , bevacizumab /placebo , gemcitabine, or 
cisplatin . 
 Consider increased  BP monitoring.  
Hypertension,  
Grade 2   Continue atezolizumab , gemcitabine, or cisplatin . 
 If asymptomatic, begin or modify baseline anti -hypertensive 
therapy and continue bevacizumab /placebo . 
 If symptomatic, start or adjust anti-hypertensive therapy.  
Hypertension, Grade 3   Continue atezolizumab , gemcitabine, or cisplatin . 
 Modify existing anti -hypertensive therapy (more than one drug or 
more intensive therapy than previously indicated).  
 Withhold  bevacizumab /placebo  until symptoms resolve and BP 
 160/90  mmHg . 
Hypertension, Grade 4   Atezolizumab , gemcitabine, or cisplatin  may be continued at the 
discretion of the investigator . 
 Permanently discontinue bevacizumab /placebo . 
Hemorrhage  
Hemorrhage, Grade 3 or 
4 (excluding cerebral 
hemorrhage)   Continue atezolizumab.  gemcitabine, or cisplatin . 
 Permanently discontinue bevacizumab /placebo . 
CNS hemorrhage, any 
grade   Atezolizumab , gemcitabine, or cisplatin  may be continued at the 
discretion of the investigator.  
 Permanently discontinue bevacizumab /placebo . 
Grade  2 hemoptysis 
( 2.5 mL of bright red 
blood per epi[INVESTIGATOR_1865])   Continue atezolizumab , gemcitabine, or cisplatin . 
 Permanently discontinue bevacizumab /placebo . 
Bleeding in patients on 
full-dose anticoagulant 
therapy   Continue atezolizumab , gemcitabine, or cisplatin . 
 Permanently discontinue bevacizumab /placebo . 
a Vascular disorders (including hypertension and hypotension) are possible adverse events of 
atezolizumab, considering the mechanism of action.  
 
Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
154/Protocol GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab/Placebo 
with or without Cisplatin and Gemcitabine  (cont.)  
Event  Action to Be Taken  
Thromboembolic events  
Venous thromboembolic event, 
Grade 3   Atezolizumab , gemcitabine, or cisplatin  may be continued at 
the discretion of the investigator . 
 Withhold bevacizumab /placebo  treatment.  If the planned 
duration of full -dose anticoagulation is  2 weeks, 
bevacizumab /placebo  should be withheld until the full -dose 
anticoagulation period is over.  The use  of direct oral 
anticoagulants is not recommended.  
 If the planned duration of full -dose anticoagulation is 
 2 weeks, bevacizumab /placebo  may be resumed during 
full-dose anticoagulation if all of the criteria below are met:  
– The patient must not have pathological conditions that 
carry high risk of bleeding (e.g., tumor involving major 
vessels or other conditions).  
– The patient must not have had hemorrhagic events 
Grade   2 while in the  study.  
– The patient must be on stable dose of heparin, 
low-molecular -weight  heparin, or have an in -range INR 
(usually 2 3) on a stable dose of warfarin prior to 
restarting bevacizumab /placebo . 
 If thromboemboli worsen/recur upon resumption of study 
therapy, discontinue bevacizumab /placebo . 
Venous thromboembolic event, 
Grade  4  Atezolizumab , gemcitabine, or cisplatin  may be continued at 
the discretion of the investigator . 
 Permanently discontinue bevacizumab /placebo . 
Arterial thromboembolic event, 
any grade   Atezolizumab , gemcitabine, or cisplatin  may be continued at 
the discretion of the investigator.  
 Permanently discontinue bevacizumab /placebo . 
Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
155/Protocol GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab/Placebo 
with or without Cisplatin and Gemcitabine  (cont.)  
Event  Action to Be Taken  
Proteinuria  
Proteinuria, Grade 1 
(1  by [CONTACT_5230]; urinary protein 
 1.0 g/24 hours)   Continue atezolizumab , bevacizumab /placebo , gemcitabine, 
and cisplatin . 
Proteinuria, Grade 2  
(2  and 3   by [CONTACT_5230]; urinary 
protein  1.03.4 g/24 hours)   Continue atezolizumab , gemcitabine, or cisplatin . 
 For 2    dipstick:  Continue bevacizumab /placebo  and collect 
24-hour urine protein prior to subsequent 
bevacizumab /placebo  administration.  
 For 3   dipstick:  Obtain 24 -hour urine prior to administering 
bevacizumab /placebo . 
 Withhold bevacizumab /placebo  for urinary protein 
 2 g/24 hours.  
 If bevacizumab is withheld and urine protein improves to 
 2 g/24 hours   42 days after event onset , resume 
bevacizumab /placebo .  If not, permanently discontinue 
bevacizumab /placebo . 
Proteinuria, Grade 3  
(4  by [CONTACT_5230]; urinary  protein 
 3.5 g/24 hours) with no 
diagnosis  of nephrotic 
syndrome   Atezolizumab , gemcitabine, or cisplatin  may be continued at 
the discretion of the investigator.  
 Withhold bevacizumab /placebo . 
 If urine protein improves to  2 g/24 hours   42 days after 
event onset , resume bevacizumab /placebo .  If not, 
permanently discontinue bevacizumab /placebo . 
Nephrotic syndrome,  
Grade 3 or  4  Atezolizumab , gemcitabine, or cisplatin  may be  continued at 
the discretion of the investigator.  
 Permanently discontinue bevacizumab /placebo . 
Fistula  
Tracheoesophageal fistula  
and fistula formation involving 
an internal organ , any grade   Withhold atezolizumab , gemcitabine, or cisplatin . 
 Permanently discontinue bevacizumab /placebo . 
 If event improves, consider resuming atezolizumab , 
gemcitabine, or cisplatin .  If not, permanently discontinue 
atezolizumab. a 
Fistula formation not involving 
an internal organ , Grade  4  Withhold atezolizumab , gemcitabine, or cisplatin . 
 Permanently discontinue bevacizumab /placebo . 
 If event improves, consider resuming atezolizumab , 
gemcitabine, or cisplatin .  If not, permanently discontinue 
atezolizumab , gemcitabine, or cisplatin . a 
a Resumption of treatment may be considered if the investigator believes the patient is likely to 
derive clinical benefit . 
Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
156/Protocol GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab/Placebo 
with or without Cisplatin and Gemcitabine  (cont.)   
Event  Action to Be Taken  
Wound dehiscence  
Wound dehiscence, any grade 
requiring medical or surgical 
therapy   Atezolizumab , gemcitabine, or cisplatin  may be continued 
at the discretion of the investigator.  
 Permanently discontinue bevacizumab /placebo . 
Congestive heart failure  
Congestive heart failure,  
Grade 3 or 4   Atezolizumab may be continued at the discretion of the 
investigator.  
 Permanently discontinue bevacizumab /placebo , 
gemcitabine, or cisplatin . 
Diarrhea  
Diarrhea, Grade 1 or 2   Follow guidelines for atezolizumab in Appendix  15. 
 Continue bevacizumab /placebo , gemcitabine and 
cisplatin.  
Diarrhea, Grade 3 or 4   Follow guidelines for atezolizumab in Appendix  15. 
 Consider withholding bevacizumab /placebo .  If event 
improves, resume bevacizumab /placebo .  If not, 
permanently discontinue bevacizumab /placebo.  
 If event resolves to Grade  1 or better within 42 days, b 
resume gemcitabine and cisplatin with dose reduced by 
[CONTACT_12691]. c, d  If not, permanently discontinue gemcitabine 
and cisplatin.  
Pulmonary toxicity  
Pulmonary toxicity,  
Grade 1 or 2   Follow guidelines for atezolizumab in  Appendix  15. 
 Continue gemcitabine and cisplatin.  
Pulmonary toxicity,  
Grade 3 or 4   Follow guidelines for atezolizumab in  Appendix  15. 
 Permanently discontinue gemcitabine.  Withhold 
bevacizumab /placebo  and cisplatin.  
 If event improves, resume bevacizumab /placebo  and 
cisplatin at current dose.  If not, permanently discontinue 
bevacizumab /placebo  and cisplatin.  
a Resumption of treatment may be considered if the investigator believes the patient is likely 
to derive clinical benefit . 
b If the investigator believes the patient is likely to derive clinical benefit, can be resumed 
after being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan ( Section  5.1.5 ). 
d Cisplatin may be resumed at current dose if the investigator believes the patient is likely to 
derive clinical benefit . 
 

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
157/Protocol GO42661 , Version 6 Table  1 Guidelines  for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab/Placebo 
with or without Cisplatin and Gemcitabine  (cont.)  
Dermatologic events  
Dermatologic event, Grade  1 
or 2  Follow guidelines for atezolizumab in Appendix  15 
Appendix  15. 
 Continue bevacizumab/placebo, gemcitabine, or cisplatin.  
Dermatologic event, Grade  3  Follow guidelines for atezolizumab in Appendix  15. 
 ·Withhold bevacizumab/placebo, gemcitabine, or cisplatin.  
 If event resolves to Grade 1 or better, resume 
{bevacizumab/placebo, gemcitabine, or cisplatin  
 Permanently discontinue bevaciz umab/placebo, 
gemcitabine, or cisplatin if withheld for  42 days.  
Dermatologic event, Grade  4  Follow guidelines for atezolizumab in Appendix  15. 
 Permanently discontinue bevacizumab/placebo, 
gemcitabine, or cisplatin.  
Neurologic toxicity  
Neurologic toxicity,  
Grade 1 or 2   Follow guidelines for atezolizumab in Appendix  15. 
 Continue bevacizumab /placebo , gemcitabine and 
cisplatin.  
Neurologic toxicity,  
Grade 3 or 4   Follow guidelines for atezolizumab in  Appendix  15. 
 Consider withholding bevacizumab /placebo .  If event 
improves, resume bevacizumab /placebo .  If not, 
permanently discontinue bevacizumab /placebo.  
 Withhold gemcitabine and cisplatin.  
 If event re solves to Grade 1 or better within 42  days, b 
resume gemcitabine and cisplatin with dose reduced by 
[CONTACT_12691]. c, d  If not, permanently discontinue gemcitabine 
and cisplatin.  
a Resumption of treatment may be considered if the investigator believes the patient is likely 
to derive clinical benefit.  
b If the investigator believes the patient is likely to derive clinical  benefit , can be resumed after 
being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan (Section  5.1.5 ). 
d Cisplatin may be resumed at current dose if the investigator believes the patient is lik ely to 
derive clinical benefit.  

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
158/Protocol  GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Be vacizumab/Placebo 
with or without Cisplatin and Gemcitabine  (cont.)  
Hepatic toxicity  
Hepatic toxicity, Grade 1 or 2   Follow guidelines for atezolizumab in  Appendix  15. 
 Continue bevacizumab /placebo , gemcitabine and 
cisplatin.  
Hepatic toxicity, Grade 3   Follow guidelines for atezolizumab in  Appendix  15. 
 Permanently discontinue gemcitabine.  
 Consider withholding bevacizumab /placebo .  If event 
improves, resume bevacizumab /placebo .  If not, 
permanently discontinue bevacizumab /placebo.  
  Withhold cisplatin . 
 If event resolves to Grade 1 or better within 42 days, a 
resume cisplatin with dose reduced by [CONTACT_12691]. c, d  
If not, permanently discontinue cisplatin.  
Hepatic toxicity, Grade 4   Follow guidelines for atezolizumab in  Appendix  15. 
 Consider withholding bevacizumab /placebo .  If event 
improves, resume bevacizumab /placebo .  If not, 
permanently discontinue bevacizumab /placebo.  
 Permanently discontinue gemcitabine and cisplatin.  
a Resumption of treatment may be considered if the investigator believes the patient is likely 
to derive clinical benefit . 
b If the investigator believes the patient is likely to deri ve clinical benefit, can be resumed after 
being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan ( Section  5.1.5 ). 
d Cisplatin may be resumed at current dose if the investigator believes the patient is likely to 
derive clinical benefit . 
  

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
159/Protocol GO42661 , Version 6 Table  1 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Atezolizumab plus Bevacizumab/Placebo 
with or without Cisplatin and Gemcitabine  (cont.)  
Bevacizumab -related toxicities not described above  
Grade 1 or 2   Continue atezolizumab, bevacizumab /placebo , gemcitabine, 
and cisplatin . 
Grade 3   Continue atezolizumab,  gemcitabine, and cisplatin .  Withhold 
bevacizumab /placebo.  
 If event resolves to Grade 1 or better  42 days after event 
onset, resume bevacizumab/placebo.  If  not, permanently 
discontinue bevacizumab/placebo. a 
Grade 4   Withhold atezolizumab, bevacizumab /placebo , gemcitabine, 
and cisplatin . 
 If event improves, consider resuming atezolizumab,  
gemcitabine, and cisplatin .  If not, permanently discontinue 
atezolizumab,  gemcitabine, and cisplatin . a 
 If event resolves to Grade 1  or better  42 days after event 
onset, resume bevacizumab/placebo.  If  not, permanently 
discontinue bevacizumab/placebo. a 
Atezolizumab -related toxicities not described above  
Grade 1 or 2   Follow guidelines for atezolizumab in Appendix  15. 
 Continue bevacizumab /placebo , gemcitabine, and cisplatin . 
Grade 3 or 4   Follow guidelines for atezolizumab in Appendix  15. 
 Withhold bevacizumab /placebo , gemcitabine, and cisplatin . 
 If event resolves to Grade 1 or better   42 days after event 
onset, resume bevacizumab/placebo,  gemcitabine, and 
cisplatin .  If not, permanently discontinue 
bevacizumab/placebo,  gemcitabine, and cisplatin . a 
a Resumption of treatment may be considered if the investigator believes the patient is likely 
to derive clinical benefit.  
b If the investigator believes the patient is likely to derive clinical benefit, can be resumed after 
being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan (Section  5.1.5). 
d Cisplatin may be resumed at current dose if the investigator believes the patient is likely to 
derive clinical benefit.  
  

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
160/Protocol GO42661 , Version 6 Table  2 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Cisplatin and Gemcitabine  
Hematologic toxicity on Day 1 : ANC  109/L (1500/L) and/or platelet  count  100109/L 
(100,000/ L) 
Nadir a ANC  0.5   109/L 
(500/L), absence of febrile 
neutropenia, and nadir platelet 
count  50   109/L (50,000/ L)  Continue atezolizumab and bevacizumab /placebo .  
Withhold gemcitabine and c isplat in. 
 If ANC is  1.5   109/L (1500/L) and platelet count is 
 100   109/L (100,000/ L) within 42 days, b resume 
gemcitabine and cisplatin at current dose. c  If not, 
permanently discontinue gemcitabine and cisplatin . 
Nadir a ANC   0.5   109/L 
(500/L) and nadir a platelet 
count  50   109/L (50,000/ L) 
or 
Febrile neutropenia  
or 
Nadir a platelet count 
 50   109/L (50,000/ L) without 
bleeding   Withhold atezolizumab,  bevacizumab /placebo , 
gemcitabine, and cisplatin.  
 If event improves, resume atezolizumab and 
bevacizumab /placebo .  If not, permanently discontinue 
atezolizumab and bevacizumab /placebo . 
 If ANC is  1.5   109/L (1500/L) and platelet count is 
 100   109/L (100,000/ L) within 42  days , b resume 
gemcitabine  and cisplatin dose reduced by [CONTACT_12691]. c, d 
If not, permanently discontinue gemcitabine and cisplatin . 
Nadir a platelet count 
 50   109/L (50,000/ L) with 
bleeding  Any occurrence  
 Withhold atezolizumab and bevacizumab /placebo . 
 If event improves, resume atezolizumab and 
bevacizumab /placebo .  If not, permanently discontinue 
atezolizumab and bevacizumab /placebo . 
First occurrence  
 Withhold gemcitabine and cisplatin.  
 If ANC is  1.5   109/L (1500/L) and platelet count is 
 100   109/L (100,000/ L) within 42  days , b resume 
gemcitabine   and cisplatin  with dose reduced by 2 levels. c  
If not, permanently discontinue gemcitabine and cisplatin.  
Second occurrence  
 Permanently discontinue gemcitabine and cisplatin.  
a Resumption of treatment may be considered if the investigator believes the patient is likely 
to derive clinical benefit.  
b If the investigator believes the patient is likely to derive clinical benefit, can be resumed after 
being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan (Section  5.1.5 ). 
d Cisplatin may be resumed at current dose if the investigator believes the patient is likely to 
derive clinical benefit.  
  

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
161/Protocol GO42661 , Version 6 Table  2 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Cisplatin and Gemcitabine  (cont.)  
Hematologic toxicity on Day 8  
ANC  1.0   109/L (1000/L), 
absence of febrile neutropenia, 
and platelet count 100   109/L 
(100,000/ L)  Continue gemcitabine  and cisplatin  at current dose.  
ANC 0.50.99   109/L 
(500999/L) 
 
or 
 
Platelet count 50 99   109/L 
(50,00090,000/L)  Continue gemcitabine and cisplatin with dose reduced by 
[CONTACT_12691]. c, d  
ANC  0.5   109/L (500/L) 
or 
Platelet count  50   109/L 
(50,000/L)  Withhold gemcitabine  and cisplatin . 
 Treatment may be resumed on Day 1 of the next cycle if 
ANC is  1.5   109/L (1500/L) and platelet count is 
 100   109/L (100,000/ L). 
Nephrotoxicity  
CrCl  60 mL/min at time of  
scheduled treatment   Continue atezolizumab, bevacizumab /placebo , 
gemcitabine, and cisplatin . 
CrCl  60 mL/min at time of 
scheduled treatment   Withhold cisplatin.  Atezolizumab, bevacizumab /placebo  
and gemcitabine  may be continued at the discretion of the 
investigator.  
If event improves to CrCl   60 mL/min within 42 days, b 
cisplatin  may be resumed with dose reduced by [CONTACT_12691]  c 
at the discretion of the investigator .  If not, permanently 
discontinue cisplatin.  
a Resumption of treatment may be considered if the investigator believes the patient is likely 
to derive clinical benefit.  
b If the investigator believes the patient is likely to derive clinical benefit, can be resumed after 
being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan (Section  5.1.5 ). 
d Cisplatin may be  resumed at current dose if the investigator believes the patient is likely to 
derive clinical benefit.  
  

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
162/Protocol GO42661 , Version 6 Table  2 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Cisplatin and Gemcitabine  (cont.)  
Mucositis  
Mucositis, Gra de 1 or 2   Continue atezolizumab, bevacizumab /placebo , 
gemcitabine, and cisplatin.  
Mucositis, Grade 3 or 4   Continue atezolizumab and bevacizumab /placebo .  
Withhold gemcitabine and cisplatin.  
 If event resolves to Grade 1 or better within 42  days, b 
resume gemcitabine and cisplatin with dose reduced by 
[CONTACT_12691]. c, d  If not, permanently discontinue gemcitabine 
and cisplatin.  
Hemolytic -uremic syndrome  
Hemolytic -uremic syndrome, 
any grade   Permanently discontinue gemcitabine.  Withhold 
atezolizumab,  bevacizumab /placebo , and cisplatin.  
 If event improves, resume atezolizumab 
bevacizumab /placebo  and cisplatin at current dose.  
If not, permanently discontinue atezolizumab , 
bevacizumab /placebo  and cisplatin.  
Capi[INVESTIGATOR_169817], 
any grade   Permanently discontinue gemcitabine.  Withhold 
atezolizumab , bevacizumab /placebo  and cisplatin.  
 If event improves, resume atezolizumab , 
bevacizumab /placebo  and cisplatin at current dose.  
If not, permanently discontinue atezolizumab, 
bevacizumab /placebo  and cisplatin.  
Ototoxicity  
  If ototoxicity is suspected, audiometry will be performed to 
assess hearing.  
For loss of greater than 
25 decibels in two consecutive 
hearing frequencies   Continue atezolizumab, bevacizumab /placebo  and 
gemcitabine.  
 Withhold cisplatin for 1 week, and audiomet ry assessment 
will be repeated.  If hearing loss is resolved, then the 
patient will be re -treated with a cisplatin dose that is one 
level lower than the prior cycle. d  Patients will not undergo 
routine audiology monitoring for this study .  If not, 
permanently discontinue cisplatin . 
a Resumption of treatment may be considered if the investigator believes the patient is likely 
to derive clinical benefit.  
b If the investigator believes the patient is likely to derive clinical benefit, can be resumed after 
being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan (Section  5.1.5 ). 
d Cisplatin may be resumed at current dose if the investigator believes the patient is likely to 
derive clinical benefit.  

Appendix 14: Overall Guidelines for Management of Patients Who Experience 
Adverse  Events  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
163/Protocol GO42661 , Version 6 Table  2 Guidelines for Management of Patients Who Experience Specific 
Adverse Events with Cisplatin and Gemcitabine  (cont.)  
Chemotherapy -related toxicities not described above  
Grade 1 or 2   Continue atezolizumab, bevacizumab /placebo , gemcitabine, 
and cisplatin.  
Grade  3  Continue atezolizumab and bevacizumab /placebo .  Withhold 
gemcitabine and c isplatin.  
 If event resolves to Grade 1 or better within 42 days, b 
resume gemcitabine and c isplatin with dose reduced by [CONTACT_169903]. c, d  If not, permanently discontinue gemcitabine and 
cisplatin.  
Grade 4   Withhold atezolizumab,  bevacizumab /placebo , gemcitabine, 
and c isplatin.  
 If event improves, resume atezolizumab and 
bevacizumab /placebo .  If not, permanently discontinue 
atezolizumab and bevacizumab.  
 If event resolves to Grade 1 or better within 42  days, a 
resume ge mcitabine and c isplatin with dose reduced by [CONTACT_169903]. c, d  If not, permanently discontinue gemcitabine and 
cisplatin.  
a Resumption of treatment may be considered if the investigator believes the patient is likely to 
derive clinical benefit.  
b If the investigator believes the patient is likely to derive clinical benefit, can be resumed after 
being withheld for  42 days.  
c Recommendations on dose modifications for gemcitabine and cisplatin are provided in the 
Safety Plan (Section  5.1.5 ). 
d Cisplatin may be resumed at current dose if the investigator believes the patient is likely to 
derive clinical benefit.   
 

 
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
164/Protocol  GO42661 , Version [ADDRESS_198348], and in severe cases, immune -mediated  
toxici ties may require acute management with topi[INVESTIGATOR_11930], systemic 
corticosteroids, or other immunosuppressive agents.  
The following are general recommendations for management of any other adverse events 
that may occur and are not specifically listed in the following subsections.  
 Patients and family caregivers should receive timely and up -to-date information 
about immunot herapi[INVESTIGATOR_014], their mechanism of action, and the clinical profile of 
possible immune -related adverse events prior to initiating therapy and throughout 
treatment and survival follow -up.  There should be a high level of suspi[INVESTIGATOR_123460].  
 In general, atezolizumab therapy should be continued with close monitoring for 
Grade 1 toxicities, with the exception of some neurologic toxicities.  
 Consider holding atezolizumab for most Grade 2 toxicities and resume when 
symptoms and/or laborato ry values resolve to Grade 1 or better.  Corticosteroids 
(initial dose of 0.5
 1 mg/kg/day of prednisone or equivalent) may be administered.  
 For Grade 2 recurrent or persistent (lasting for more than 5 days) events, treat as a 
Grade 3 event.   
 Hold atezoliz umab for Grade 3 toxicities and initiate treatment with high -dose 
corticosteroids (1
 2 mg/kg/day prednisone or equivalent).  Corticosteroids should 
be tapered over 1 month to 10 mg/day oral prednisone or equivalent, before 
atezolizumab can be resumed.  If symptoms do not improve within 48 to 72 hours 
of high -dose corticosteroid use, other immunosuppressants may be offered for some 
toxicities.  
 In general, Grade 4 toxicities warrant permanent discontinuation of atezolizumab 
treatment, with the exception of en docrinopathies that are controlled by 
[CONTACT_123595] -replacement therapy.  
 
The investigator should consider the benefit risk balance a given patient may be 
experiencing prior to  further administration of atezolizumab.  Resumption of 
atezolizumab may be considered  in patients who are  deriving benefit and have fully 
recovered from the immune -mediated  event.  The decision to re -challenge patients with 
atezolizumab should be based on  the investigator’s assessment of the benefits and risks 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
165/Protocol GO42661 , Version [ADDRESS_198349] computed 
tomography (CT) scans of the chest performed at every tumor assessment.  
All pulmonary events should be thoroughly evaluated for other commonly reported 
etiologies such as pneumonia or  other infection, lymphangitic carcinomatosis, pulmonary 
embolism, heart failure, chronic obstructive pulmonary disease, or pulmonary 
hypertension.  Coronavirus disease 2019 ( COVID -19) evaluation should be performed 
per institutional guidelines where relev ant.  Management guidelines for pulmonary 
events are provided in Table  1. 
Table  1 Management Guidelines for Pulmonary Events, Including 
Pneumonitis  
Event  Management  
Pulmonary event, 
Grade 1   Continue atezolizumab and monitor closely.  
 Re-evaluate on serial imaging.  
 Consider patient referral to pulmonary specialist.  
 For Grade 1 pneumonitis, consider withholding atezolizumab  
Pulmonary event, 
Grade 2   Withhold atezolizumab for up to 12 weeks after event onset. a 
 Refer patient to pulmonary and infectious disease specialists and 
consider bronchoscopy or BAL  with or without transbronchial biopsy . 
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day oral 
prednisone.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198350]  the  
Medical Monitor. c, d 
 For recurrent events  or events with no improvement after 48 –72 hours 
of corticosteroids , treat as a Grade 3 or 4 event.  
Pulmonary event, 
Grade 3 or 4   Permanently discontinue atezolizumab and contact  [CONTACT_22955]. c, d 
 Oral or IV broad -spectrum antibiotics should be administered in 
parallel to the immunosuppressive treatment.  
 Bronchoscopy or BAL  with or without transbronchial biopsy  is 
recommended.  
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone . 

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
166/Protocol GO42661 , Version 6  If event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
BAL   bronchoscopic alveolar lavage ; IV  Intravenous  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the ext ended period of time must be based on the 
investigator’s  benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor  is 
available to advise as needed . 
b If corticosteroids have been initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have ful ly recovered from the immune -mediated  event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
d In case of pneumonitis, atezolizumab should not be resumed after permanent 
discontinuation.  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
170/Protocol GO42661 , Version 6 Table  3 Management Guidelines for Gastrointestinal Events (Diarrhea or 
Colitis)  
Event  Management  
Diarrhea or 
colitis, Grade 1   Continue atezolizumab.  
 Initiate symptomatic  treatment.  
 Endoscopy is reco mmended if symptoms persist for  7 days.  
 Monitor closely.  
Diarrhea or 
colitis, Grade 2   Withhold atezolizumab for up to 12 weeks after event onset. a 
 Initiate symptomatic treatment.  
 If strong clinical suspi[INVESTIGATOR_79296] -mediated colitis, start empi[INVESTIGATOR_169818].  
 Patient referral to GI specialist is recommended.  
 For recurrent events or events that persist  5 days, initiate treatment 
with corticosteroids equivalent to 1 2 mg/ kg/day oral prednisone.   If the 
event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198351]  the 
Medical  Monitor. c 
Diarrhea or 
colitis, Grade 3   Withhold atezolizumab for up to 12 weeks after event onset. a 
 Refer patient to GI specialist for evaluation and con firmatory biopsy.  
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone and convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.   If event does not improve within 
48  hours after initiating corticosteroids, consider adding an 
immunosuppressive agent.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198352]  the 
Medical  Monitor. c 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
171/Protocol GO42661 , Version 6 Table  3 Management Guidelines for Gastrointestinal Events (Diarrhea or 
Colitis)  (cont.)   
Event  Management  
Diarrhea or 
colitis, Grade 4   Permanently discontinue atezolizumab and contact [CONTACT_22955]. c 
 Refer patient to GI specialist for evaluation and confirmatory biopsy.  
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone and convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
 If event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
GI  gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s  benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be cons idered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 
ENDOCRINE EVENTS  
Management guidelines for endocrine events are provided in Table  4. 
Patients with unexplained symptoms such as headache, fatigue, myalgias, impotence, 
constipation, or mental status changes should be investigated for the presence of 
thyroid, pi[INVESTIGATOR_2117], or ad renal endocrinopathies.  The patient should be referred to an 
endocrinologist if an endocrinopathy is suspected.  Thyroid -stimulating hormone and 
free triiodothyronine and thyroxine levels should be measured to determine whether 
thyroid abnormalities are p resent.  Pi[INVESTIGATOR_33418] (e.g., 
TSH, growth hormone, luteinizing hormone, follicle -stimulating hormone, testosterone, 
prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH stimulation test) and 
magnetic resonance imagin g (MRI) of the brain (with detailed pi[INVESTIGATOR_33419]) may 
help to differentiate primary pi[INVESTIGATOR_33420].  

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
172/Protocol GO42661 , Version 6 Table  4 Management Guidelines for Endocrine Events  
Event  Management  
Grade 1 hypothyroidism   Continue atezolizumab.  
 Initiate treatment with thyroid replacement hormone.  
 Monitor TSH closely . 
Grade 2 hypothyroidism   Consider withholding atezolizumab.  
 Initiate treatment with thyroid replacement hormone.  
 Monitor TSH closely.  
 Consider patient referral to endocrinologist.  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
Grade 3 or 4 
hypothyroidism   Withhold atezolizumab.  
 Initiate treatment with thyroid replacement hormone.  
 Monitor TSH closely . 
 Refer  to an endocrinologist.  
 Admit patient to the hospi[INVESTIGATOR_123463] 
(bradycardia, hypothermia, and altered mental status).  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
 Permanently discontinue atezolizumab and contact [CONTACT_169904] -threatening immune -mediated hypothyroidism. 
c 
Grade 1 hyperthyroidism  TSH  0.1 mU/L and  0.5 mU/L:  
 Continue atezolizumab.  
 Monitor TSH every 4 weeks  
 Consider patient referral to endocrinologist . 
TSH  0.1 mU/L:  
 Follow guidelines for Grade 2 hyperthyroidism.  
 Consider patient referral to endocrinologist.  
Grade 2 
hyperthyroidism   Consider withholding atezolizumab.  
 Initiate treatment with anti -thyroid drug such as methimazole 
or carbimazole as needed.  
 Consider patient referral to endocrinologist.  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
Grade 3 or 4 
hyperthyroidism   Withhold atezolizumab.  
 Initiate treatment with anti -thyroid drug s such as methimazole or 
carbimazole as needed.  
 Refer  to an endocrinologist.  
 Resume atezolizumab when symptoms are controlled and 
thyroid function is improving.  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
173/Protocol GO42661 , Version 6  Permanently discontinue atezolizumab and contact  [CONTACT_123596] -threatening immune -mediated  
hyperthyroidism. c 
  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
174/Protocol GO42661 , Version 6 Table  4 Management Guidelines for Endocrine Events  (cont.)  
Event  Management  
Symptomatic adrenal 
insufficiency, Grade  24   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to endocrinologist.  
 Perform appropriate imaging.  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/day IV methylprednisolone and convert to 
12 mg/kg/day oral prednisone or equivalent upon 
improvement . 
 If event resolves to Grade 1 or better and patient is stabl e on 
replacement therapy, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198353] the Medical  Monitor. c 
Hyperglycemia,  
Grade  1 or 2   Continue atezolizumab.  
 Investigate for diabetes.  If patient has Type [ADDRESS_198354] Type  1 
diabetes, treat as per institutional guidelines.  
 Monitor for glucose control.  
Hyperglycemia,  
Grade  3 or 4   Withhold atezolizumab.  
 Initiate treatment with insulin.  
 Evaluate for diabetic ketoacidosis and manage as per 
institutional guidelines.  
 Monitor for glucose control.  
 Resume atezolizumab when symptoms resolve and glucose 
levels ar e stable.  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
175/Protocol GO42661 , Version 6 Table  4 Management Guidelines for Endocrine Events  (cont.)  
Event  Management  
Hypophysitis 
(pan-hypopi[INVESTIGATOR_297]), 
Grade 2 or 3   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to endocrinologist.  
 Perform brain MRI (pi[INVESTIGATOR_33421]).  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/day IV methylprednisolone and convert to 
12 mg/kg/day oral prednisone or equivalent upon improvement.  
 Initiate hormone replacement if clinically indicated.  
 If event reso lves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198355] the Medical Monitor. c 
 For recurrent hypophysitis, treat as a Grade 4 event.  
Hypophysitis 
(pan-hypopi[INVESTIGATOR_297]), 
Grade 4   Permanently discontinue atezolizumab and contact [CONTACT_76962]. c 
 Refer patient to endocrinologist.  
 Perform brain MRI (pi[INVESTIGATOR_33421]).  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/da y IV methylprednisolone and convert to 
12 mg/kg/day oral prednisone or equivalent upon improvement.  
 Initiate hormone replacement if clinically indicated.  
MRI   magnetic resonance imaging . 
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equiva lent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessmen t 
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
176/Protocol GO42661 , Version [ADDRESS_198356] should evaluate visual complaints (e.g., uveitis, retinal events).  
Management guidelines for ocular events are provided in Table  5. 
Table  5 Management Guidelines for Ocular Events  
Event  Management  
Ocular event, 
Grade 1   Continue atezolizumab.  
 Patient referral to ophthalmologist is strongly recommended.  
 Initiate treatment with topi[INVESTIGATOR_33422].  
 If symptoms persist, treat as a Grade 2 event.  
Ocular event, 
Grade 2   Withhold atezolizumab for up to 12 weeks after event onset . a 
 Patient referral to ophthalmologist is strongly recommended.  
 Initiate treatment with topi[INVESTIGATOR_33422].  
 If event resolves to Grade 1 or better, resume  atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198357] the 
Medical Monitor. c 
Ocular event, 
Grade 3 or 4   Permanently discontinue atezolizumab and contact  [CONTACT_22955]. c 
 Refer patient to ophthalmologist.  
 Initiate treatment with corticosteroids equivalent to 12 mg/kg/day oral 
prednisone.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have b een initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessmen t 
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
177/Protocol GO42661 , Version [ADDRESS_198358] IAC EVENTS  
Management guidelines for cardiac events are provided in Table  6. 
IMMUNE -MEDIATED MYOC ARDITIS  
Immune -mediated myocarditis should be suspected in any patient presenting with signs 
or symptoms suggestive of myocarditis, including, but not limited to, laboratory (e.g., B -
type natriuretic peptide) or cardiac imaging abnormalities, dyspnea, chest pain, 
palpi[INVESTIGATOR_814], fatigue, decreased exercise tolerance, or syncope.   Myocarditis may also be 
a clinical manifestation of myositis or associated with pericardi tis (see section on 
pericardial disorders below) and should be managed accordingly.   Immune -mediated 
myocarditis needs to be distinguished from myocarditis resulting from infection 
(commonly viral, e.g., in a patient who reports a recent history of gastroi ntestinal illness), 
ischemic events, underlying arrhythmias, exacerbation of preexisting cardiac conditions, 
or progression of malignancy.  
All patients with possible myocarditis should be urgently evaluated by [CONTACT_33500], an ECG, a chest X -ray, an echocardiogram, and a cardiac MRI as 
appropriate per institutional guidelines.  A cardiologist should be consulted.  
An endomyocardial biopsy may be considered to enable a definitive diagnosis and 
appropriate treatment, if clinically indi cated.  
Patients with signs and symptoms of myocarditis, in the absence of an identified 
alternate etiology, should be treated according to the guidelines in Table  6. 

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
178/Protocol GO42661 , Version [ADDRESS_198359] 
pain and may be associated with immune -mediated myocarditis (see section on 
myocarditis above).  
Immune -mediated pericardial effusion and cardiac tamponade should be suspected in 
any patient presenting with chest pain associated with dyspnea or hemodynamic 
instability.  
Patients should be evaluated for other causes of pericardial disorders such as infection  
(commonly viral), cancer related (metastatic disease or chest radiotherapy), cardiac 
injury related (post myocardial infarction or iatrogenic), and autoimmune disorders, 
and should be managed accordingly.  
All patients with suspected pericardial disorders should be urgently evaluated by 
[CONTACT_123598], chest X -ray, transthoracic echocardiogram, and cardiac MRI as 
appropriate per institutional guidelines.  A cardiologist should be consulted.  
Pericardiocentesis should be considered for diagnostic or thera peutic purposes, if 
clinically indicated.  
Patients with signs and symptoms of pericarditis, pericardial effusion, or cardiac 
tamponade, in the absence of an identified alternate etiology, should be treated 
according to the guidelines in Table  6.  Withhold treatment with atezolizumab for 
Grade  [ADDRESS_198360] a detailed cardiac evaluation to determine the etiology 
and manage accordingly . 

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
179/Protocol GO42661 , Version 6 Table  6 Management Guidelines for Immune -Mediated  Cardiac Events  
Event  Management  
Immu ne-mediated 
myocarditis,  
Grade s 24 
 
Immune mediated 
pericardial disorders, 
Grade s 24  Permanently discontinue atezolizumab and contact  [CONTACT_169905]. a 
 Refer patient to cardiologist.  
 Initiate treatment as per institutional guidelines and consider  
antiarrhythmic drugs, temporary pacemaker, ECMO,  VAD , or 
pericardiocentesis as appropriate.  
 Initiate treatment with corticosteroids equivalent to 12 mg/kg/day 
IV methylprednisolone and convert to 1 2 mg/kg/day oral 
prednisone or equivalent upon improveme nt. 
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over  
 1 month.  
ECMO   extracorporeal membrane oxygenation; VAD   ventricular assist device.  
 
 
INFUSION -RELATED REACTIONS A ND CYTOKINE RELEASE SYNDROME  
No premedication is indicated for the administration of Cycle 1 of atezolizumab.  
However, patients who experience an infusion -related reaction (IRR) or cytokine release 
syndrome (CRS) with atezolizumab may receive premedication with antihistamines, 
antipyretic medications , and/or analgesics (e.g., acetaminophen) for subsequent 
infusions.  Metamizole (dipyrone) is prohibited in treating atezolizumab -associated IRRs  
because of its potential for causing agranulocytosis.  
Infusion -related reactions  are known to occur with the administration of monoclonal 
antibodies and have been reported with atezolizumab.  These reactions, which are 
thought to be due to release of cyto kines and/or other chemical mediators, occur within 
24 hours of atezolizumab administration and are generally mild to moderate in severity.  
Cytokine  release syndrome  is defined as a supraphysiologic response following 
administration of any immune therapy t hat results in activation or engagement of 
endogenous or infused T cells and/or other immune effector cells.  Symptoms can be 
progressive, always include fever at the onset, and may include hypotension, capi[INVESTIGATOR_169819] (hypoxia), and end -organ dysfunction ( Lee et al. 2019).  Cytokine release syndrome  
has been well -documented with chimeric antigen receptor T -cell therapi[INVESTIGATOR_70074] 
T-cell engager antibody therapi[INVESTIGATOR_169820] -1 or PD -L1 (Rotz et al. 20 17; Adashek and Feldman 2019), including 
atezolizumab.  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
180/Protocol GO42661 , Version 6 There may be significant overlap in signs and symptoms of IRRs and CRS, and in 
recognition of the challenges in clinically distinguishing between the two, consolidated 
guidelines for the medical manage ment of IRRs and CRS are provided in Table  7. 
Severe SARS -CoV-2 infection  appears to be associated with a CRS involving the 
inflammatory cytokines interleukin (IL) -6, IL-10, IL -2, and IFN - (Merad and Martin 2020 ).  
If a patient develops suspected CRS during the study, a differential diagnosis should 
include SARS -CoV-2 infectio n, which should be confirmed or refuted through 
assessment of exposure history, appropriate laboratory testing, and clinical or radiologic 
evaluations per investigator ’s judgment.  If a diagnosis of SARS -CoV-2 infection  is 
confirmed, the disease should be managed as per local or institutional guidelines.  

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
181/Protocol GO42661 , Version 6 Table  7 Management Guidelines for Infusion -Related Reactions and 
Cytokine Release Syndrome  
Event  Management  
Grade 1 a 
Fever b with or 
without 
constitutional 
symptoms   Immediately interrupt infusion.  
 Upon symptom resolution, wait for 30 minutes and then restart infusion at 
half the rate being given at the time of event onset.  
 If the infusion is tolerated at the reduced rate for 30 minutes, the infusion 
rate may be increased to the o riginal rate.  
 If symptoms recur, discontinue infusion of this dose.  
 Administer symptomatic treatment, c including maintenance of IV fluids for 
hydration.  
 In case of rapid decline or prolonged CRS (  2 days) or in patients with 
significant symptoms and/or c omorbidities, consider managing as per 
Grade 2.  
 For subsequent infusions, consider administration of oral premedication 
with antihistamines, anti pyretic  medications , and/or analgesics, and 
monitor closely for IRRs and/or CRS.  
Grade 2 a 
Fever b with 
hypotension not 
requiring 
vasopressors  
and/or  
Hypoxia requiring 
low-flow oxygen d 
by [CONTACT_123599] -by  Immediately interrupt infusion.  
 Upon symptom resolution, wait for 30 minutes and then restart infusion at 
half the rate being given at the time of event onset.  
 If symptoms recur, discontinue infusion of this dose.  
 Administer symptomatic treatment. c 
 For hypotension, administer IV fluid bolus as needed.  
 Monitor cardiopulmonary and other organ f unction closely (in the ICU, 
if appropriate).  Adm inister IV fluids as clinically indicated, and manage 
constitutional symptoms and organ toxicities as per institutional practice.  
 Rule out other inflammatory conditions that can mimic CRS (e.g.,  sepsis).  
If no improvement within 24 hours, initiate workup and assess for signs 
and symptoms of HLH or MAS as described in this appendix.  
 Consider IV corticosteroids (e.g., methylprednisolone 2  mg/kg/day or 
dexamethasone 10 mg every 6 hours).  
 Consider anti -cytokine therapy.  
 Consider hospi[INVESTIGATOR_169821].  If no 
improvement within 24 hours, manage as per Grade 3, that is,  hospi[INVESTIGATOR_169822] (monitoring in the ICU is recommended), permanently discontinue 
atezolizumab, and contact  [CONTACT_1689] . 
 If symptoms resolve to Grade 1 o r better for 3 consecutive days, the next 
dose of atezolizumab may be administered.  For subsequent infusions, 
consider administration of oral premedication with antihistamines, 
antipyretic  medications , and/or analgesics and monitor closely for IRRs 
and/o r CRS.  
 If symptoms do not resolve to Grade [ADDRESS_198361] the Medical Monitor.  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
182/Protocol GO42661 , Version 6 Table  7 Management Guidelines for Infusion -Related Reactions and 
Cytokine Release Syndrome  (cont.)  
Event  Management  
Grade 3 a 
Fever b with 
hypotension 
requiring a 
vasopressor (with 
or without 
vasopressin)  
and/or  
Hypoxia requiring 
high-flow oxygen d 
by [CONTACT_21294], 
face mask, 
non-rebreather 
mask, or Venturi 
mask   Permanently discontinue atezolizumab and contact [CONTACT_22955]. e 
 Administer symptomatic treatment. c 
 For hypotension, administer IV fluid bolus and vasopressor as 
needed.  
 Monitor cardiopulmonary and other organ function closely; monitoring 
in the ICU is recommended.  Administer IV fluids as clinically 
indicated, and manag e constitutional symptoms and organ toxicities 
as per institutional practice.  
 Rule out other inflammatory conditions that can mimic CRS 
(e.g.,  sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as d escribed in this 
appendix.  
 Administer IV corticosteroids (e.g., methylprednisolone 2  mg/kg/day or 
dexamethasone 10 mg every 6 hours).  
 Consider anti -cytokine therapy.  
 Hospi[INVESTIGATOR_70078].  If no 
improvement within 24 hours, manage as per Grade 4, that is,  admit 
patient to ICU and initiate hemodynamic monitoring, mechanical 
ventilation, and/or IV fluids and vasopressors as needed; fo r patients 
who are refractory to anti -cytokine therapy, experimental treatments 
may be considered at the discretion of the investigator and in 
consultation with the Medical Monitor . 
Grade 4 a 
Fever b with 
hypotension 
requiring multiple 
vasopressors 
(excluding 
vasopressin)  
and/or  
Hypoxia requiring 
oxygen by [CONTACT_70193] (e.g., 
CPAP, BiPAP, 
intubation , and 
mechanical 
ventilation)   Permanently discontinue atezolizumab and contact [CONTACT_22955]. f 
 Administer symptomatic treatment. c 
 Admit patient to ICU and initiate hemodynamic monitoring, mechanical 
ventilation, and/or IV fluids and vasopressors as needed.  Monitor 
other organ function closely.  Manage constitutional symptoms and 
organ toxicitie s as per institutional practice.  
 Rule out other inflammatory conditions that can mimic CRS 
(e.g.,  sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and symptoms of HLH or MAS as described in this 
appendix.  
 Administer IV cort icosteroids (e.g., methylprednisolone 2  mg/kg/day or 
dexamethasone 10 mg every 6 hours).  
 Consider anti -cytokine therapy.   For patients who are refractory to 
anti-cytokine therapy, experimental treatments f may be considered at 
the discretion of the invest igator and in consultation with the 
Medical  Monitor.  
 Hospi[INVESTIGATOR_70078].  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
183/Protocol GO42661 , Version 6 Table  7 Management Guidelines for Infusion -Related Reactions and 
Cytokine Release Syndrome  (cont.)  
ASTCT   American Society for Transplantation  and Cellular Therapy; BiPAP   bi-level positive 
airway pressure; CAR   chimeric antigen receptor; CPAP   continuous positive airway 
pressure; CRS   cytokine release syndrome; CTCAE   Common Terminology Criteria for 
Adverse Events; eCRF   electronic Case R eport Form; HLH   hemophagocytic 
lymphohistiocytosis; ICU   intensive care unit; IRR   infusion -related reaction; 
MAS   macrophage activation syndrome; NCCN   National Cancer Comprehensive Network; 
NCI   National Cancer Institute . 
Note:  The management gui delines have been adapted from the NCCN guidelines for the 
management of CAR T -cellrelated toxicities (Version 2.2019).  
a Grading system for management guidelines is based on ASTCT consensus grading for 
CRS.  National Cancer Institute  CTCAE v 5.0 should be  used when reporting severity of 
IRRs, CRS, or organ toxicities associated with CRS on the Adverse Event eCRF.  Organ 
toxicities associated with CRS should not influence overall CRS grading.  
b Fever is defined as temperature  38C not attributable to any other cause.  In patients who 
develop CRS and then receive anti -pyretic, anti -cytokine, or corticosteroid therapy, fever is 
no longer required when subsequently determining event severity (grade).  In this case, the 
grade is driven by [CONTACT_169906]/or hypoxia.  
c Symptomatic treatment may include oral or IV antihistamines, anti pyretic  medications , 
analgesics, bronchodilators, and/or oxygen.  For bronchospasm, urticaria, or dyspnea, 
additional treatment may be administered as per institutio nal practice.  
d Low flow is defined as oxygen delivered at  6 L/min, and high flow is defined as oxygen 
delivered at  6 L/min.  
e Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the event.  The decision to  re-challenge  patients  with 
atezolizumab should be based on  the investigator's benefit risk assessment and 
documented by [CONTACT_093] .  The Medical Monitor  is available to advise as needed .  For 
subsequent infusions, administer oral prem edication with antihistamines, anti pyretic  
medications , and/or analgesics, and monitor closely for IRRs and/or CRS.  Premedication 
with corticosteroids and extending the infusion time may also be considered after  assessing  
the benefit risk ratio.  
f See Riegler et al. (2019).  
 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
184/Protocol GO42661 , Version 6 PANCREATIC EVENTS  
The differential diagnosis of acute abdominal pain should include pancreatitis.  
Appropriate workup  should include an evaluation for ductal obstruction, as well as serum 
amylase and lipase tests.  Management guid elines for pancreatic events, including 
pancreatitis, are provided in Table  8. 
Table  8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis  
Event  Management  
Amylase and/or lipase 
elevation, Grade 2  Amylase and/or lipase  1.52.0   ULN: 
 Continue atezolizumab.  
 Monitor amylase and lipase weekly.  
 For prolonged elevation (e.g.,  3 weeks), consider treatment 
with cortico steroids equivalent to 10 mg/day oral prednisone.  
Asymptomatic with amylase and/or lipase  2.05.0   ULN: 
 Treat as a Grade 3 event.  
Amylase and/or lipase 
elevation, Grade 3 or 4   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to GI specialist.  
 Monitor amylase and lipase every other day.  
 If no improvement, consider treatment with cortico steroids 
equivalent to 12 mg/kg/day oral prednisone.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198362] the Medical  Monitor. c 
 For recurrent events, p ermanently discontinue atezolizumab 
and contact [CONTACT_1689]. c 
GI   gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on of the 
investigator’s  benefitrisk assessment and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equiv alent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with  atezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
185/Protocol GO42661 , Version 6 Table  8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis  (cont.)  
Event  Management  
Immu ne-mediated 
pancreatitis, 
Grade  2 or 3  Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to GI specialist.  
 Initiate treatment with cortico steroids equivalent to 
12 mg/kg/day IV methylprednisolone and convert  to 
12 mg/kg/day oral prednisone or equivalent upon improvement.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198363] the Medical Monitor. c 
 For recurrent events, p ermanently discontinue atezolizumab and 
contact [CONTACT_1689]. c  
Immune -mediated 
pancreatitis, Grade  4  Permanently discontinue atezolizumab and contact [CONTACT_22955]. c 
 Refer patient to GI specialist.  
 Initiate treatment with cortico steroids equivalent to 
12 mg/kg/day IV methylprednisolone and convert to 
12 mg/kg /day oral prednisone or equivalent upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
GI   gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s benefitrisk assessment and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessmen t 
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
186/Protocol GO42661 , Version [ADDRESS_198364] should evaluate 
persistent and/or severe rash or pruritus.  A biopsy should be c onsidered unless 
contraindicated.  Management guidelines for dermatologic events are provided in 
Table  9. 
Table  9 Management Guidelines for Dermatologic Events  
Event  Management  
Dermatologic 
event, Grade  1   Continue atezolizumab.  
 Consider treatment with topi[INVESTIGATOR_33423]/or other symptomatic 
therapy (e.g., antihistamines).  
Dermatologic 
event, Grade  2   Continue atezolizumab.  
 Consider patient referral to dermatologist  for evaluation and, if indicated, 
biopsy . 
 Initiate treatment with topi[INVESTIGATOR_33424].  
 Consider treatment with higher -potency topi[INVESTIGATOR_169823].  
 If unresp onsive to topi[INVESTIGATOR_11930], consider oral prednisone 
0.5 mg/kg/day.  
Dermatologic 
event, Grade  3   Withhold atezolizumab  for up to 12 weeks after event onset . a 
 Refer patient to dermatologist  for evaluation and, if indicated, biopsy . 
 Initiate treatment with cortico steroids equivalent to 10 mg/day oral 
prednisone, increasing dose to 1 2 mg/kg/day if event does not improve 
within 4872 hours.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198365] the 
Medical Monitor. c 

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
187/Protocol GO42661 , Version 6 Table 9  Management Guidelines for Dermatologic Events (cont.)   
Event  Management  
Dermatologic 
event, Grade 4   Permanently discontinue atezolizumab and contact [CONTACT_22955].  c 
Stevens -Johnson 
syndrome or toxic 
epi[INVESTIGATOR_7387] (any 
grade)  Additional guidance for Stevens -Johnson syndrome or toxic 
epi[INVESTIGATOR_194]:  
 Withhold atezolizumab for suspected Stevens -Johnson syndrome or 
toxic epi[INVESTIGATOR_194].  
 Confirm diagnosis by [CONTACT_123602] a specialist (dermatologist, 
ophthalmologist, or urologist as relevant) for evaluation and, if 
indicated, biopsy.  
 Follow the applicable treatment an d management guidelines above.  
 If Stevens -Johnson syndrome or toxic epi[INVESTIGATOR_123466], permanently discontinue atezolizumab.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corti costeroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s  benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 
NEUROLOGIC DISORDERS  
Patients may present with signs and symptoms of sensory and/or motor neuropathy.  
Diagnostic workup  is essential for an accurate characterization to differentiate between 
alternative etiologies.  Management guidelines for neurologic disorders are provided in 
Table  10, with specific guidelines for myelitis provided in Table  1. 
 

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
188/Protocol GO42661 , Version 6 Table  10 Management Guidelines for Neurologic Disorders  
Event  Management  
Immune -mediated 
neuropathy, 
Grade  1  Continue atezolizumab.  
 Investigate etiology.  
 Any cranial nerve disorder (including facial paresis) should be 
managed as per Grade 2 management guidelines below.  
Immune -mediated 
neuropathy, 
including facial 
paresis , Grade  2  Withhold atezolizumab for up to 12 weeks after event onset . a 
 Investigate etiology  and refer patient to neurologist . 
 Initiate treatment as per institutional guidelines.  
 For general immune -mediated neuropathy:  
– If event resolves to Grade 1 or better, resume atezolizumab. b 
– If event does not resolve to Grade [ADDRESS_198366] the Medical Monitor. c 
 For facial paresis:  
– If event resolves fully, resume atezolizumab . b 
– If event does not resolve fully while  withholding atezolizumab, 
permanently discontinue atezolizumab and contact [CONTACT_5134].  c 
Immune -mediated 
neuropathy,  
including facial 
paresis,  
Grade  3 or 4   Permanently discontinue atezolizumab and contact [CONTACT_22955]. c 
 Refer patient to  neurologist.  
 Initiate treatment as per institutional guidelines.  
Myasthenia gravis 
and Guillain -Barré 
syndrome (any 
grade)   Permanently discontinue atezolizumab and contact [CONTACT_22955]. c 
 Refer patient to neurologist.  
 Initiate treatment as per ins titutional guidelines.  
 Consider initiation of cortico steroids equivalent to 12 mg/kg/day oral 
or IV prednisone.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s benefitrisk assessment  and i n alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equival ent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with a tezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
189/Protocol GO42661 , Version 6 Table  1 Management Guidelines for Immune -Mediated Myelitis  
Event  Management  
Immune -mediated myelitis, 
Grade  1  Continue atezolizumab unless symptoms worsen or do not 
improve.  
 Investigate etiology and refer patient to a neurologist.   
Immune -mediated myelitis, 
Grade  2  Permanently discontinue atezolizumab and contact [CONTACT_5134].  
 Investigate etiology and refer patient to a neurologist.  
 Rule out infection.  
 Initiate treatment with corticosteroids equivalent to 
12 mg/kg/day oral prednisone.  
Immune -mediated myelitis, 
Grade  3 or 4   Permanently discontinue atezolizumab and contact [CONTACT_5134].  
 Refer patient to a neurologist.  
 Initiate treatment as per institutional guidelines.  
 
IMMUNE -MEDIATED MENI NGOENCEPHALITIS  
Immune -mediated meningoencephalitis should be suspected in any patient presenting 
with signs or symptoms suggestive of meningitis or encephalitis, including, but not 
limited to, headache, neck pain, confusion, seizure, motor or sensory dysfunction, and 
altered or depressed level of conscious ness.  Encephalopathy from metabolic or 
electrolyte imbalances needs to be distinguished from potential meningoencephalitis 
resulting from infection (bacterial, viral, or fungal) or progression of malignancy, or 
secondary to a paraneoplastic process.  
All patients being considered for meningoencephalitis should be urgently evaluated with 
a CT scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, or 
edema.  If deemed safe by [CONTACT_1963], a lumbar puncture should be 
performed a nd a neurologist should be consulted.  
Patients with signs and symptoms of meningoencephalitis, in the absence of an 
identified alternate etiology, should be treated according to the guidelines in Table  . 
Table  1112 Management Guidelines for Immune -Mediated  
Meningoencephalitis  
Event  Management  
Immune -mediated 
meningoencephalitis, 
all grades   Permanently discontinue atezolizumab and contact [CONTACT_22955].  
 Refer patient to neurologist.  

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
190/Protocol GO42661 , Version 6 Event  Management  
 Initiate treatment with cortico steroids equivalent to 12 mg/kg/day 
IV methylprednisolone and convert to 1 2 mg/kg/day oral 
prednisone or equivalent upon im provement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 [ADDRESS_198367] adequate renal function.  Renal function, including serum 
creatinine, should be monitored throughout study treatment.  Patients with abnormal 
renal function should be evaluated and treated for other more common etiologies 
(including prerenal and postrenal causes, and concomitant medications such as 
non-steroidal anti -inflammatory drugs).  Refer the patient to a renal specialist if clinically 
indicated.  A renal biopsy may be required to enable a definitive diagnosis and 
appropriate treatment.  
Patients with signs and symptoms of nephritis, in the absence of an identified alternate 
etiology, should be treated according to the guidelines in Table  . 
Table  1213 Management Guidelines for Renal Events  
Event  Management  
Renal event, 
Grade  1  Continue atezolizumab.  
 Monitor kidney function, including creatinine  and urine protein , closely 
until values resolve to  within normal limits or to baseline values.  
Renal event, 
Grade  2  Withhold atezolizumab for up to 12 weeks after event onset. a 
 Refer patient to renal specialist.  
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day oral 
prednisone.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198368]  the 
Medical Monitor. c 
Renal event, 
Grade  3 or 4   Permanently discontinue atezolizumab and contact  [CONTACT_22955].c 
 Refer patient to renal specialist and consider renal biopsy.  
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day oral 
prednisone.  

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
191/Protocol GO42661 , Version 6 Event  Management  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s  benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 
IMMUNE -MEDIATED MYOS ITIS 
  Myositis or inflammatory myopathies are a group of disorders sharing the common 
feature of inflammatory muscle injury; dermatomyositis and polymyositis are among the 
most common disorders.  Initial diagnosis is based on clinical (muscle weakness, muscle 
pain, skin rash in dermatomyositis), bioch emical (serum creatine kinase increase), and 
imaging (electromyography/MRI) features, and is confirmed with a muscle biopsy.   
Patients with possible myositis should be referred to a rheumatologist or neurologist.  
Patients with possible myositis should be monitored for signs of myocarditis  
Patients with signs and symptoms of myositis, in the absence of an identified alternate 
etiology, should be treated according to the guidelines in Table  . 
Table  14 Management Guidelines for Immune -Mediated  Myositis  
Event  Management  
Immune -mediated 
myositis, Grade  1  Continue atezolizumab.  
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
Immune -mediated 
myositis, Grade  2  Withhold atezolizumab for up to [ADDRESS_198369] the Medical Monitor.  
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
 Consider treatment with corticosteroids equivalent to 1 2 mg/kg/day 
IV methylprednisolone and convert to 1 2 mg/kg/day oral prednisone 
or equivalent upon improvement.  

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
192/Protocol GO42661 , Version 6 Event  Management  
 If corticosteroids are initiated and e vent does not improve wit hin 
48 hours after initiating corticosteroids, consider adding an 
immunosuppressive agent.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198370]  the 
Medical Monitor. c 
a Atezolizumab may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be based on the 
investigator’s  benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be cons idered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  The decision to re -challenge 
patients with atezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
193/Protocol GO42661 , Version 6 Table  14 Management Guidelines for Immune -Mediated Myositis (cont.)  
Event  Management  
Immune -mediated 
myositis, Grade  3  Withhold atezolizumab for up to [ADDRESS_198371] the Medical Monitor.  
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
 Respi[INVESTIGATOR_70079].  
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylpred nisolone, or higher -dose bolus if patient is severely 
compromised (e.g., cardiac or respi[INVESTIGATOR_1856], dysphagia, or 
weakness that severely limits mobility); convert to 1 2 mg/kg/day oral 
prednisone or equivalent upon improvement.  
 If event does not impr ove within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, resume atezolizumab. b 
 If event does not resolve to Grade [ADDRESS_198372]  the 
Medical Monitor. c 
 For recurrent events, treat as a Grade [ADDRESS_198373] the Medical Monitor. c 
Immune -mediated 
myositis, Grade  4  Permanently discontinue atezolizumab and contact [CONTACT_22955]. c 
 Refer patient to rheumatologist or neurologist.  
 Initiate treatment as per institutional guidelines.  
 Respi[INVESTIGATOR_70079].  
 Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone, or higher -dose bolus if patient is severely 
compromised (e.g., cardiac or respi[INVESTIGATOR_1856], dysphagia, or 
weakness that severely limits mobility); convert to 1 2 mg/kg/day oral 
prednisone or equivalent upon improvement.  
 If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
 If event resolves to Grade 1 or better, taper corticosteroids over 
 1 month.  
a Atezolizumab  may be withheld for a longer period of time (i.e.,  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10 mg/day oral 
prednisone.  The acceptable length of the extended period of time must be base d on the 
investigator’s  benefitrisk assessment  and in alignment with the protocol requirements for 
the duration of treatment and documented by [CONTACT_093].  The Medical Monitor is 
available to advise as needed.  
b If corticosteroids have been initiated, they must be tapered over  1 month to the equivalent 
of 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have ful ly recovered from the immune -mediated event.  The decision to re -challenge 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
194/Protocol GO42661 , Version 6 patients with atezolizumab should be based on the investigator's benefit risk assessment  
and documented by [CONTACT_093].  The Medical Monitor is available to advise as needed.  
 
HEMOPHAGOCYTIC LYMPH OHISTIOCYTOSIS AND M ACROPHAGE 
ACTIVATION SYNDROME  
Immune -mediated reactions may involve any organ system and may lead to 
hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome 
(MAS).  
Clinical and laboratory features of severe CRS overlap with HLH, and HLH should be 
considered when CRS presentation is atypi[INVESTIGATOR_123467].  
Patients with suspected HLH should be diagnosed according to published criteria by 
[CONTACT_70195] 2014.  A patient should be classif ied as having HLH if 5 of the 
following 8 criteria are met:  
 Fever   38.5°C  
 Splenomegaly  
 Peripheral blood cytopenia consisting of at least two of the following:  
– Hemoglobin  90 g/L (9  g/dL) (100 g/L [10 g/dL] for infants   4 weeks old)  
– Platel et count  100   109/L (100,000/ L) 
– ANC   1.0  109/L (1000/L) 
 Fasting triglycerides  2.992 mmol/L (265  mg/dL)  and/or  fibrinogen  1.5 g/L 
(150 mg/dL)  
 Hemophagocytosis in bone marrow, spleen, lymph node, or liver  
 Low or absent natural killer cell activity  
 Ferritin  500 mg/L (500  ng/mL)  
 Soluble IL -2 receptor (soluble CD25) elevated  [ADDRESS_198374] deviations above 
age-adjusted laboratory -specific norms  
 
Patients with suspected MAS should be diagnosed according to published criteria for 
systemic juvenile idiopathic arthritis by [CONTACT_70196]. 2016.  A febrile patient should be 
classified as having MAS if the following criteria are met:  
 Ferritin  684 mg/L (684  ng/mL)  
 At least two of the following:  
– Platelet count  181   109/L (181,000/ L) 
– AST  48 U/L 
Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
195/Protocol GO42661 , Version 6 – Triglycerides  1.761 mmol/L (156  mg/dL)  
– Fibrinogen  3.6 g/L (360  mg/dL)  
 
Patients with suspected HLH or MAS should be treated according to the guidelines in 
Table  . 
Table  1315 Management Guidelines for Suspected Hemophagocytic 
Lymphohistiocytosis or Macrophage Activation Syndrome  
Event  Management  
Suspected HLH 
or MAS   Permanently discontinue atezolizumab and contact  [CONTACT_22955].  
 Consider patient referral to hematologist.  
 Initiate supportive care, including intensive care monitoring if indicated 
per institutional guidelines.  
 Consider initiation of IV corticosteroids , an immunosuppressive agent , 
and/or anti -cytokin e therapy . 
 If event does not respond to treatment within [ADDRESS_198375]  the 
Medical  Monitor and initiate treatment as appropriate according to 
published guidelines (La Ros ée 2015; Schram and Berliner 2015; 
La Rosée et al. 2019).  
 If event resolves to Gra de 1 or better, taper corticosteroids over 
 1 month.  
HLH   hemophagocytic lymphohistiocytosis; MAS   macrophage activation syndrome.  
 
REFERENCES  
Adashek ML, Feldman M. Cytokine release syndrome resulting from anti programmed 
death -1 antibody: raising awareness among community oncologist. J Oncol 
Practice 2019;15:502 4. 
La Ros ée P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology 
Am Soc Hematol Educ Pro gram 2015;1:190 6. 
La Ros ée P, Horne A, Hines M, et al. Recommendations for the management of 
hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465 77. 
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine 
release syndrome and neurologic toxicity associated with immune effector cells. 
Biol Blood Marr ow Transplant 2019;25:625 38. 
McClain KL, Eckstein O. Clinical features and diagnosis of hemophagocytic 
lymphohistiocytosis. Up to Date [resource on the Internet]. 2014 [updated 
29 October 2018; cited: 17 May 2019]. Available from: 

Appendix 15: Risks Associated with Atezolizumab and Guidelines for Management of 
Adverse Events Associated with Atezolizumab  
  
Atezolizumab and Bevacizumab —F. Hoffmann -La [COMPANY_002] Ltd  
196/Protocol GO42661 , Version 6 https://www.uptodate.com/contents/clinical -features -and-diagnosis -of-
hemophagocytic -lymphohistiocytosis.  
Merad M, Martin JC. Pathological inflammation in patients with COVID -19: a key role for 
monocytes and macrophages. Nat Rev Immunol 2020;20:355 62. 
Rave lli A, Minoia F, Davi S, et al. 2016 classification criteria for macrophage activation 
syndrome complicating systemic juvenile idiopathic arthritis: a European League 
Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology 
International  Trials Organisation Collaborative Initiative. Ann Rheum Dis 
2016;75:481 9. 
Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of 
cytokine release syndrome after chimeric antigen receptor T -cell therapy. Ther Clin 
Risk Manag 201 9;15:32335. 
Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient 
receiving PD -1-directed therapy. Pediatr Blood Cancer 2017;64:e26642.  
Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult 
patient. B lood 2015;125:2908 14. 
 
Signature [CONTACT_123613] - GO42661 - TECENTRIQ - v6 - Global/Core - Published
System identifier: RIM-CLIN-466913
Approval Task
Company Signatory
03-Feb-2023 17:20:55 GMT[PHONE_006]
